U.S. patent application number 10/366451 was filed with the patent office on 2003-09-18 for microplate thermal shift assay for ligand development using 5- (4"-dimethylaminophenyl) -2- (4' -phenyl) oxazole derivative fluorescent dyes.
This patent application is currently assigned to 3-Dimensional Pharmaceuticals, Inc.. Invention is credited to Pantoliano, Michael W., Petrella, Eugenio C., Salemme, F. Raymond, Springer, Barry A..
Application Number | 20030175813 10/366451 |
Document ID | / |
Family ID | 26805508 |
Filed Date | 2003-09-18 |
United States Patent
Application |
20030175813 |
Kind Code |
A1 |
Pantoliano, Michael W. ; et
al. |
September 18, 2003 |
Microplate thermal shift assay for ligand development using 5-
(4"-dimethylaminophenyl) -2- (4' -phenyl) oxazole derivative
fluorescent dyes
Abstract
The present invention provides a method for ranking the affinity
of each of a multiplicity of different molecules for a target
molecule which is capable of unfolding due to a thermal change. The
method comprises (a) contacting the target molecule with one
molecule of a multiplicity of different molecules, in the presence
of a 5-(4"-dimethylaminophenyl)-2-(4- '-phenyl)oxazole derivative
dye, in each of a multiplicity of containers; (b) simultaneously
heating the multiplicity of containers; (c) measuring the
fluorescence in each of the containers; (d) generating thermal
unfolding information for the target molecule as a function of
temperature for each of the containers; (e) comparing the thermal
unfolding information obtained for each of the containers to the
thermal unfolding information for the target molecule in the
absence of any of the molecules in the multiplicity of different
molecules; and (f) ranking the affinities of each of the molecules
according to the difference in the thermal unfolding information
between the target molecule in each of the containers and the
target molecule in the absence of any of the molecules in the
multiplicity of different molecules.
Inventors: |
Pantoliano, Michael W.;
(Avondale, PA) ; Petrella, Eugenio C.; (Wayne,
PA) ; Salemme, F. Raymond; (Yardley, PA) ;
Springer, Barry A.; (Wilmington, DE) |
Correspondence
Address: |
STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVENUE, N.W.
WASHINGTON
DC
20005
US
|
Assignee: |
3-Dimensional Pharmaceuticals,
Inc.
|
Family ID: |
26805508 |
Appl. No.: |
10/366451 |
Filed: |
February 14, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10366451 |
Feb 14, 2003 |
|
|
|
09438357 |
Nov 12, 1999 |
|
|
|
6569631 |
|
|
|
|
60108085 |
Nov 12, 1998 |
|
|
|
Current U.S.
Class: |
435/7.1 ;
436/518 |
Current CPC
Class: |
G01N 33/582 20130101;
G01N 33/5375 20130101 |
Class at
Publication: |
435/7.1 ;
436/518 |
International
Class: |
G01N 033/53; G01N
033/543 |
Goverment Interests
[0002] Part of the work performed during development of this
invention utilized U.S. Government funds. The U.S. Government has
certain rights in this invention.
Claims
What is claimed is:
1. A method for ranking the affinity of each of a multiplicity of
different molecules for a target molecule which is capable of
unfolding due to a thermal change, said method comprising (a)
contacting the target molecule with one molecule of a multiplicity
of different molecules, in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye, in
each of a multiplicity of containers; (b) simultaneously heating
said multiplicity of containers; (c) measuring the fluorescence in
each of said containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature
for each of said containers; (e) comparing the thermal unfolding
information obtained for each of said containers to (i) the thermal
unfolding information obtained for each of the other containers,
and (ii) the thermal unfolding information obtained for the target
molecule in the absence of any of said molecules in said
multiplicity of different molecules; and (f) ranking the affinities
of each of said molecules according to the difference in said
thermal unfolding information between the target molecule in each
of said containers and the target molecule in the absence of any of
said molecules in the multiplicity of different molecules.
2. The method of claim 1, wherein said thermal unfolding
information is the thermal unfolding T.sub.m.
3. The method of claim 1, wherein said target molecule is a
protein.
4. The method of claim 1, wherein said multiplicity of different
molecules comprises a combinatorial library.
5. The method of claim 1, wherein said fluorescence in each of said
containers is measured simultaneously.
6. The method of claim 1, wherein said heating, said measuring,
said generating, and said comparing are performed
automatically.
7. The method of claim 6, wherein said contacting is performed
automatically.
8. The method of claim 6, wherein said ranking is performed
automatically.
9. The method of claim 6, wherein said method is
high-throughput.
10. The method of claim 1, wherein said
5-(4"-dimethylaminophenyl)-2-(4'-p- henyl)oxazole derivative dye is
selected from the group consisting of
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole butylsulfonamide,
or a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-(2-
-aminoethyl)sulfonamide, or a salt or ester thereof,
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-3-sulfonamidophyenylboron-
ic acid, or a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-phen- yl)oxazole sulfonic acid, or
a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonyl hydrazine,
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-(2-bromoacetamidoethyl)su-
lfonamide, or a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-ph-
enyl)oxazole-2-(3-(2-pyridyldithio) propionamidoethyl)sulfonamide,
or a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonyl chloride,
or a salt or ester thereof; 5-(4"-dimethylaminophenyl)-
-2-(4'-phenyl)oxazole-3-sulfonamidopropionic acid, or a salt or
ester thereof; 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole
carboxylic acid, or a salt or ester thereof; and
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)o- xazole sulfonate, or a
salt or ester thereof.
11. The method of claim 10, wherein said
5-(4"-dimethylaminophenyl)-2-(4'-- phenyl)oxazole derivative dye is
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)o- xazole sulfonate, or a
salt or ester thereof.
12. The method of claim 11, wherein said
5-(4"-dimethylaminophenyl)-2-(4'-- phenyl)oxazole derivative dye is
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)o- xazole sulfonate, sodium
salt.
13. A multi-variable method for ranking the affinity of a
combination of two or more of a multiplicity of different molecules
for a target molecule which is capable of unfolding due to a
thermal change, said method comprising: (a) contacting said target
molecule with a combination of two or more different molecules of
said multiplicity of different molecules, in the presence of
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxa- zole derivative dye,
in each of a multiplicity of containers; (b) simultaneously heating
said multiplicity of containers; (c) measuring the fluorescence in
each of said containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature in
each of said containers; (e) comparing said thermal unfolding
information obtained for each of said containers to (i) the thermal
unfolding information obtained for each of said other containers,
and (ii) the thermal unfolding information obtained for the target
molecule in the absence of any of the two or more different
molecules; and (f) ranking the affinities of the combinations of
said two or more of the multiplicity of different molecules
according to the difference in said thermal unfolding information
between the target molecule in each of said containers and the
thermal unfolding information obtained for the target molecule in
the absence of any of said molecules in said multiplicity of
different molecules.
14. The method of claim 13, wherein said thermal unfolding
information is the thermal unfolding T.sub.m.
15. A method for assaying a collection of a multiplicity of
different molecules for a molecule which binds to a target molecule
which is capable of unfolding due to a thermal change, said method
comprising: (a) contacting said target molecule with a collection
of at least two molecules of said multiplicity of different
molecules, in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye, in
each of a multiplicity of containers; (b) simultaneously heating
said multiplicity of containers; (c) measuring the fluorescence in
each of said containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature
for each of said containers; (e) comparing said thermal unfolding
information obtained for each of said containers to (i) the thermal
unfolding information obtained for each of said containers, and
(ii) the thermal unfolding information obtained for the target
molecule in the absence of any of said multiplicity of different
molecules; and (f) ranking the affinities of said collections of
different molecules according to the difference in said thermal
unfolding information between the target molecule in each of said
containers and the thermal unfolding information obtained for the
target molecule in the absence of any of said molecules in said
multiplicity of different molecules; (g) selecting the collection
of different molecules which contains a molecule with affinity for
the target molecule; (h) dividing the selected collection into
smaller collections of molecules in each of a multiplicity of
containers; and (i) repeating the above steps until a single
molecule, from said multiplicity of different molecules, is
identified.
16. The method of claim 15, wherein said thermal unfolding
information is the thermal unfolding T.sub.m.
17. A multi-variable method for ranking the efficacy of one or more
of a multiplicity of different biochemical conditions for
stabilizing a target molecule which is capable of unfolding due to
a thermal change, said method comprising: (a) contacting said
target molecule with one or more of said multiplicity of
biochemical conditions, in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye, in
each of a multiplicity of containers; (b) simultaneously heating
said multiplicity of containers; (c) measuring the fluorescence in
each of said containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature
for each of said containers; (e) comparing said thermal unfolding
information obtained for each of said containers to (i) the thermal
unfolding information obtained for each of the other containers,
and (ii) the thermal unfolding information obtained for said target
molecule under a reference set of biochemical conditions; and (f)
ranking the efficacies of each of said biochemical conditions for
each of said containers according to the difference in said thermal
unfolding information between the target molecule for each of said
containers and the target molecule under said reference set of
biochemical conditions.
18. The method of claim 17, wherein said thermal unfolding
information is the thermal unfolding T.sub.m.
19. A multi-variable method for optimizing the shelf life of a
target molecule which is capable of unfolding due to a thermal
change, said method comprising: (a) contacting said target molecule
with one or more of a multiplicity of different molecules or
different biochemical conditions, in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)- oxazole derivative dye,
in each of a multiplicity of containers; (b) simultaneously heating
said multiplicity of containers; (c) measuring the fluorescence in
each of said containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature
for each of said containers; (e) comparing said thermal unfolding
information obtained for each of said containers to (i) the thermal
unfolding information obtained for each of the other containers,
and (ii) the thermal unfolding information obtained for said target
molecule under a reference set of biochemical conditions; and (f)
ranking the efficacies of each of said biochemical conditions for
each of said containers according to the difference in said thermal
unfolding information between the target molecule for each of said
containers and the target molecule under said reference set of
biochemical conditions.
20. The method of claim 19, wherein said thermal unfolding
information is the thermal unfolding T.sub.m.
21. A multi-variable method for ranking the efficacies of one or
more of a multiplicity of different biochemical conditions to
facilitate the refolding or renaturation of a sample of a denatured
or unfolded protein, said method comprising: (a) placing one of the
refolded protein samples, in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye, in
each of a multiplicity of containers, wherein each of the refolded
protein samples has been previously refolded or renatured according
to one or more of the multiplicity of conditions; (b)
simultaneously heating said multiplicity of containers; (c)
measuring the fluorescence in each of said containers; (d)
generating thermal unfolding information for the target molecule as
a function of temperature for each of said containers; (e)
comparing said thermal unfolding information obtained for each of
said containers to (i) the thermal unfolding information obtained
for each of the other containers, and (ii) the thermal unfolding
information obtained for said target molecule under a reference set
of biochemical conditions; and (f) ranking the efficacies of each
of said biochemical conditions for each of said containers
according to the difference in said thermal unfolding information
between the target molecule for each of said containers and the
target molecule under said reference set of biochemical
conditions.
22. The method of claim 21, wherein said thermal unfolding
information is the thermal unfolding T.sub.m.
23. A multi-variable method for ranking the efficacies of one or
more of a multiplicity of different biochemical conditions to
facilitate the refolding or renaturation of a sample of a denatured
unfolded protein, said method comprising (a) Determining one or
more combinations of a multiplicity of different conditions which
promote protein stabililty, incubate the denatured protein under
said one or more combinations of biochemical conditions that were
identified as promoting protein stabilization; (b) assessing folded
protein yield according to the method of claim 18; (c) ranking the
efficacies of said multiplicity of different refolding conditions
according to folded protein yield; and (d) repeating these steps
until a combination of biochemical conditions that promote optimal
protein folding are identified.
24. The method of claim 23, wherein said thermal unfolding
information is the thermal unfolding T.sub.m.
25. A multi-variable method for ranking the efficacy of one or more
of a multiplicity of different biochemical conditions for
facilitating the crystallization of a protein which is capable of
unfolding due to a thermal change, said method comprising: (a)
contacting the protein with one or more of the multiplicity of
different biochemical conditions, in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye, in
each of a multiplicity of containers; (b) simultaneously heating
said multiplicity of containers; (c) measuring the fluorescence in
each of said containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature
for each of said containers; (e) comparing said thermal unfolding
information obtained for each of said containers to (i) the thermal
unfolding information obtained for each of the other containers,
and (ii) the thermal unfolding information obtained for said target
molecule under a reference set of biochemical conditions; and (f)
ranking the efficacies of each of said biochemical conditions for
each of said containers according to the difference in said thermal
unfolding information between the target molecule for each of said
containers and the target molecule under said reference set of
biochemical conditions.
26. The method of claim 23, wherein said thermal unfolding
information is the thermal unfolding T.sub.m.
Description
[0001] This application claims priority benefit of U.S. provisional
Appl. No. 60/108,085, filed Nov. 12, 1998, the entirety of which is
hereby incorporated by reference.
BACKGROUND OF THE INVENTION
[0003] 1. Field of the Invention
[0004] The present invention relates generally to the screening of
compound and combinatorial libraries. More particularly, the
present invention relates to a method and apparatus for performing
assays, particularly thermal shift assays.
[0005] 2. Related Art
[0006] In recent years, pharmaceutical researchers have turned to
combinatorial libraries as sources of new lead compounds for drug
discovery. A combinatorial library is a collection of chemical
compounds which have been generated, by either chemical synthesis
or biological synthesis, by combining a number of chemical
"building blocks" as reagents. For example, a combinatorial
polypeptide library is formed by combining a set of amino acids in
every possible way for a given compound length (i.e., the number of
amino acids in a polypeptide compound). Millions of chemical
compounds can theoretically be synthesized through such
combinatorial mixing of chemical building blocks. Indeed, one
investigator has observed that the systematic, combinatorial mixing
of 100 interchangeable chemical building blocks results in the
theoretical synthesis of 100 million tetrameric compounds or 10
billion pentameric compounds (Gordon, E. M. et al., J. Med. Chem.
37:1233-1251 (1994)).
[0007] The rate of combinatorial library synthesis is accelerated
by automating compound synthesis and evaluation. For example,
DirectedDiversity.RTM. is a computer based, iterative process for
generating chemical entities with defined physical, chemical and/or
bioactive properties. The DirectedDiversity.RTM. system is
disclosed in U.S. Pat. No. 5,463,564, which is herein incorporated
by reference in its entirety.
[0008] Once a library has been constructed, it must be screened to
identify compounds which possess some kind of biological or
pharmacological activity. To screen a library of compounds, each
compound in the library is equilibrated with a target molecule of
interest, such as an enzyme. A variety of approaches have been used
to screen combinatorial libraries for lead compounds. For example,
in an encoded library, each compound in a chemical combinatorial
library can be made so that an oligonucleotide "tag" is linked to
it. A careful record is kept of the nucleic acid tag sequence for
each compound. A compound which exerts an effect on the target
enzyme is selected by amplifying its nucleic acid tag using the
polymerase chain reaction (PCR). From the sequence of the tag, one
can identify the compound (Brenner, S. et al, Proc. Natl. Acad.
Sci. USA 89:5381-5383 (1992)). This approach, however, is very time
consuming because it requires multiple rounds of oligonucleotide
tag amplification and subsequent electrophoresis of the
amplification products.
[0009] A filamentous phage display peptide library can be screened
for binding to a biotinylated antibody, receptor or other binding
protein. The bound phage is used to infect bacterial cells and the
displayed determinant (i.e., the peptide ligand) is then identified
(Scott, J. K. et al., Science 249:386-390(1990)). This approach
suffers from several drawbacks. It is time consuming. Peptides
which are toxic to the phage or to the bacterium cannot be studied.
Moreover, the researcher is limited to investigating peptide
compounds.
[0010] In International Patent Application WO 94/05394 (1994),
Hudson, D. et al., disclose a method and apparatus for synthesizing
and screening a combinatorial library of biopolymers on a
solid-phase plate, in an array of 4.times.4 to 400.times.400. The
library can be screened using a fluorescently labeled,
radiolabeled, or enzyme-linked target molecule or receptor. The
drawback to this approach is that the target molecule must be
labeled before it can be used to screen the library.
[0011] A challenge presented by currently available combinatorial
library screening technologies is that they provide no information
about the relative binding affinities of different ligands for a
receptor protein. This is true whether the process for generating a
combinatorial library involves phage library display of peptides
(Scott, J. K. et al, Science 249:386-390 (1990)), random synthetic
peptide arrays (Lam, K. S. et al., Nature 354:82-84 (1991)),
encoded chemical libraries (Brenner, S. et al., Proc. Natl. Acad.
Sci. USA 89:5381-5383 (1992)), the method of Hudson (Intl. Appl. WO
94/05394), or most recently, combinatorial organic synthesis
(Gordon, E. et al., J. Med. Chem. 37:1385-1399 (1994)).
[0012] To acquire quantitative binding data from the high
throughput screening of ligand affinities for a target enzyme,
researchers have relied on assays of enzyme activity. Enzymes lend
themselves to high throughput screening because the effect of
ligand binding can be monitored using kinetic assays. The
experimental endpoint is usually a spectrophotometric change. Using
a kinetic assay, most researchers use a two-step approach to lead
compound discovery. First, a large library of compounds is screened
against the target enzyme to determine if any of the library
compounds are active. These assays are usually performed in a
single concentration (between 10.sup.-4-10.sup.-6 M) with one to
three replicates. Second, promising compounds obtained from the
first screen (i.e., compounds which display activity greater than a
predetermined value) are usually re-tested to determine a 50%
inhibitory concentration (IC.sub.50), an inhibitor association
constant (K.sub.i), or a dissociation constant (K.sub.d). This
two-step approach, however, is very labor intensive, time-consuming
and prone to error. Each retested sample must either be retrieved
from the original assay plate or weighed out and solubilized again.
A concentration curve must then be created for each sample and a
separate set of assay plates must be created for each assay.
[0013] There are other problems associated with the biochemical
approach to high throughput screening of combinatorial libraries.
Typically, a given assay is not applicable to more than one
receptor. That is, when a new receptor becomes available for
testing, a new assay must be developed. For many receptors,
reliable assays are simply not available. Even if an assay does
exist, it may not lend itself to automation. Further, if a K.sub.i
is the endpoint to be measured in a kinetic assay, one must first
guess at the concentration of inhibitor to use, perform the assay,
and then perform additional assays using at least six different
concentrations of inhibitor. If one guesses too low, an inhibitor
will not exert its inhibitory effect at the suboptimal
concentration tested.
[0014] In addition to the drawbacks to the kinetic screening
approach described above, it is difficult to use the kinetic
approach to identify and rank ligands that bind outside of the
active site of the enzyme. Since ligands that bind outside of the
active site do not prevent binding of spectrophotometric
substrates, there is no spectrophotometric change to be monitored.
An even more serious drawback to the kinetic screening approach is
that non-enzyme receptors cannot be assayed at all.
[0015] Thermal protein unfolding, or thermal "shift," assays have
been used to determine whether a given ligand binds to a target
receptor protein. In a physical thermal shift assay, a change in a
biophysical parameter of a protein is monitored as a function of
increasing temperature. For example, in calorimetric studies, the
physical parameter measured is the change in heat capacity as a
protein undergoes temperature induced unfolding transitions.
Differential scanning calorimetry has been used to measure the
affinity of a panel of azobenzene ligands for streptavidin (Weber,
P. et al., J. Am. Chem. Soc. 16:2717-2724 (1994)). Titration
calorimetry has been used to determine the binding constant of a
ligand for a target protein (Brandts, J. et al., American
Laboratory 22:30-41 (1990)). The calorimetric approach, however,
requires that the researcher have access to a calorimetric device.
In addition, calorimetric technologies do not lend themselves to
the high throughput screening of combinatorial libraries, three
thermal scans per day are routine. Like calorimetric technologies,
spectral technologies have been used to monitor temperature induced
protein unfolding (Bouvier, M. et al., Science 265:398-402 (1994);
Chavan, A. J. et al., Biochemistry 33:7193-7202 (1994); Morton, A.
et al., Biochemistry 1995:8564-8575 (1995)).
[0016] The single sample heating and assay configuration, as
conventionally performed, has impeded the application of thermal
shift technologies to high throughput screening of combinatorial
libraries. Thus, there is a need for a thermal shift technology
which can be used to screen combinatorial libraries, can be used to
identify and rank lead compounds, and is applicable to all receptor
proteins.
[0017] Thermal shift assays have been used to determine whether a
ligand binds to DNA. Calorimetric, absorbance, circular dichroism,
and fluorescence technologies have been used (Pilch, D. S. et al.,
Proc. Natl. Acad. Sci. U.S.A. 91:9332-9336 (1994); Lee, M. et al.,
J. Med. Chem. 36:863-870 (1993); Butour, J.-L. et al., Eur. J.
Biochem. 202:975-980 (1991); Barcelo, F. et al., Chem. Biol.
Interactions 74:315-324 (1990)). As used conventionally, however,
these technologies have impeded the high throughput screening of
nucleic acid receptors for lead compounds which bind with high
affinity. Thus, there is a need for a thermal shift technology
which can be used to identify and rank the affinities of lead
compounds which bind to DNA sequences of interest.
[0018] When bacterial cells are used to overexpress exogenous
proteins, the recombinant protein is often sequestered in bacterial
cell inclusion bodies. For the recombinant protein to be useful, it
must be purified from the inclusion bodies. During the purification
process, the recombinant protein is denatured and must then be
renatured. It is impossible to predict the renaturation conditions
that will facilitate and optimize proper refolding of a given
recombinant protein. Usually, a number of renaturing conditions
must be tried before a satisfactory set of conditions is
discovered. In a study by Tachibana et al., each of four disulfide
bonds were singly removed, by site-directed mutagenesis, from hen
lysozyme (Tachibana et al., Biochemistry 33:15008-15016(1994)). The
mutant genes were expressed in bacterial cells and the recombinant
proteins were isolated from inclusion bodies. Each of the isolated
proteins were renatured under different temperatures and glycerol
concentrations. The efficacy of protein refolding was assessed in a
bacteriolytic assay in which bacteriolytic activity was measured as
a function of renaturing temperature. The thermal stability of each
protein was studied using a physical thermal shift assay. In this
study, however, only one sample reaction was heated and assayed at
a time. The single sample heating and assay configuration prevents
the application of thermal shift technologies to high throughput
screening of a multiplicity of protein refolding conditions. Thus,
there is a need for a thermal shift technology which can be used to
rank the efficacies of various protein refolding conditions.
[0019] Over the past four decades, X-ray crystallography and the
resulting atomic models of proteins and nucleic acids have
contributed greatly to an understanding of structural, molecular,
and chemical aspects of biological phenomena. However,
crystallographic analysis remains difficult because there are not
straightforward methodologies for obtaining X-ray quality protein
crystals. Conventional methods cannot be used quickly to identify
crystallization conditions that have highest probability of
promoting crystallization (Garavito, R. M. et al., J. Bioenergtics
and Biomembranes 28:13-27 (1996)). Even the use of factorial design
experiments and successive automated grid searches (Cox, M. J.,
& Weber, P. C., J. Appl. Cryst. 20:366-373 (1987); Cox, M. J.,
& Weber, P. C., J. Crystal Growth 90:318-324 (1988)) do not
facilitate rapid, high throughput screening of biochemical
conditions that promote the crystallization of X-ray quality
protein crystals. Moreover, different proteins are expected to
require different conditions for protein crystallization, just as
has been the experience for their folding (McPherson, A., In:
Preparation and Analysis of Protein Crystals, Wiley Interscience,
New York, (1982)). Conventional methods of determining
crystallization conditions are cumbersome, slow, and labor
intensive. Thus, there is a need for a rapid, high throughput
technology which can be used to rank the efficacies of protein
crystallization conditions.
[0020] Rapid, high throughput screening of combinatorial molecules
or biochemical conditions that stabilize target proteins in thermal
shift assays would be facilitated by the simultaneous heating of
many samples. To date, however, thermal shift assays have not been
performed that way. Instead, the conventional approach to
performing thermal shift assays has been to heat and assay only one
sample at a time. That is, researchers conventionally 1) heat a
sample to a desired temperature in a heating apparatus; 2) assay a
physical change, such as absorption of light or change in
secondary, tertiary, or quaternary protein structure; 3) heat the
samples to the next highest desired temperature; 4) assay for a
physical change; and 5) continue this process repeatedly until the
sample has been assayed at the highest desired temperature.
[0021] This conventional approach is disadvantageous for at least
two reasons. First, this approach is labor intensive. Second, this
approach limits the speed with which thermal shift screening assays
can be performed and thereby precludes rapid, high-throughput
screening of combinatorial molecules binding to a target receptor
and biochemical conditions that stabilize target proteins.
[0022] Fluorescent molecules whose spectra or quantum yields are
sensitive to their environments are valuable in the study of
heterogeneous media, organized media and biological media and many
fluorescent dyes have been developed for these applications.
However, many dyes either have short absorption and emission
wavelengths (potentially causing high background due to the auto
fluorescence of samples), low extinction coefficients, low quantum
yields, or small Stokes shifts.
[0023] Rapid, high-throughput screening using fluorescence
methodologies would also be facilitated by the use of fluorescence
probe molecules that fluoresce at wavelengths longer than
fluorescence molecules such as 1-anilinonaphthalene-8-sulfonate.
That is because many molecules in compound and combinatorial
libraries fluoresce at the same wavelengths at which fluorescence
probe molecules fluoresce. In addition, plastic microplates used in
high-throughput screening assays may also fluoresce at the same
wavelengths at which fluorescence probe molecules fluoresce.
[0024] Thus, there is a need for a rapid, high-throughput,
fluorescence screening procedure in which fluorescence readings are
taken at wavelengths longer than fluorescence molecules such as
1-anilinonaph-thalene-8-sulfonate.
SUMMARY OF THE INVENTION
[0025] The present invention provides a method for ranking the
affinity of each of a multiplicity of different molecules for a
target molecule which is capable of unfolding due to a thermal
change, the method comprising (a) contacting the target molecule
with one molecule of a multiplicity of different molecules, in the
presence of a 5-(4"-dimethylaminophenyl)-2-(4- '-phenyl)oxazole
derivative dye, in each of a multiplicity of containers; (b)
simultaneously heating the multiplicity of containers; (c)
measuring the fluorescence in each of the containers; (d)
generating thermal unfolding information for the target molecule as
a function of temperature for each of the containers; (e) comparing
the thermal unfolding information obtained for each of the
containers to (i) the thermal unfolding information obtained for
each of the other containers, and (ii) the thermal unfolding
information obtained for the target molecule in the absence of any
of the molecules in the multiplicity of different molecules; and
(f) ranking the affinities of each of the molecules according to
the difference in the thermal unfolding information between the
target molecule in each of the containers and the target molecule
in the absence of any of the molecules in the multiplicity of
different molecules.
[0026] The present invention also provides a multi-variable method
for ranking the affinity of a combination of two or more of a
multiplicity of different molecules for a target molecule which is
capable of unfolding due to a thermal change, the method
comprising: (a) contacting the target molecule with a combination
of two or more different molecules of the multiplicity of different
molecules, in the presence of
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye, in
each of a multiplicity of containers; (b) simultaneously heating
the multiplicity of containers; (c) measuring in the fluorescence
in each of the containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature in
each of the containers; (e) comparing the thermal unfolding
information obtained for each of the containers to (i) the thermal
unfolding information obtained for each of the other containers,
and (ii) the thermal unfolding information obtained for the target
molecule in the absence of any of the two or more different
molecules; and (f) ranking the affinities of the combinations of
the two or more of the multiplicity of different molecules
according to the difference in the thermal unfolding information
between the target molecule in each of the containers and the
thermal unfolding information obtained for the target molecule in
the absence of any of the molecules in the multiplicity of
different molecules.
[0027] The present invention also provides a method for assaying a
collection of a multiplicity of different molecules for a molecule
which binds to a target molecule which is capable of unfolding due
to a thermal change, the method comprising: (a) contacting the
target molecule with a collection of at least two molecules of the
multiplicity of different molecules, in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)o- xazole derivative dye,
in each of a multiplicity of containers; (b) simultaneously heating
the multiplicity of containers; (c) measuring the fluorescence in
each of the containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature
for each of the containers; (e) comparing the thermal unfolding
information obtained for each of the containers to (i) the thermal
unfolding information obtained for each of the other containers,
and (ii) the thermal unfolding information obtained for the target
molecule in the absence of any of the multiplicity of different
molecules; and (f) ranking the affinities of the collections of
different molecules according to the difference in the thermal
unfolding information between the target molecule in each of the
containers and the thermal unfolding information obtained for the
target molecule in the absence of any of the molecules in the
multiplicity of different molecules; (g) selecting the collection
of different molecules which contains a molecule with affinity for
the target molecule; (h) dividing the selected collection into
smaller collections of molecules in each of a multiplicity of
containers; and (i) repeating the above steps until a single
molecule, from the multiplicity of different molecules, is
identified.
[0028] The present invention also provides a multi-variable method
for ranking the efficacy of one or more of a multiplicity of
different biochemical conditions for stabilizing a target molecule
which is capable of unfolding due to a thermal change, the method
comprising: (a) contacting the target molecule with one or more of
the multiplicity of biochemical conditions, in the presence of a
5-(4"-dimethylaminophenyl)-2- -(4'-phenyl)oxazole derivative dye,
in each of a multiplicity of containers; (b) simultaneously heating
the multiplicity of containers; (c) measuring the fluorescence in
each of the containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature
for each of the containers; (e) comparing the thermal unfolding
information obtained for each of the containers to (i) the thermal
unfolding information obtained for each of the other containers,
and (ii) the thermal unfolding information obtained for the target
molecule under a reference set of biochemical conditions; and (f)
ranking the efficacies of each of the biochemical conditions for
each of the containers according to the difference in the thermal
unfolding information between the target molecule for each of the
containers and the target molecule under the reference set of
biochemical conditions.
[0029] The present invention also provides a multi-variable method
for optimizing the shelf life of a target molecule which is capable
of unfolding due to a thermal change, the method comprising: (a)
contacting the target molecule with one or more of a multiplicity
of different molecules or different biochemical conditions, in the
presence of a 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole
derivative dye, in each of a multiplicity of containers; (b)
simultaneously heating the multiplicity of containers; (c)
measuring the fluorescence in each of the containers; (d)
generating thermal unfolding information for the target molecule as
a function of temperature for each of the containers; (e) comparing
the thermal unfolding information obtained for each of the
containers to (i) the thermal unfolding information obtained for
each of the other containers, and (ii) the thermal unfolding
information obtained for the target molecule under a reference set
of biochemical conditions; and (f) ranking the efficacies of each
of the biochemical conditions for each of the containers according
to the difference in the thermal unfolding information between the
target molecule for each of the containers and the target molecule
under the reference set of biochemical conditions.
[0030] The present invention also provides a multi-variable method
for ranking the efficacies of one or more of a multiplicity of
different biochemical conditions to facilitate the refolding or
renaturation of a sample of a denatured or unfolded protein, the
method comprising: (a) placing one of the refolded protein samples,
in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye, in
each of a multiplicity of containers, wherein each of the refolded
protein samples has been previously refolded or renatured according
to one or more of the multiplicity of conditions; (b)
simultaneously heating the multiplicity of containers; (c)
measuring the fluorescence in each of the containers; (d)
generating thermal unfolding information for the target molecule as
a function of temperature for each of the containers; (e) comparing
the thermal unfolding information obtained for each of the
containers to (i) the thermal unfolding information obtained for
each of the other containers, and (ii) the thermal unfolding
information obtained for the target molecule under a reference set
of biochemical conditions; and (f) ranking the efficacies of each
of the biochemical conditions for each of the containers according
to the difference in the thermal unfolding information between the
target molecule for each of the containers and the target molecule
under the reference set of biochemical conditions.
[0031] The present invention also provides a multi-variable method
for ranking the efficacies of one or more of a multiplicity of
different biochemical conditions to facilitate the refolding or
renaturation of a sample of a denatured unfolded protein, the
method comprising: (a) determining one or more combinations of a
multiplicity of different conditions which promote protein
stabililty, incubating denatured protein under the one or more
combinations of biochemical conditions that were identified as
promoting protein stabilization; (b) assessing folded protein
yield; (c) ranking the efficacies of the multiplicity of different
refolding conditions according to folded protein yield; and (d)
repeating these steps until a combination of biochemical conditions
that promote optimal protein folding are identified.
[0032] The present invention also provides a multi-variable method
for ranking the efficacy of one or more of a multiplicity of
different biochemical conditions for facilitating the
crystallization of a protein which is capable of unfolding due to a
thermal change, the method comprising: (a) contacting the protein
with one or more of the multiplicity of different biochemical
conditions, in the presence of a
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye, in
each of a multiplicity of containers; (b) simultaneously heating
the multiplicity of containers; (c) measuring the fluorescence in
each of the containers; (d) generating thermal unfolding
information for the target molecule as a function of temperature
for each of the containers; (e) comparing the thermal unfolding
information obtained for each of the containers to (i) the thermal
unfolding information obtained for each of the other containers,
and (ii) the thermal unfolding information obtained for the target
molecule under a reference set of biochemical conditions; and (f)
ranking the efficacies of each of the biochemical conditions for
each of the containers according to the difference in the thermal
unfolding information between the target molecule for each of the
containers and the target molecule under the reference set of
biochemical conditions.
[0033] Optimization of protein stability, ligand binding, protein
folding, and protein crystallization are multi-variable events.
Multi-variable optimization problems require large numbers of
parallel experiments to collect as much data as possible in order
to determine which variables influence a favorable response. For
example, multi-variable optimization problems require large numbers
of parallel experiments to collect as much data as possible in
order to determine which variables influence protein stabililty. In
this regard, both protein crystallization and quantitative
structure activity relationship analyses have greatly benefited
from mass screening protocols that employ matrix arrays of
incremental changes in biochemical or chemical composition. Thus,
in much the same way that quantitative structure activity
relationships are constructed to relate variations of chemical
functional groups on ligands to their effect on binding affinity to
a given therapeutic receptor, the methods and apparatus of the
present invention facilitate the construction of a quantitative
model that relates different biochemical conditions to
experimentally measured protein stability, ligand specificity,
folded protein yield, and crystallized protein yield.
[0034] Using the fluorescence microplate thermal shift assay, one
can determine one or more biochemical conditions that have an
additive effect on protein stability. Once a set of biochemical
conditions that facilitate an increase in protein stability have
been identified using the thermal shift assay, the same set of
conditions can be used in protein folding experiments with
recombinant protein. If the conditions that promote protein
stability in the thermal shift assay correlate with conditions that
promote folding of recombinant protein, conditions can be further
optimized by performing additional thermal shift assays until a
combination of stabilizing conditions that result in further
increase protein stability are identified. Recombinant protein is
then folded under those conditions. This process is repeated until
optimal folding conditions are identified.
[0035] The present invention offers a number of advantages over
previous technologies that are employed to optimize multi-variable
events such as protein stabilization, ligand binding, protein
folding, and protein crystallization. Foremost among these
advantages is that the present invention facilitates high
throughput screening. The use of
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dyes to
practice the microplate thermal shift assay of the present
invention affords increased assay sensitivity and increased assay
throughput, because these dyes have long emission wavelengths, high
extinction coefficients, high quantum yields, and large Stokes
shifts.
[0036] Further, the methods of the present invention offers a
number of advantages over previous technologies that are employed
to screen combinatorial libraries. Foremost among these advantages
is that the present invention facilitates high throughput screening
of combinatorial libraries for lead compounds. Many current library
screening technologies simply indicate whether a ligand binds to a
receptor or not. In that case, no quantitative information is
provided. No information about the relative binding affinities of a
series of ligands is provided. In contrast, the present invention
facilitates the ranking of a series of compounds for their relative
affinities for a target receptor. With this information in hand, a
structure-activity relationship can be developed for a set of
compounds. The ease, reproducibility, and speed of using
ligand-dependent changes in midpoint unfolding temperature
(T.sub.m) to rank relative binding affinities makes the present
invention a powerful tool in the drug discovery process.
[0037] Typically, the conventional kinetic screening approach
requires at least six additional well assays at six different
concentrations of inhibitor to determine a K.sub.i. Using the
present invention, throughput is enhanced .about.6 fold over the
enzyme based assays because one complete binding experiment can be
performed in each well of a multiwell microplate. The kinetic
screening approached are even further limited by the usual
compromise between dilution and signal detection, which usually
occurs at a protein concentration of about 1 nM. In this regard,
the calorimetric approaches, either differential scanning
calorimetry or isothermal titrating calorimetry, are at an even
worse disadvantage since they are limited to solitary binding
experiments, usually 1 per hour. In contrast, the present invention
affords a wide dynamic range of measurable binding affinities, from
.about.10.sup.-4 to 10.sup.-15 M, in a single well.
[0038] A very important advantage of the present invention is that
it can be applied universally to any receptor that is a drug
target. Thus, it is not necessary to invent a new assay every time
a new receptor becomes available for testing. When the receptor
under study is an enzyme, researchers can determine the rank order
of affinity of a series of compounds more quickly and more easily
than they can using conventional kinetic methods. In addition,
researchers can detect ligand binding to an enzyme, regardless of
whether binding occurs at the active site, at an allosteric
cofactor binding site, or at a receptor subunit interface. The
present invention is equally applicable to non-enzyme receptors,
such as proteins and nucleic acids.
[0039] Further features and advantages of the present invention are
described in detail below with reference to the accompanying
drawings.
BRIEF DESCRIPTION OF THE FIGURES
[0040] The present invention is described with reference to the
accompanying drawings. In the drawings, like reference numbers
indicate identical or functionally similar elements. Additionally,
the left-most digit(s) of a reference number identifies the drawing
in which the reference number first appears.
[0041] FIG. 1 shows the results of a microplate thermal shift assay
for ligands which bind to the active site of human .alpha.-thrombin
(with turbidity as the experimental signal).
[0042] FIG. 2 shows the results of a microplate thermal shift assay
for ligands which bind to acidic fibroblast growth factor (aFGF)
(with turbidity as the experimental signal).
[0043] FIG. 3 shows the results of a microplate thermal shift assay
for ligand binding to the active site of human .alpha.-thrombin
(with fluorescence emission as the experimental signal). The lines
drawn through the data points represent non-linear least squares
curve fits of the data using the equation shown at the bottom of
the figure. There are five fitting parameters for this equation of
y(T) vs. T: (1) y.sub.f, the pre-transitional fluorescence for the
native protein; (2) y.sub.u, the post-transitional fluorescence for
the unfolded protein; (3) T.sub.m, the temperature at the midpoint
for the unfolding transition; (4) .DELTA.H.sub.u, the van't Hoff
unfolding enthalpy change; and (5) .DELTA.C.sub.pu, the change in
heat capacity upon protein unfolding. The non-linear least squares
curve fitting was accomplished using KALEIDAGRAPH.TM. 3.0 software
(Synergy Software, Reading Pa.), which allows the five fitting
parameters to float while utilizing Marquardt methods for the
minimization of the sum of the squared residuals.
[0044] FIG. 4 shows the result of a microplate thermal shift assay
of ligands which bind to the D(II) domain of human FGF receptor 1
(D(II) FGFR1) (with fluorescence emission as the experimental
signal). The lines drawn through the data points represent
non-linear least squares curve fits of the data using the equation
shown at the bottom of the figure, as described for FIG. 3.
[0045] FIG. 5 shows the results of a miniaturized microplate
thermal shift assay for Factor D in the absence of any ligands.
[0046] FIG. 6 shows the results of a microplate thermal shift assay
for Factor Xa in the absence of any ligands.
[0047] FIG. 7 shows the results of a miniaturized microplate
thermal shift assay of a ligand that binds to the catalytic site of
human .alpha.-thrombin.
[0048] FIGS. 8A and 8B show the results of a miniaturized
microplate thermal shift assay of aprosulate binding to the D(II)
domain of human FGF receptor 1.
[0049] FIG. 9 shows the results of a miniaturized microplate
thermal shift assay for urokinase in the presence of glu-gly-arg
chloromethylketone.
[0050] FIG. 10 shows the results of a miniaturized microplate
thermal shift assay of human .alpha.-thrombin in which the assay
volume is 2 .mu.l. Thermal denaturation curves for three
experiments are shown.
[0051] FIG. 11 shows the results of a miniaturized microplate
thermal shift assay of human .alpha.-thrombin in which the assay
volume is 5 .mu.l. Thermal denaturation curves for five experiments
are shown.
[0052] FIG. 12 shows the results of a single temperature microplate
thermal shift assay of human .alpha.-thrombin in the presence of
four different compounds in four separate experiments.
[0053] FIG. 13 shows the results of a microplate thermal shift
assay of the intrinsic tryptophan fluorescence of human
.alpha.-thrombin. In this assay, blank well fluorescence was not
subtracted from sample fluorescence.
[0054] FIG. 14 shows the results of a microplate thermal shift
assay of the intrinsic tryptophan fluorescence of human
.alpha.-thrombin. In this assay, blank well fluorescence was
subtracted from sample fluorescence.
[0055] FIG. 15 shows the results of microplate thermal shift assays
of single ligand binding interactions to three different classes of
binding sites for human .alpha.-thrombin.
[0056] FIG. 16 shows the results of microplate thermal shift assays
of multi-ligand binding interactions for human
.alpha.-thrombin.
[0057] FIGS. 17A-D show the results of microplate thermal shift
assays of the effect of pH and various sodium chloride
concentrations on the stability of human .alpha.-thrombin. In FIG.
17A, the fluorophore is 1,8-ANS. In FIG. 17B, the fluorophore is
2,6-ANS. In FIG. 17C, the fluorophore is 2,6-TNS. In FIG. 17D, the
fluorophore is bis-ANS.
[0058] FIG. 18 shows the results of microplate thermal shift assays
of the effect of calcium chloride, ethylenediaminetetraacetic acid,
dithiothreitol, and glycerol on the stability of human
.alpha.-thrombin.
[0059] FIG. 19 shows the results of microplate thermal shift assays
of the effect of pH and sodium chloride concentration of the
stability of human D(II) FGF receptor 1.
[0060] FIG. 20 shows the results of microplate thermal shift assays
of the effect of various biochemical conditions on the stability of
human D(II) FGF receptor 1.
[0061] FIG. 21 shows the results of microplate thermal shift assays
of the effect of various biochemical conditions on the stability of
human D(II) FGF receptor 1.
[0062] FIG. 22 shows the results of microplate thermal shift assays
of the effect of various biochemical conditions on the stability of
human D(II) FGF receptor 1.
[0063] FIG. 23 shows the results of microplate thermal shift assays
of the effect of various biochemical conditions on the stability of
human D(II) FGF receptor 1.
[0064] FIG. 24 shows the results of microplate thermal shift assays
of the effect of various biochemical conditions on the stability of
human D(II) FGF receptor 1.
[0065] FIG. 25 shows the results of microplate thermal shift assays
of the effect of various biochemical conditions on the stability of
human urokinase.
[0066] FIG. 26 is a schematic diagram of a thermodynamic model for
the linkage of the free energies of protein folding and ligand
binding.
[0067] FIG. 27 is a schematic diagram of a method of screening
biochemical conditions that optimize protein folding.
[0068] FIG. 28 shows the results of microplate thermal shift assays
of human .alpha.-thrombin stability using various fluorophores.
[0069] FIG. 29 shows a schematic diagram of an assay apparatus that
can be used to practice the methods of present invention.
[0070] FIG. 30 shows a schematic diagram of another embodiment of
the assay apparatus that can be used to practice the methods of
present invention.
[0071] FIG. 31 shows a schematic diagram of another embodiment of
the assay apparatus that can be used to practice the methods of
present invention.
[0072] FIGS. 32A-E illustrate one embodiment of a thermal electric
stage for the assay apparatus of the present invention. FIG. 32A
shows a side view of the thermal electric stage. FIG. 32B shows a
top view of the thermal electric stage. FIGS. 32C-E show three
configurations of inserts that can be attached to the thermal
electric stage. In one embodiment, inserts accommodate a microtitre
plate. In such an embodiment, assay samples are contained within
the containers of the microtitre plate.
[0073] FIG. 33 is a schematic diagram illustrating a top view of
another embodiment of the assay apparatus of the present
invention.
[0074] FIG. 34 is a schematic diagram illustrating the top view of
the embodiment of the assay apparatus shown in FIG. 33 with a
housing installed.
[0075] FIG. 35 is a schematic diagram illustrating a side view of
the embodiment of the assay apparatus shown in FIGS. 33 and 34.
[0076] FIGS. 36A and 36B illustrate a temperature profile and how
the temperature profile is implemented using the automated assay
apparatus of the present invention.
[0077] FIG. 37 shows an exemplary computer system suitable for use
with an assay apparatus.
[0078] FIG. 38 shows a flow diagram illustrating one embodiment for
implementation of the present invention.
[0079] FIG. 39 shows a flow diagram illustrating an alternate
embodiment for implementation of the present invention.
[0080] FIG. 40 shows a comparison of the results of microplate
thermal shift assays of human .alpha.-thrombin denaturation
performed using a fluorescence scanner and a CCD camera.
[0081] FIGS. 41A and 41B show photographs of microplate thermal
shift assay of human .alpha.-thrombin denaturation performed using
a CCD camera. FIG. 41A: V-bottom well microplate. FIG. 41B: dimple
microplate.
[0082] FIG. 42 shows a comparison of the results of microplate
thermal shift assays of human .alpha.-thrombin denaturation
performed using a fluorescence scanner and a CCD camera.
[0083] FIGS. 43A and 43B show a comparison of fluorescence
background collected using a 435/550 nm bandpass (FIG. 43A), and a
475/550 nm bandpass. (FIG. 43B)
[0084] FIG. 44 shows the comparison of fluorescence signals for
1,8-ANS and 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole
sulfonate. The protein is chicken muscle pyruvate kinase.
[0085] FIGS. 45A and 45B show the results of a bandpass study using
1,8-ANS (FIG. 45A) and
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate (FIG.
45B).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0086] In the following description, reference will be made to
various terms and methodologies known to those of skill in the
biochemical and pharmacological arts. Publications and other
materials setting forth such known terms and methodologies are
incorporated herein by reference in their entireties as though set
forth in full.
[0087] The present invention provides a method for ranking a
multiplicity of different molecules in the order of their ability
to bind to a target molecule which is capable of unfolding due to a
thermal change. In one embodiment of this method, the target
molecule is contacted with one molecule of a multiplicity of
different molecules in each of a multiplicity of containers. The
containers are then simultaneously heated, in intervals, over a
range of temperatures. After each heating interval, thermal
unfolding information (e.g., the thermal unfolding temperature
midpoint (T.sub.m)) is measured. In an alternate embodiment of this
method, the containers are heated in a continuous fashion, and
thermal unfolding information (e.g., the thermal unfolding T.sub.m)
is obtained for each container. Preferably, the temperature
midpoint T.sub.m is identified and is then compared to the T.sub.m
for the target molecule in the absence of any of the molecules in
the containers. Alternatively, an entire thermal unfolding curve
can be compared to other entire thermal unfolding curves using
computer analytical tools.
[0088] The steps in any of the methods of the present invention can
be repeated, until a molecule that binds to a target molecule is
identified, or until a set of biochemical conditions that stabilize
a target molecule is determined, or until a set of biochemical
conditions that facilitate refolding or renaturation of a protein
is determined, or until a set of biochemical conditions that
optimize the shelf life of a protein is determined, or until a set
of biochemical conditions that facilitate protein crystallization
is determined.
[0089] The term "combinatorial library" refers to a plurality of
molecules or compounds which are formed by combining, in every
possible way for a given compound length, a set of chemical or
biochemical building blocks which may or may not be related in
structure. Alternatively, the term can refer to a plurality of
chemical or biochemical compounds which are formed by selectively
combining a particular set of chemical building blocks.
Combinatorial libraries can be constructed according to methods
familiar to those skilled in the art. For example, see Rapoport et
al., Immunology Today 16:43-49 (1995); Sepetov, N. F. et al., Proc.
Natl. Acad. Sci. U.S.A. 92:5426-5430 (1995); Gallop, M. A. et al.,
J. Med. Chem. 9:1233-1251 (1994); Gordon, E. M. et al., J. Med.
Chem. 37:1385-1401 (1994); Stankova, M. et al., Peptide Res.
7:292-298 (1994); Erb, E. et al., Proc. Natl. Acad. Sci. U.S.A.
91:11422-11426 (1994); DeWitt, S. H. et al., Proc. Natl. Acad. Sci.
U.S.A. 90:6909-6913 (1993); Barbas, C. F. et al., Proc. Natl. Acad.
Sci. U.S.A. 89:4457-4461 (1992); Brenner, S. et al. Proc. Natl.
Acad. Sci. U.S.A. 89:5381-5383 (1992); Lam, K. S. et al., Nature
354:82-84 (1991); Devlin, J. J. et al., Science 245:404-406 (1990);
Cwirla, S. E. et al., Proc. Natl. Acad. Sci. U.S.A.
87:6378-6382(1990); Scott, J. K. et al., Science249:386-390(1990).
Preferably, the term "combinatorial library" refers to a directed
diversity chemical library, as set forth in U.S. Pat. No.
5,463,564. Regardless of the manner in which a combinatorial
library is constructed, each molecule or compound in the library is
catalogued for future reference.
[0090] The term "compound library" refers to a plurality of
molecules or compounds which were not formed using the
combinatorial approach of combining chemical or biochemical
building blocks. Instead, a compound library is a plurality of
molecules or compounds which are accumulated and are stored for use
in future ligand-receptor binding assays. Each molecule or compound
in the compound library is catalogued for future reference.
[0091] The terms "multiplicity of molecules," "multiplicity of
compounds," or "multiplicity of containers" refer to at least two
molecules, compounds, or containers.
[0092] The term "multi-variable" refers to more than one
experimental variable.
[0093] The term "screening" refers to the testing of a multiplicity
of molecules or compounds for their ability to bind to a target
molecule which is capable of unfolding. Screening is a repetitive,
or iterative, process, in which molecules are tested for binding to
a target molecule (e.g, a protein receptor) in a thermal shift
assay. For example, if none of a subset of molecules from the
multiplicity of molecules (e.g., a combinatorial library) bind to
the target molecule, then a different subset is tested for binding
in a thermal shift assay.
[0094] The term "ranking" refers to the ordering of the affinities
of a multiplicity of molecules or compounds for a target molecule,
according to the ability of the molecule or compound to shift the
thermal unfolding information (e.g., thermal unfolding T.sub.m)
obtained for the target molecule, relative to the thermal unfolding
information of the target molecule in the absence of any molecule
or compound.
[0095] The term "high-throughput" encompasses screening activity in
which human intervention is minimized, and automation is maximized.
For example, high-throughput screening involves automated
pipetting, mixing, and heating, software-controlled generation of
thermal unfolding information, and software-controlled comparisons
of thermal unfolding information. Alternatively, a high-throughput
method is one in which hundreds of compounds can be screened per 24
hour period by a single individual operating a single suitable
apparatus.
[0096] "Performed automatically" means that at least some aspects
of the screening process are performed by a machine, and optionally
are computer-controlled.
[0097] The term "ranking" also refers to the ordering of the
efficacies of a multiplicity of biochemical conditions in
optimizing protein stabilization, protein folding, protein
crystallization, or protein shelf life. In the context of
optimization of protein stabilization, optimization of protein
folding, optimization of protein crystallization, and optimization
of protein shelf life, the term "ranking" refers to the ordering of
the efficacies of one or more combinations of biochemical
conditions to shift the thermal unfolding information (e.g.,
thermal unfolding T.sub.m) obtained for the target molecule,
relative to the thermal unfolding information of the target
molecule under a reference set of conditions.
[0098] As discussed above, ranking molecules, compounds, or
biochemical conditions according to a change in the T.sub.m is
preferable. Alternatively, molecules, compounds, or biochemical
conditions can be ranked for their ability to stabilize a target
molecule according to the change in entire thermal unfolding
curve.
[0099] As used herein, the terms "protein" and "polypeptide" are
synonymous. For proteins or peptides, the term "unfolding"
encompasses any change in structure due to heating. For example,
the term "unfolding" refers to the transition of from the liquid
crystalline state to the molten globule state. In the molten
globule state, tertiary and quaternary structure has been altered,
relative to the native state of the protein, and at least some
secondary structure remains intact. The term "unfolding" also
encompasses loss of crystalline ordering of amino acid side-chains,
secondary, tertiary or quaternary structure. The term "unfolding"
also encompasses formation of a random coil.
[0100] The terms "folding," "refolding," and "renaturing" refer to
the acquisition of the correct amino acid side-chain ordering,
secondary, tertiary, or quaternary structure, of a protein or a
nucleic acid, which affords the full chemical and biological
function of the biomolecule.
[0101] The term "denatured protein" refers to a protein which has
been treated to remove native amino acid side-chain ordering,
secondary, tertiary, or quaternary structure. The term "native
protein" refers to a protein which possesses the degree of amino
acid side-chain ordering, secondary, tertiary or quaternary
structure that provides the protein with full chemical and
biological function. A native protein is one which has not been
heated and has not been treated with a chemical unfolding agent,
such as urea.
[0102] For nucleic acids, the term "unfolding" refers to the loss
of secondary, tertiary and quaternary structure through unfolding,
uncoiling, untwisting or loss of helical structure. The loss of
double- or triple-helical structure through the interruption of
base-paring is an example of unfolding of a nucleic acid.
[0103] The terms "unfolded nucleic acid" and "denatured nucleic
acid" refer to a nucleic acid which has been treated to remove
folded, coiled, helical, or twisted structure. Unfolding of a
triple-stranded nucleic acid complex is complete when the third
strand has been removed from the two complementary strands.
Unfolding of a double-stranded DNA is complete when the base
pairing between the two complementary strands has been interrupted
and has resulted in single-stranded DNA molecules that have assumed
a random form. Unfolding of single-stranded RNA is complete when
intramolecular hydrogen bonds have been interrupted and the RNA has
assumed a random, non-hydrogen bonded form.
[0104] An "unfolding curve" is a plot of the physical change
associated with the unfolding of a protein as a function
temperature, denaturant concentration, pressure, etc. An unfolding
curve can be generated digitally or by plotting on paper or a
computer screen. A "thermal unfolding curve" is a plot of the
physical change associated with the unfolding of a protein or a
nucleic acid as a function of temperature. See, for example,
Davidson et al., Nature Structure Biology 2:859 (1995); and Clegg,
R. M. et al., Proc. Natl. Acad. Sci. U.S.A. 90:2994-2998 (1993). A
thermal unfolding curve can be generated digitally or by plotting
on paper or a computer screen, Preferably, a thermal unfolding
curve is generated digitally
[0105] The "midpoint temperature, T.sub.m" is the temperature
midpoint of a thermal unfolding curve. At the temperature midpoint
T.sub.m, one half of the target molecules in a sample are unfolded,
and one half of the target molecules in the sample remain folded.
The T.sub.m can be readily determined using methods well known to
those skilled in the art. See, for example, Weber, P. C. et al., J.
Am. Chem. Soc. 116:2717-2724(1994); Clegg, R. M. et al., Proc.
Natl. Acad. Sci. U.S.A. 90:2994-2998 (1993). Preferably, the
T.sub.m is extracted digitally from a digital thermal unfolding
curve
[0106] "Thermal unfolding information" is information relating to
target molecule unfolding in response to heating. For example, a
thermal unfolding curve is one kind of thermal unfolding
information. A thermal unfolding curve can be plotted on a computer
screen, or on paper. Preferably, a thermal unfolding curve is
generated digitally, using computer software, and may then be
visualized on a computer screen. More preferably, thermal unfolding
information is thermal unfolding T.sub.m. A digitally generated
thermal unfolding curve need not be printed or displayed in order
for the thermal unfolding T.sub.m to be extracted from the
digitally generated curve. Most preferably, the thermal unfolding
T.sub.m is digitally extracted from a digitally generated thermal
unfolding curve.
[0107] When thermal unfolding information is generated digitally,
five fitting parameters are evaluated: (1) y.sub.f, the
pre-transitional fluorescence for the native protein; (2) y.sub.u,
the post-transitional fluorescence for the unfolded protein; (3)
T.sub.m, the temperature at the midpoint for the unfolding
transition; (4) .DELTA.H.sub.u, the van't Hoff unfolding enthalpy
change; and (5) .DELTA.C.sub.pu, the change in heat capacity upon
protein unfolding. The non-linear least squares curve fitting can
be performed using a suitable software, such as KALEIDAGRAP.TM. 3.0
software (Synergy Software, Reading Pa.), which allows the five
fitting parameters to float while utilizing Marquardt methods for
the minimization of the sum of the squared residuals. The
temperature midpoint T.sub.m is extracted from the digitally
generated thermal unfolding information.
[0108] The term "lead molecule" refers to a molecule or compound,
from a combinatorial library, which displays relatively high
affinity for a target molecule. The terms "lead compound" and "lead
molecule" are synonymous. The term "relatively high affinity"
relates to affinities in the K.sub.d range of from 10.sup.-4 to
10.sup.-15 M.
[0109] The term "target molecule" encompasses peptides, proteins,
nucleic acids, and other receptors. The term encompasses both
enzymes, and proteins which are not enzymes. The term encompasses
monomeric and multimeric proteins. Multimeric proteins may be
homomeric or heteromeric. The term encompasses nucleic acids
comprising at least two nucleotides, such as oligonucleotides.
Nucleic acids can be single-stranded, double-stranded or
triple-stranded. The term encompasses a nucleic acid which is a
synthetic oligonucleotide, a portion of a recombinant DNA molecule,
or a portion of chromosomal DNA. The term target molecule also
encompasses portions of peptides, proteins, and other receptors
which are capable of acquiring secondary, tertiary, or quaternary
structure through folding, coiling or twisting. The target molecule
may be substituted with substituents including, but not limited to,
cofactors, coenzymes, prosthetic groups, lipids, oligosaccharides,
or phosphate groups.
[0110] The terms "target molecule" and "receptor" are synonymous.
The term "target molecule" refers more specifically to proteins
involved in the blood coagulation cascade, fibroblast growth
factors, fibroblast growth factor receptors, urokinase, and factor
D.
[0111] Examples of target molecules are included, but not limited
to those disclosed in Faisst, S. et al., Nucleic Acids Research
20:3-26 (1992); Pimentel, E., Handbook of Growth Factors, Volumes
I-III, CRC Press, (1994); Gilman, A. G. et al., The Pharmacological
Basis of Therapeutics, Pergamon Press (1990); Lewin, B., Genes V,
Oxford University Press (1994); Roitt, I., Essential Immunology,
Blackwell Scientific Publ. (1994); Shimizu, Y., Lymphocyte Adhesion
Molecules, R G Landes (1993); Hyams, J. S. et al., Microtubules,
Wiley-Liss (1995); Montreuil, J. et al., Glycoproteins, Elsevier
(1995); Woolley, P., Lipases: Their Structure Biochemistry and
Applications, Cambridge University Press (1994); Kurjan, J., Signal
Transduction: Prokaryotic and Simple Eukaryotic Systems, Academic
Press (1993); Kreis, T., et al., Guide Book to the Extra Cellular
Matrix and Adhesion Proteins, Oxford University Press (1993);
Schlesinger, M. J., Lipid Modifications of Proteins, CRC Press
(1992); Conn, P. M., Receptors: Model Systems and Specific
Receptors, Oxford University Press (1993); Lauffenberger, D. A. et
al., Receptors: Models For Binding Trafficking and Signaling,
Oxford University Press (1993); Webb, E. C., Enzyme Nomenclature,
Academic Press (1992); Parker, M. G., Nuclear Hormone Receptors;
Molecular Mechanisms, Cellular Functions Clinical Abnormalities,
Academic Press Ltd. (1991); Woodgett, J. R., Protein Kinases,
Oxford University Press (1995); Balch, W. E. et al., Methods in
Enzymology, 257, Pt. C: Small GTPases and Their Regulators:
Proteins Involved in Transport, Academic Press (1995); The
Chaperonins, Academic Press (1996); Pelech, L., Protein Kinase
Circuitry in Cell Cycle Control, R G Landes (1996); Atkinson,
Regulatory Proteins of the Complement System, Franklin Press
(1992); Cooke, D. T. et al., Transport and Receptor Proteins of
Plant Membranes: Molecular Structure and Function, Plenum Press
(1992); Schumaker, V. N., Advances in Protein Chemistry:
Lipoproteins, Apolipoproteins, and Lipases, Academic Press (1994);
Brann, M., Molecular Biology of G-Protein-Coupled Receptors:
Applications of Molecular Genetics to Pharmacology, Birkhauser
(1992); Konig, W., Peptide and Protein Hormones: Structure,
Regulations, Activity--A Reference Manual, VCH Publ. (1992); Tuboi,
S. et al., Post-Translational Modification of Proteins, CRC Press
(1992); Heilmeyer, L. M., Cellular Regulation by Protein
Phosphorylation, Springer-Verlag (1991); Takada, Y., Integrin: The
Biological Problem, CRC Press (1994); Ludlow, J. W., Tumor
Suppressors: Involvement in Human Disease, Viral Protein
Interactions, and Growth Regulation, R G Landes (1994);
Schlesinger, M. J., Lipid Modification of Proteins, CRC Press
(1992); Nitsch, R. M., Alzheimer's Disease: Amyloid Precursor
Proteins, Signal Transduction, and Neuronal Transplantation, New
York Academy of Sciences (1993); Cochrane, C. G. et al., Cellular
and Molecular Mechanisms of Inflammation, Vol. 3: Signal
Transduction in Inflammatory Cells, Part A, Academic Press (1992);
Gupta, S. et al., Mechanisms of Lymphocyte Activation and Immune
Regulation IV: Cellular Communications, Plenum Press (1992); Authi,
K. S. et al,, Mechanisms of Platelet Activation and Control, Plenum
Press (1994); Grunicke, H., Signal Transduction Mechanisms in
Cancer, R G Landes (1995); Latchman, D. S., Eukaryotic
Transcription Factors, Academic Press (1995).
[0112] The term "molecule" refers to the compound which is tested
for binding affinity for the target molecule. This term encompasses
chemical compounds of any structure, including, but not limited to
nucleic acids and peptides. More specifically, the term "molecule"
encompasses compounds in a compound or a combinatorial library.
[0113] The term "fluorescence" encompasses the release of
fluorescent energy. Less broadly, the term "fluorescence" refers to
fluorescent emission, the rate of change of fluorescence over time
(i.e., fluorescence lifetime), fluorescence polarization,
fluorescence anisotropy, and fluorescence resonance energy
transfer. See Eftink, M. R., Biophysical J. 66: 482-501 (1994).
[0114] The term "contacting a target molecule" refers broadly to
placing the target molecule in solution with the molecule to be
screened for binding or with the condition(s) to be tested for
stabilizing the target molecule. Less broadly, contacting refers to
the turning, swirling, shaking or vibrating of a solution of the
target molecule and the molecule to be screened for binding. More
specifically, contacting refers to the mixing of the target
molecule with the molecule to be tested for binding. Mixing can be
accomplished, for example, by repeated uptake and discharge through
a pipette tip, either manually or using an automated pipetting
device. Preferably, contacting refers to the equilibration of
binding between the target molecule and the molecule to be tested
for binding. Contacting can occur in the container (infra) or
before the target molecule and the molecule to be screened are
placed in the container.
[0115] The target molecule may be contacted with a nucleic acid
prior to being contacted with the molecule to be screened for
binding. The target molecule may be complexed with a peptide prior
to being contacted with the molecule to be screened for binding.
The target molecule may be phosphorylated or dephosphorylated prior
to being contacted with the molecule to be screened for
binding.
[0116] A carbohydrate moiety may be added to the target molecule
before the target molecule is contacted with the molecule to be
screened for binding. Alternatively, a carbohydrate moiety may be
removed from the target molecule before the target molecule is
contacted with the molecule to be screened for binding.
[0117] The term "container" refers to any vessel or chamber in
which the receptor and molecule to be tested for binding can be
placed. The term "container" encompasses reaction tubes (e.g., test
tubes, microtubes, vials, etc.). In the methods of the present
invention, the the term "container" preferably refers to a well in
a multiwell microplate or multiwell microtiter plate.
[0118] The term "sample" refers to the contents of a container.
[0119] The terms "spectral emission," "thermal change" and
"physical change" encompass the release of energy in the form of
light or heat, the absorption of energy in the form or light or
heat, changes in turbidity and changes in the polar properties of
light. Specifically, the terms refer to fluorescent emission,
fluorescent energy transfer, absorption of ultraviolet or visible
light, changes in the polarization properties of light, changes in
the polarization properties of fluorescent emission, changes in the
rate of change of fluorescence over time (i.e., fluorescence
lifetime), changes in fluorescence anisotropy, changes in
fluorescence resonance energy transfer, changes in turbidity, and
changes in enzyme activity. Preferably, the terms refer to
fluorescence, and more preferably to fluorescence emission.
Fluorescence emission can be intrinsic to a protein or can be due
to a fluorescence reporter molecule. The use of fluorescence
techniques to monitor protein unfolding is well known to those of
ordinary skill in the art. For example, see Eftink, M. R.,
Biophysical J. 66: 482-501 (1994).
[0120] The fluorescence microplate thermal shift assay is disclosed
in U.S. patent application Nos. 08/853,464 and 08/853,459, filed
May 9, 1997, and in international patent Appl. No. PCT/US97/08154
(published Nov. 13, 1997 as publication no. WO 97/42500).
[0121] A 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole
"derivative" dye is a molecule that comprises the
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)- oxazole structure. In the
methods of the present invention,
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dyes can
be selected from the group consisting of the following
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dyes:
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole butylsulfonamide,
or a salt or ester thereof; 5-(4
"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-(-
2-aminoethyl)sulfonamide, or a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-3-sulfonamidophyenylboron-
ic acid, or a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-phen- yl)oxazole sulfonic acid, or
a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonyl hydrazine,
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-(2-bromoacetamidoethyl)su-
lfonamide, or a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-ph-
enyl)oxazole-2-(3-(2-pyridyldithio) propionamidoethyl)sulfonamide,
or a salt or ester thereof;
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonyl chloride,
or a salt or ester thereof; 5-(4"-dimethylaminophenyl)-
-2-(4'-phenyl)oxazole-3-sulfonamidopropionic acid, or a salt or
ester thereof; 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole
carboxylic acid, or a salt or ester thereof; and
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)o- xazole sulfonate, or a
salt or ester thereof.
[0122] Examples of acid salts are hydrochloric, nitric, sulfuric,
phosphoric, formic, acetic, trifluoroacetic, propionic, maleic,
succinic, malonic, methane sulfonic and the like, salts formed from
cations such as sodium, potassium, aluminum, calcium, lithium,
magnesium, zinc, and from bases such as ammonia, ethylenediamine,
N-methyl-glutamine, lysine, arginine, ornithine, choline,
N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine,
procaine, N-benzylphenethylamine, diethylamine, piperazine,
tris(hydroxymethyl)aminomethane, and tetramethylammonium
hydroxide.
[0123] The ester can be methyl; ethyl; butyl; acetate; maleate;
pivaloyloxymethyl; phenyl; substituted phenyl; alkyl; benzyl;
pivaloyloxymethyl; methoxyrnethyl; (1-6C)alkanoyloxymethyl esters,
for example pivaloyloxymethyl, phthalidyl esters;
(3-8C)cycloalkoxycarbonylox- y esters; (1-6C)alkyl esters, for
example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl
esters, for example 5-methyl-1,3-dioxolen-2-ony- lmethyl;
(1-6C)alkoxycarbonyloxyethyl esters; phosphate esters;
alpha-acyloxyalkyl ethers and related compounds which as a result
of the in-vivo hydrolysis of the ester breakdown to give the parent
hydroxy group acetoxymethoxy and
2,2-dimethylpropionyloxymethoxy.
[0124] 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole dyes can be
purchased from Molecular Probes, Inc., Eugene, Oreg., and such dyes
are provided in Diwu, Z. et al., Photochemistry and Photobiology
66(4): 424-431 (1997), and in BioProbes 25: pp. 8-9, Molecular
Probes, Inc., Eugene, Oreg. (1997). Such dyes include
5-(4"-dimethylaminophenyl)-2-(4'-- phenyl)oxazole butylsulfonamide
(Molecular Probes catalogue no. D-12801),
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-(2-aminoethyl)sulfonamide
(Molecular Probes catalogue no. D-10460),
5-(4"-dimethylaminophenyl)-2-(4-
'-phenyl)oxazole-3-sulfonamidophyenylboronic acid (Molecular Probes
catalogue no. D-10402),
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonic acid,
sodium salt (Molecular Probes catalogue no. D-12800),
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonyl hydrazine
(Molecular Probes catalogue no. D-10430),
5-(4"-dimethylaminophenyl)-2-(4-
'-phenyl)oxazole-(2-bromoacetamidoethyl)sulfonamide (Molecular
Probes catalogue no. D-10300),
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-2-
-(3-(2-pyridyldithio) propionamidoethyl)sulfonamide (Molecular
Probes catalogue no. D-10301),
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonyl chloride
(Molecular Probes catalogue no. D-10160),
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole-3-sulfonamidopropionic
acid, succinimidyl ester (Molecular Probes catalogue no. D-10162),
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole carboxylic acid,
succinimidyl ester (Molecular Probes catalogue no. D-10161).
[0125] In the methods of the present invention, the
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dye is
preferably 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole
sulfonate, sodium salt (MolecularProbes catalogue no. D-12800).
[0126] 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative
dye provide a higher fluorescence signal than does
1-anilinonaphthalene-8-sul- fonate (1,8-ANS).
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dyes can
be used to monitor fluorescence associated with protein unfolding
in at a wavelength from about 475 nm to about 570 nm, more
preferably from about 500 nm to about 550 nm, and still more
preferably at about 500 nm or 525 nm.
[0127] Methods for synthesizing other
5-(4"-dimethylaminophenyl)-2-(4'-phe- nyl)oxazole derivative dyes
are well known to those of ordinary skill in the art. For example,
see Diwu, Z. et al, Photochemistry and Photobiology 66(4): 424-431
(1997).
[0128] The term "fluorescence probe molecule" refers to an
extrinsic fluorophore, which is a fluorescent molecule or a
compound which is capable of associating with an unfolded or
denatured receptor and, after excitement by light of a defined
wavelength, emits fluorescent energy. The term fluorescence probe
molecule encompasses all fluorophores. More specifically, for
proteins, the term encompasses fluorophores such as thioinosine,
and N-ethenoadenosine, formycin, dansyl, dansyl derivatives,
fluorescein derivatives, 6-propionyl-2-(dimethylamino)-napthalene
(PRODAN), 2-anilinonapthalene, and N-arylamino-naphthalene
sulfonate derivatives such as 1-anilinonaphthalene-8-sulfonate
(1,8-ANS), 2-anilinonaphthalene-6-sulfonate (2,6-ANS),
2-amino-naphthalene-6-sulfona- te,
N,N-dimethyl-2-aminonaphthalene-6-sulfonate,
N-phenyl-2-aminonaphthal-- ene,
N-cyclohexyl-2-aminonaphthalene-6-sulfonate,
N-phenyl-2-amino-naphtha- lene-6-sulfonate,
N-phenyl-N-methyl-2-aminonaphthalene-6-sulfonate,
N-(o-toluyl)-2-amino-naphthalene-6-sulfonate,
N-(m-toluyl)-2-amino-naphth- alene-6-sulfonate,
N-(p-toluyl)-2-aminonaphthalene-6-sulfonate,
2-(p-toluidinyl)-naphthalene-6-sulfonic acid (2,6-TNS),
4-(dicyanovinyl) julolidine (DCVJ),
6-dodecanoyl-2-dimethylaminonaphthalene (LAURDAN),
6-hexadecanoyl-2-(((2-(trimethylammonium)ethyl)methyl)-amino)naphthalene
chloride (PATMAN), nile red, N-phenyl-1-naphthylamine,
1,1-dicyano-2-[6-(dimethylamino)naphthalen-2-yl]propene (DDNP),
4,4'-dianilino-1,1-binaphthyl-5,5-disulfonic acid (bis-ANS), and
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole derivative dyes,
sold under the trademark DAPOXYL.TM. (Molecular Probes, Inc.,
Eugene, Oreg.), including the
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole dyes provided in
Diwu, Z. et al., Photochemistry and Photobiology 66(4): 424-431
(1997), and in BioProbes 25: pp. 8-9, Molecular Probes, Inc.,
Eugene, Oreg. (1997).
[0129] If the target molecule or receptor to be studied is a
nucleic acid, fluorescence spectrometry can be performed using
fluorescence resonance emission transfer. The transfer of
fluorescent energy, from a donor fluorophore on one strand of an
oligonucleotide to an acceptor fluorophore on the other strand, is
monitored by measuring the fluorescence of the acceptor
fluorophore. Unfolding or denaturation prevent the transfer of
fluorescent energy. The fluorescence resonance emission transfer
methodology is well known to those skilled in the art. Fore
example, see Ozaki, H. et al., Nucleic Acids Res. 20:5205-5214
(1992); Clegg, R. M. et al., Proc. Natl. Acad. Sci. U.S.A.
90:2994-2998 (1993); Clegg, R. M. et al., Biochemistry 31:4846-4856
(1993).
[0130] One strand of a double-stranded oligonucleotide will contain
the donor fluorophore. The other strand of the oligonucleotide will
contain the acceptor fluorophore. For a nucleic acid to "contain" a
donor or an acceptor fluorophore, the fluorophore can be
incorporated directly into the oligonucleotide sequence.
Alternatively, the fluorophore can be attached to either the 5'- or
3'-terminus of the oligonucleotide.
[0131] A donor fluorophore is one which, when excited by light,
will emit fluorescent energy. The energy emitted by the donor
fluorophore is absorbed by the acceptor fluorophore. The term
"donor fluorophore" encompasses all fluorophores including, but not
limited to, carboxyfluorescein, iodoacetamidofluorescein, and
fluorescein isothiocyanate. The term "acceptor fluorophore"
encompasses all fluorophores including, but not limited to,
iodoacetamidoeosin and tetramethylrhodamine.
[0132] The term "carrier" encompasses a platform or other object,
of any shape, which itself is capable of supporting at least two
containers. The carrier can be made of any material, including, but
not limited to glass, plastic, or metal. Preferably, the carrier is
a multiwell microplate. The terms microplate and microtiter plate
are synonymous. The carrier can be removed from the heating
element. In the present invention, a plurality of carriers are
used. Each carrier holds a plurality of wells.
[0133] The term "biochemical conditions" encompasses any component
of a physical, chemical, or biochemical reaction. Specifically, the
term refers to conditions of temperature, pressure, protein
concentration, pH, ionic strength, salt concentration, time,
electric current, potential difference, concentrations of cofactor,
coenzyme, oxidizing agents, reducing agents, detergents, metal ion,
ligands, or glycerol.
[0134] The term "efficacy" refers to the effectiveness of a
particular set of biochemical conditions in facilitating the
refolding or renaturation of an unfolded or denatured protein.
[0135] The term "reference set of conditions" refers to a set of
biochemical conditions under which thermal unfolding information
for a target molecule is obtained. Thermal unfolding information
obtained under conditions different than the reference conditions
is compared to the thermal unfolding information obtained for the
target molecule under reference conditions.
[0136] The term "polarimetric measurement" relates to measurements
of changes in the polarization of fluorescence.
[0137] The term "collection" refers to a pool or a group of at
least two molecules to be tested for binding to a target molecule
or receptor in a single container.
[0138] A "host" is a bacterial cell that has been transformed with
recombinant DNA for the purpose of expressing protein which is
heterologous to the host bacterial cell.
[0139] The fluorescence thermal shift assay is based on the
ligand-dependent change in thermal unfolding information (e.g., the
T.sub.m) of a target receptor, such as a protein or a nucleic acid.
When heated over a range of temperatures, a receptor will unfold.
By plotting the degree of unfolding as a function of temperature,
one obtains a thermal unfolding curve for the receptor. Naturally,
a thermal unfolding curve can be generated digitally, using
computer software. The temperature midpoint T.sub.m is the
temperature at which one half of the receptor molecules are
unfolded, and one half of the molecules remain folded.
[0140] Ligand binding stabilizes the receptor (Schellman, J.,
Biopolymers 14:999-1018 (1975)). The extent of binding and the free
energy of interaction follow parallel courses as a function of
ligand concentration (Schellman, J., Biophysical Chemistry
45:273-279 (1993); Barcelo, F. et al., Chem. Biol. Interactions
74:315-324 (1990)). As a result of stabilization by ligand, more
energy (heat) is required to unfold the receptor. Thus, ligand
binding shifts the thermal unfolding information (e.g., the
T.sub.m). This property can be exploited to determine whether a
ligand binds to a receptor: a change, or "shift", in the thermal
unfolding information, and thus means that the ligand binds to the
receptor.
[0141] The thermodynamic basis for the thermal shift assay has been
described by Schellman, J. A. (Biopolymers 15:999-1000 (1976)), and
also by Brandts et al. (Biochemistry 29:6927-6940 (1990)).
Differential scanning calorimetry studies by Brandts et al.,
(Biochemistry 29:6927-6940 (1990)) have shown that for tight
binding systems of 1:1 stoichiometry, in which there is one
unfolding transition, one can estimate the binding affinity at
T.sub.m from the following expression: 1 K L T m = exp { - H u T 0
R [ 1 T m - 1 T 0 ] + C pu R [ ln ( T m T 0 ) + T 0 T m - 1 ] } [ L
T m ] ( equation 1 )
[0142] where
[0143] K.sub.L.sup.T.sup..sub.m=the ligand association constant at
T.sub.m;
[0144] T.sub.m=the midpoint for the protein unfolding transition in
the presence of ligand;
[0145] T.sub.0=the midpoint for the unfolding transition in the
absence of ligand;
[0146] .DELTA.H.sub.u.sup.T.sup..sub.0=the enthalpy of protein
unfolding in the absence of ligand at T.sub.0;
[0147] .DELTA.C.sub.pu=the change in heat capacity upon protein
unfolding in the absence of ligand;
[0148] [L.sub.T.sub..sub.m]=the free ligand concentration at
T.sub.m; and
[0149] R=the gas constant.
[0150] The parameters .DELTA.H.sub.u and .DELTA.C.sub.pu are
usually observed from differential scanning calorimetry experiments
and are specific for each receptor. To calculate the binding
constant from equation 1, one should have access to a differential
scanning calorimetry instrument to measure .DELTA.H.sub.u, and
.DELTA.C.sub.pu for the receptor of interest. One can also locate
these parameters for the receptor of interest, or a receptor
closely related to it, in the literature. In these situations,
equation (1) will allow the accurate measurement of K.sub.L at
T.sub.m.
[0151] It is also possible to calculate the ligand equilibrium
association constant at any temperature, K.sub.L at T, using
equation 2. To use equation 2, calorimetry data for the binding
enthalpy at T, .DELTA.H.sub.L, and the change of heat capacity upon
ligand binding, .DELTA.C.sub.pL must be known (Brandts et al,
Biochemistry 29:6927-6940 (1990)). 2 K L T = K L T m exp { - H L T
R [ 1 T - 1 T m ] + C pL R [ ln ( T T m ) - T T m + 1 ] } (
equation 2 )
[0152] where
[0153] K.sub.L.sup.T=the ligand association constant at any
temperature T;
[0154] K.sub.L.sup.T.sup..sub.m=the ligand association constant at
T.sub.m;
[0155] T.sub.m=the midpoint for the protein unfolding transition in
the presence of ligand;
[0156] .DELTA.H.sub.L.sup.T=the enthalpy of ligand binding in the
absence of ligand at T;
[0157] .DELTA.C.sub.pL=the change in heat capacity upon binding of
ligand; and
[0158] R=the gas constant.
[0159] The second exponential term of equation 2 is usually small
enough to be ignored so that approximate values of K.sub.L at T can
be obtained using just the first exponential term: 3 K L T = K L T
m exp { - H L T R [ 1 T - 1 T m ] } ( equation 3 )
[0160] One need not, however, calculate binding constants according
to equations 1-3 in order to rank the affinities of a multiplicity
of different ligands for a receptor. The present invention provides
a method for ranking affinities of ligands according to differences
in thermal unfolding information for the target molecule in the
presence and absence of a ligand. Thus, it is possible to obtain
estimates of K.sub.L at T.sub.m, even in the absence of accurate
values of .DELTA.H.sub.u, .DELTA.C.sub.pu, and .DELTA.H.sub.L.
[0161] The present invention is particularly useful for screening a
combinatorial or a compound library, such as a directed diversity
chemical library. To achieve high throughput screening, it is best
to house samples on a multicontainer carrier or platform. A
multicontainer carrier facilitates the heating of a plurality of
samples simultaneously. In one embodiment, a multiwell microplate,
for example a 96 or a 384 well microplate, which can accommodate 96
or 384 different samples, is used as the carrier.
[0162] In one embodiment, one sample is contained in each well of a
multi-well microplate. The control well contains receptor, but no
molecule to be tested for binding. Each of the other samples
contains at least one molecule to be tested for binding. The
thermal unfolding information for the receptor in the control well
is compared to the thermal unfolding information for each of the
other samples.
[0163] The rate of screening is accelerated when the sample
contains more than one molecule to be tested for binding. For
example, the screening rate is increased 20-fold when the sample
contains a pool or collections of 20 molecules. Samples which
contain a binding molecule must then be divided into samples
containing a smaller collection of molecules to be tested for
binding. These divided collections must then be assayed for binding
to the target molecule. These steps must be repeated until a single
molecule responsible for the original thermal shift is
obtained.
[0164] The element upon which the sample carrier is heated can be
any element capable of heating samples rapidly and in a
reproducible fashion. In the present invention, a plurality of
samples is heated simultaneously. The plurality of samples can be
heated on a single heating element. Alternatively, the plurality of
samples can be heated to a given temperature on one heating
element, and then moved to another heating element for heating to
another temperature. Heating can be accomplished in regular or
irregular intervals. To generate a smooth unfolding transition, the
samples can be heated evenly, in intervals of 1 or 2.degree. C. The
temperature range across which the samples can be heated is from 25
to 110.degree. C. Fluorescence readings are taken after each
heating step. Samples can be heated and read by the fluorescence
device in a continuous fashion. Alternatively, after each heating
step, the samples may be cooled to a lower temperature prior to
taking the fluorescence readings. Preferably, the samples are
heated continuously and fluorescence readings are taken while the
samples are being heated.
[0165] Fluorescence readings can be taken on all of the samples in
the carrier simultaneously. Alternatively, readings can be taken on
samples in groups of at least two at a time. Finally, the readings
can be taken one sample at a time.
[0166] In one embodiment, thermal unfolding is monitored by
fluorescence using an assay apparatus such as the one shown in FIG.
29. The instrument consists of a scanner and a control software
system. The system is capable of quantifying soluble and
cell-associated fluorescence. Fluorescence is detected by a
photomultiplier tube in a light-proof detection chamber. The
software runs on a personal computer and the action of the scanner
is controlled through the software. A precision X-Y mechanism scans
the microplate with a sensitive fiber-optic probe to quantify the
fluorescence in each well. The microplate and samples can remain
stationary during the scanning of each row of the samples, and the
fiber-optic probe is then is moved to the next row. Alternatively,
the microplate and samples can be moved to position a new row of
samples under the fiber-optic probe. The scanning system is capable
of scanning 96 samples in under one minute. The scanner is capable
of holding a plurality of excitation filters and a plurality of
emission filters to measure the most common fluorophores. Thus,
fluorescence readings can be taken one sample at a time, or on a
subset of samples simultaneously. An alternate embodiment of the
assay apparatus is shown in FIG. 33.
[0167] The heat conducting element or block upon which the sample
carrier is heated can be any element capable of heating samples
rapidly and reproducibly. The plurality of samples can be heated on
a single heating element. Alternatively, the plurality of samples
can be heated to a given temperature on one heating element, and
then moved to another heating element for heating to another
temperature. Heating can be accomplished in regular or irregular
intervals. To generate a smooth thermal unfolding transition, the
samples should be heated evenly, in intervals of 1 or 20.degree. C.
The temperature range across which the samples can be heated is
from 4 to 110.degree. C.
[0168] In the present invention, a plurality of samples can be
heated simultaneously. If samples are heated in discrete
temperature intervals, in a stairstep fashion, fluorescence
readings are taken after each heating step. Alternatively, after
each heating step, the samples may be cooled to a lower temperature
prior to taking the fluorescence readings. Alternatively, samples
can be heated in a continuous fashion and fluorescence readings are
taken during heating.
[0169] The present invention also provides an improved method for
generating lead compounds. After a compound or a combinatorial
library of compounds has been screened using the thermal shift
assay, compounds which bind to the target receptor are chemically
modified to generate a second library of compounds. This second
library is then screened using the thermal shift assay. This
process of screening and generating a new library continues until
compounds that bind to the target receptor with affinities in the
K.sub.d range of from 10.sup.-4 to 10.sup.-15 M are obtained.
[0170] A fluorescence imaging system can be used to monitor the
thermal unfolding of a target molecule or a receptor. Fluorescence
imaging systems are well known to those skilled in the art. For
example, the AlphaImager.TM. Gel Documentation and Analysis System
(Alpha Innotech, San Leandro, Calif.) employs a high performancd
charge coupled device camera with 768.times.494 pixel resolution.
The charge coupled device camera is interfaced with a computer and
images are anlayzed with Image analysis software.TM.. The
CHEMIIMAGER.TM. (Alpha Innotech) is a cooled charge coupled device
that performs all of the functions of the ALPHAIMAGER.TM. and in
addition captures images of chemiluminescent samples and other low
intensity samples. The CHEMIIMAGER.TM. charge coupled device
includes a Pentium processor (1.2 Gb hard drive, 16 Mb RAM),
AlphaEase.TM. analysis software, a light tight cabinet, and a UV
and white light trans-illuminator. For example, the MRC-1024
UV/Visible Laser Confocal Imaging System (BioRad, Richmond, Calif.)
facilitates the simultaneous imaging of more than one fluorophore
across a wide range of illumination wavelengths (350 to 700 nm).
The Gel Doc 1000 Fluorescent Gel Documentation System (BioRad,
Richmond, Calif.) can clearly display sample areas as large as
20.times.20 cm, or as small as 5.times.4 cm. At least two 96 well
microplates can fit into a 20.times.20 cm area. The Gel Doc 1000
system also facilitates the performance of time-based
experiments.
[0171] A fluorescence thermal imaging system can be used to monitor
receptor unfolding in a microplate thermal shift assay. In this
embodiment, a plurality of samples is heated simultaneously at
temperatures between 25 to 110.degree. C. A fluorescence reading is
taken for each of the plurality of samples simultaneously. For
example, the fluorescence in each well of a 96 or a 384 well
microplate can be monitored simultaneously. Alternatively,
fluorescence readings can be taken continuously and simultaneously
for each sample. At lower temperatures, all samples display a low
level of fluorescence. As the temperature is increased, the
fluorescence in each sample increases. Wells which contain ligands
which bind to the target molecule with high affinity shift the
thermal unfolding T.sub.m to a higher temperature. As a result,
wells which contain ligands which bind to the target molecule with
high affinity fluoresce less, at a given temperature above the
T.sub.m of the target molecule in the absence of any ligands, than
wells which do not contain high-affinity ligands. If the samples
are heated in incremental steps, the flourescence of all of the
plurality of samples is simultaneoulsy imaged at each heating step.
If the samples are heated continuously, the fluorescence of all of
the plurality of samples is simultaneously imaged during
heating.
[0172] A fluorescence thermal shift assay can be performed in a
volume of 100 .mu.L. For the following reasons, however, it is
preferable to perform a thermal shift assay in a volume of 1-10
.mu.L. First, approximately 10- to 100-fold less protein is
required for the miniaturized assay. Thus, only .about.4 to 40
pmole of protein are required (0.1 .mu.g to 1.0 .mu.g for a 25 kDa
protein) for the assay (i.e. 1 to 10 .mu.L working volume with a
target molecule concentration of about 1 to about 4 .mu.M). Thus,
as little as 1 mg of protein can be used to conduct 1,000 to 10,000
assays in the miniaturized format. This is particularly
advantageous when the target molecule is available in minute
quantities.
[0173] Second, approximately 10- to 100-fold less ligand is
required for the miniaturized assay. This advantage is very
important to researchers when screening valuable combinatorial
libraries for which library compounds are synthesized in minute
quantities. In the case of human .alpha.-thrombin, the ideal ligand
concentration is about 50 .mu.M, which translates into 25-250
pmoles of ligand, or 10-100 ng (assuming a MW of 500 Da) of ligand
per assay in the miniaturized format.
[0174] Third, the smaller working volume allows the potential of
using larger arrays of assays because the miniaturized assay can
fit into a much smaller area. For example, a 384 well (16.times.24
array) or 864 well (24.times.36 array) plates have the same
dimensions as the 96 well plates (8.5.times.12.5 cm). The 384 well
plate and the 864 well plate allows the user to perform 4 and 9
times as many assays, respectively, as can be performed using a 96
well plate.
[0175] Alternatively, 1536 well plates (32.times.48 arrays; Matrix
Technologies Corp.) can be used. A 1536 well plate will facilitate
sixteen times the throughput afforded by a 96 well plate. Thus,
using the 1536 well plate configuration, the assay speed can be
increased by about 16 times, relative to the speed at which the
assay can be performed using the 96 well format. The 8.times.12
assay array arrangement (in a 96-well plate) facilitates the
performance of 96 assays/hr, or about 2300 assays/24 hours. The
32.times.48 array assay arrangement facilitates the performance of
about 1536 assays hr., or about 37,000 assays/24 hours can be
performed using a 32.times.48 assay array configuration.
[0176] Alternatively, microplates containing more than 1536 wells
per plate can be used in the methods of the present invention.
[0177] The assay volume can be 1-100 .mu.L. Preferably, the assay
volume is 1-50 .mu.L. More preferably, the assay volume is 1-25
.mu.L. More preferably still, the assay volume is 1-10 .mu.L. More
preferably still, the assay volume is 1-5 .mu.L. More preferably
still, the assay volume is 5 .mu.L. Most preferably, the assay
volume is 1 .mu.L or 2 .mu.L.
[0178] Preferably, the assay is performed in V-bottom polycarbonate
plates or polycarbonate dimple plates. A dimple plate is a plate
that contains a plurality of round-bottom wells that hold a total
volume of 15 .mu.L.
[0179] In the methods of the present invention, generation of
thermal unfolding information can further comprise determining a
thermal unfolding T.sub.m, and the comparing step comprises
comparing the T.sub.m for the target molecule in each container to
(i) the T.sub.m for the target molecule in each of the other
containers, and to (ii) the T.sub.m obtained for the target
molecule in the absence of any of the different molecules or
obtained under a reference set of biochemical conditions, and
wherein the ranking step comprises ranking the efficacies of the
multiplicity of different molecules or the multiplicity of
different biochemical conditions according to differences in the
T.sub.m.
[0180] In the methods of the present invention, the measuring step
comprise contacting the protein with the one or more different
molecules or different biochemical conditions, in the presence of a
fluorescence probe molecule present in each of the multiplicity of
containers, and wherein the measuring step comprises exciting the
fluorescence probe molecule, in each of the multiplicity of
containers with light; and measuring the fluorescence from each of
the multiplicity of containers.
[0181] In the methods of the present invention, when the target
molecule is a double-stranded oligonucleotide, one strand contains
a donor fluorophore and the other strand of the oligonucleotide
contains an acceptor fluorophore. the contacting step can comprise
contacting the oligonucleotide with the multiplicity of different
molecules, or with the multiplicity of different biochemical
conditions, in each of the multiplicity of containers, and wherein
the measuring step exciting the donor fluorophore, in each of the
multiplicity of containers, with light; and measuring the
fluorescence from the acceptor fluorophore in each of the
multiplicity of containers
[0182] In the methods of the present invention, fluorescence can be
measured in all of the containers simultaneously. Alternatively,
fluorescence can be measured in a subset of the containers
simultaneously. Alternatively, fluorescence can be measured one
container at a time.
[0183] One alternative to taking fluorescence readings over a
temperature range around the T.sub.m of the therapeutic target to
obtain a full thermal unfolding curve for the ligand/target
complex, in order to identify shifts in T.sub.m, is to perform the
assay at a single temperature near the T.sub.m of the target
molecule. In this embodiment, samples that fluorescence less,
relative to a control sample (containing a target molecule, but no
candidate ligand) indicate that the candidate ligand binds to the
target molecule.
[0184] In this embodiment, the fluorescence associated with the
thermal unfolding of a target molecule resulting from heating is
determined by generating thermal unfolding information for the
target molecule as a function of temperature over a range of one or
more discrete or fixed temperatures. The fluorescence associated
with thermal unfolding, is measured. The fluorescence at the
discrete or fixed temperature for the target molecule in the
absence of any ligand is noted. The fluorescence in the presence of
each of a multiplicity of different molecules, for example,
combinatorial compounds, is measured. The fluorescence associated
with thermal unfolding of the target molecule in the presence of
each of the multiplicity of molecules is compared to fluorescence
obtained for the target molecule at the discrete or fixed
temperature in the absence of any of the multiplicity of different
molecules. The affinities of the multiplicity of different
molecules are ranked according to the change in the
fluorescence.
[0185] The discrete or fixed temperature at which the fluorescence
is measured can be any temperature that is useful for
discriminating shifts in thermal stability. Preferably, the
discrete or fixed temperature is the midpoint temperature T.sub.m
for the target molecule in the absence of any of the multiplicity
of different molecules tested for binding to the target
molecule.
[0186] The methods of the present invention are not limited to
assaying ligand-protein interactions. The methods of the present
invention can be used to rapidly assay any multi-variable system
related to protein stabilization. For example, the methods of the
present invention can be used to simultaneously assay the binding
of more than one compound or ligand to a target molecule. Using
this approach, the additive effect of multiple-ligand binding can
be assessed. Positive and negative cooperativity can be determined.
To accomplish this method, fluorescence thermal shift assays are
performed for a target molecule, such as a protein, in the absence
of any ligands, in the presence of a single ligand, and in the
presence of two or more ligands. Thermal unfolding information is
generated for the protein alone and for each combination of protein
and ligand(s). The midpoint temperature T.sub.m is then determined
for the protein alone and for each combination. Each T.sub.m is
then compared to each of the other T.sub.m's for the other
combinations. Alternatively, an unfolding curve is generated for
the protein alone and for each combination, and each thermal
unfolding curve is compared to each of the other thermal unfolding
curves. In either of these manners, the additive contribution of
more than one ligand to binding interaction or to protein stability
can be determined.
[0187] In a similar fashion, the additive contributions of one or
more biochemical conditions to protein stability can be determined.
Thus, the present invention can be used to rapidly identify
biochemical conditions that optimize protein stabililty, and hence
shelf-life. of a protein. Further, the methods and the assay
apparatus of the present invention can be used to rank the
efficacies of various biochemical conditions for refolding or
renaturing an unfolded or denatured protein. This embodiment
addresses the need in the art for a reliable method for screening
for effective refolding or renaturing conditions.
[0188] For example, expression of recombinant DNA in a bacterial
cell usually results in the sequestration of recombinant protein
into bacterial inclusion bodies (Marston, F. A. O., Biochem. J.
240:1-12 (1986)). Although other expression systems can be used
instead of bacterial expression systems, expression in bacterial
cells remains the method of choice for the high-level production of
recombinant proteins (Rudolph, R., Protein Engineering: Principles
and Practices, pp. 283-298, John Wiley & Sons (1995)). In many
cases, recovery of recombinant protein requires that protein be
isolated from inclusion bodies. Protein purification from inclusion
bodies process necessitates the denaturation of recombinant
protein. As a result, recombinant protein must be renatured or
refolded under conditions suitable to generate the protein in its
native, fully functional form.
[0189] In each of these cases, denatured protein must be renatured
or refolded in order to be useful for further study or use.
Unfortunately, one cannot easily predict the exact conditions under
which a given protein or fragment of the protein should be
renatured. Each protein is different. One must always resort to
testing a number of different combinations of renaturing conditions
before one can know which set of conditions is optimal. Thus, it is
desirable to have a reliable and rapid method for ranking the
efficacies of various renaturing conditions.
[0190] Recombinant DNA technology has allowed the biosynthesis of a
wide variety of heterologous polypeptides of interest in relatively
large quantities through the recruitment of the bacterial protein
expression apparatus. However, the promise of cheap and abundant
supplies of correctly folded rare human proteins of high
therapeutic value expressed in E. coli has foundered due to the
overwhelmingly predominant aggregation of unfolded or partially
unfolded target proteins into insoluble protein inclusion bodies.
For recent reviews, see Rudolph, R., & Lilie, H., FASEB J.
10:49-56 (1995); Sadana, A., Biotechnology & Bioengineering
48:481-489 (1995); Jaenicke, R., Phil. Trans. Royal Soc. London
Ser. B-Biol. Sci. 348:97-105 (1995)). Reasons for the prevailing
self aggregation reaction in E. coli have centered on the
relatively high concentration of the heterologous protein (as high
as 30% of the weight of the cell) found to various degrees in
partially unfolded states. Thus, at the elevated protein
concentrations of an overexpressing E. coli strain, the exposed
hydrophobic residues of unfolded proteins are more likely to
encounter other molecules with similarly exposed groups
(inter-molecular reaction) than they are to sample self collapsed
polypeptide conformations where these hydrophobic residues are
packed in a proper orientation (intra-molecular transition state)
for proceeding to the fully folded native state (see FIG. 26). From
this perspective, the insoluble protein inclusion bodies are seen
as kinetically trapped side reaction products that thwart the
preferred protein folding process.
[0191] Techniques for isolating inclusion bodies, purifying
recombinant protein from inclusion bodies, and techniques for
refolding or renaturing protein are well known to those skilled in
the art. For example, see Sambrook, J. et al., Molecular Cloning: a
Laboratory Manual, pp. 17.37-17.41, Cold Spring Harbor Laboratory
Press (1989); Rudolph, R. et al., FASEB J. 10:49-56 (1995).
[0192] Another impediment to producing large quantities of
correctly folded proteins in E. coli is that the reducing redox
potential of the E. coli cytosol impedes the formation of disulfide
bonds in vivo. The formation of disulfide bonds is an important co-
and post-translational event in the biosynthesis of many
extracellular proteins that is often coupled to protein folding. In
addition, the cis-trans proline isomerization reaction has been
demonstrated to be a rate determining step for correct folding of
certain proteins (Lin, L.-N., & Brandts, J. F., Biochemistry
22:564-573 (1983)). As a result, partially folded intermediates
accumulate in sufficient quantity in vivo that they aggregate and
precipitate into protein masses.
[0193] Cells employ a class of host proteins called molecular
chaperonins that assist in vivo protein folding by apparently
preventing many of the unproductive side reactions discussed above
with regard to inclusion body formation, i.e. aggregation and
improper disulfide bond formation. However, the E. coli chaperonin
machinery, which is comprised in part by the proteins, GroEL and
GroES, presumably becomes overwhelmed by massive overexpression.
Despite many attempts to correct this chaperonin deficit by
co-expression of molecular chaperonins with the protein of interest
(Rudolph, R., & Lilie, H., The FASEB J. 10:49-56 (1995))
positive results have been reported in only one case (Goloubinoff,
P., et al., Nature 342:884-889 (1989)).
[0194] Two hypotheses have been promoted to explain how GroEL and
GroES assist in vivo protein folding. Under the first hypothesis,
the Anfinsen cage hypothesis, the function of a molecular
chaperonin is to provide a protected environment where folding of
the protein to its native state can proceed without interference by
pro-aggregation conditions in the cell (Martin, et al., Nature
352:36-42 (1991); Ellis, R. J., Current Biology 4:633-635 (1994)).
Under the second hypothesis, the "iterative annealing" hypothesis,
the function of the chaperonin is to partly unfold misfolded
proteins (that is, kinetically trapped intermediates) with some of
the energy of ATP hydrolysis being channeled into the
conformational energy of the substrate polypeptide, forcing the
polypeptide into a higher energy state from which it could once
again attempt to refold correctly after being released into
solution (Todd, M. J. et al., Science 265:659-666 (1994); Jackson,
et al., Biochemistry 32:2554-2563 (1993); Weissman, J. S., et al.,
Cell 78:693-702 (1994); Weissman, J. S., & Kim, P. S., Science
253:1386-1393 (1991)).
[0195] The in vivo results discussed above are in many ways
consistent with the more recent experiences with in vitro refolding
of recombinant heterologous proteins expressed in E. coli. That is,
while the primary amino acid sequence of a protein may contain
sufficient information to determine its native folded conformation
(Anfinsen, C. B., Science 181:223-230 (1973)), the biochemical
conditions in which the folding reaction takes place can strongly
influence the partitioning between unfolded, aggregated, and
correctly folded forms.
[0196] For example, pH can be understood to influence the folding
reaction by its effect on the long range electrostatic interactions
summed in the fourth term of the equation (4).
.DELTA.G.sub..function.old=.DELTA.G.sub.con.function.+.SIGMA..DELTA.g.sub.-
i,int+.SIGMA..DELTA.g.sub.i,s+.DELTA.W.sub.el+(.DELTA.G.sub.bind)
Equation (4)
[0197] where
[0198] .DELTA.G.sub.con.function.=conformational free energy
(order/disorder term);
[0199] .DELTA.g.sub.i,int=short range interactions (H-bonds, van
der Walls interactions, salt bridges, cofactor binding, etc.);
[0200] .DELTA.g.sub.i,s=short range interactions with solvent
(hydrophobic effect, hydration of ions, etc.); and
[0201] .DELTA.W.sub.el=long range electrostatic interactions.
[0202] .DELTA.G.sub.bind=ligand binding free energy
[0203] As the pH of a protein solution is lowered below the pI for
the protein, functional groups on the polypeptide become
increasingly protonated, to the point where the electrostatic
repulsion between functional groups eventually out balances the
other terms in the free energy equation (equation (4)), and the
protein is no longer able to adopt the native conformation.
[0204] Another important biochemical parameter for protein folding
is the solvent, water, which repels aliphatic and aromatic side
chains (and possibly the main chain to some extent) to minimize
their exposed surface area. The influence of solvent over the
folding reaction is summed in the third term of the free energy
equation (equation (4)). Certain salts are known to increase the
hydrophobic interaction among protein side chains in water
solutions. The effect depends upon the nature of the ions following
the Hofmeister series: Cations: Mg.sup.2+>Li.sup.+>Na.sup-
.+>K.sup.+>NH.sub.4.sup.+. Anions:
SO.sub.4.sup.2->HPO.sub.4.sup.-
2->acetate>citrate>tartrate>Cl.sup.->NO.sub.3->ClO.sub.3-
.sup.->I.sup.->ClO.sub.4.sup.->SCN.sup.-. Stabilizing
Hofmeister anions, such as SO.sub.4.sup.2- and HPO.sub.4.sup.2- at
0.4 M have been found to increase the yield of correctly folded
proteins (Creighton, T. E., In: Proteins: Structures and Molecular
Properties, Freeman, New York, (1984)). This favorable outcome for
the native conformation of the protein has been attributed to the
cations' and anions' "salting out" effect which leads to the
preferential hydration of the protein (Creighton, T. E., In:
Proteins: Structures and Molecular Properties, Freeman, New York,
(1984)).
[0205] Glycerol alters the solvation properties of water to favor
the native conformation of proteins. The mechanism by which this
occurs is the co-solvent exclusion and preferential hydration of
the protein, not unlike the effect of salts of the salts of the
Hofmeister series (Timasheff & Arakawa, In: Protein Structure,
A Practical Approach, T. E. Creighton, ed., IRL Press, Oxford, UK
(1989), pp. 331-354).
[0206] Another example of how the environment influences protein
folding is the effect that known ligands and cofactors have on the
yield of folded protein. Ligand binding has the effect of shifting
the equilibrium from an unfolded state to a native-ligand complex
through a coupling of the binding free energy to that of the
folding reaction. The role of metal ions in the refolding of bovine
carbonic anhydrase II has been described (Bergenhem & Carlsson,
Biochim. Biophys. Acta 998:277-285 (1989)). Other biochemical
parameters that have been shown to affect protein folding are:
protein concentration, temperature, glutathione redox buffers (GSH,
GSSG), the presence of detergents, and the presence of other
additives, such as glycerol, arginine-HCl, polyethylene glycol
(PEG), and organic solvents.
[0207] During incubation under refolding conditions, recombinant
proteins can be immobilized to solid phase support. This
configuration resembles the "Anfinsen cage" hypothesis for the
function of GroEL and GroES where an unfolded protein becomes
temporarily immobilized in a protected environment where folding to
the native state can proceed without interference from competing
aggregation reactions. Confirmation of protein folding on solid
supports has now come from two recent reports in the literature. A
poly-histidine tagged TIMP-2 protein could be refolded by dialysis
while still bound to a metal chelate column (Negro, A. et al., FEBS
Lett. 360:52-56 (1995)). A polyionic fusion peptide attached to the
amino or carboxyl terminus of .alpha.-glucosidase allowed folding
while bound to heparin-Sepharose resin at about 5 mg/mL (Rudolph
& Lilie, FASEB J. 10:49-56 (1995)). A polyionic arginine tag
metholdology for immobilizing and refolding .alpha.-glucosidase is
disclosed in Stempfer, G. et al., Nature Biotechnology 14:329-334
(1996).
[0208] In the present invention, the thermal shift assay is used to
rank the efficacy of various refolding or renaturing conditions.
Each of a multiplicity of aliquots of a protein of interest, which
has been incubated under a variety of different biochemical folding
conditions, are placed in a container in a multicontainer carrier.
An aliquot of the native, fully functional protein of known
concentration is placed in the control container. The samples can
be placed in any multicontainer carrier. Preferably, each sample
can be placed in a well of a multiwell microplate.
[0209] In considering the many biochemical variables that can
influence the outcome of the protein folding reaction, optimization
of protein folding is a multi-variable optimization problem, not
unlike protein crystallization and quantitative structure activity
relationships (QSAR) in drug discovery. Multi-variable optimization
problems require large numbers of parallel experiments to collect
as much data as possible in order to influence a favorable
response. In this regard, both protein crystallization and QSAR
analyses have greatly benefited from mass screening protocols that
employ matrix arrays of incremental changes in biochemical or
chemical composition.
[0210] The present invention can be used to rank the efficacies of
refolding or renaturing conditions. Such conditions include, but
are not limited to, the concentration of glycerol, the
concentration of protein, the use of agents which catalyze the
formation of disulfide bond formation, temperature, pH, ionic
strength, type of solvent, the use of thiols such as reduced
glutathione (GSH) and oxidized glutathione (GSSG), chaotropes such
as urea, guanidinium chlorides, alkyl-urea, organic solvents such
as carbonic acid amides, L-arginine HCl, Tris buffer, polyethylene
glycol, nonionic detergents, ionic detergents, zwitterionic
detergents, mixed micelles, and a detergent in combination with
cyclodextrin. The present invention can be used regardless of
whether a denaturation agent is removed from the protein using
dialysis, column chromatographic techniques, or suction
filtration.
[0211] Using a fluorescence thermal shift assay, the conditions
which facilitate optimal protein refolding can be determined
rapidly. In this embodiment, the renatured protein samples and a
control protein sample (i.e., a sample of native protein in its
fully functional form) are heated over a temperature range. At
discrete temperature intervals, a fluorescence reading is taken.
Alternatively, fluorescence readings can be taken during a
continuous, pre-determined temperature profile. Thermal unfolding
information (for example, thermal unfolding T.sub.m) is generated
for each sample. The T.sub.m for the native, fully functional
reference protein is determined. The relative efficacies of the
refolding conditions are ranked according to the magnitude of the
fluorescence associated with unfolding at the T.sub.m of the
native, fully functional reference protein, relative to the
magnitude of the fluorescence of a known quantity of the sample
proteins in the biochemical conditions at that T.sub.m. The
magnitude of fluorescence intensity change is used to monitor
protein unfolding (reflected on the ordinate, or y-axis, of a
thermal unfolding curve) is proportional to the amount of correctly
folded protein.
[0212] The present invention provides a method for screening
biochemical conditions that facilitate and optimize protein
folding. To screen conditions for a given protein, it is first
necessary to determine the thermal unfolding profile for a protein
of interest. This is accomplished by generating thermal unfolding
information using the microplate thermal shift assay. Various
conditions can be optimized, including pH optimum, ionic strength
dependence, concentration of salts of the Hofmeister series,
glycerol concentration, sucrose concentration, arginine
concentration, dithiothreitol concentration, metal ion
concentration, etc.
[0213] Using the microplate thermal shift assay, one can determine
one or more biochemical conditions have an additive effect on
protein stability. Once a set of biochemical conditions that
facilitate an increase in protein stability have been identified
using the thermal shift assay, the same set of conditions can be
used in protein folding experiments with recombinant protein. See
FIG. 27. If the conditions that promote protein stability in the
thermal shift assay correlate with conditions that promote folding
of recombinant protein, conditions can be further optimized by
performing additional thermal shift assays until a combination of
stabilizing conditions that result in further increase protein
stability are identified. Recombinant protein is then folded under
those conditions. This process is repeated until optimal folding
conditions are identified. Protein stability is expected to
correlate with improved yields of protein folding. Yield of
correctly folded protein can be determined using any suitable
technique. For example, yield of correctly folded protein can be
calculated by passing refolded protein over an affinity column, for
example, a column to which a ligand of the protein is attached, and
quantifying the amount of protein that is present in the sample. In
this way, folding conditions can be assessed for their additive
contributions to correct folding. The transition state for the
protein folding reaction resembles the native form of the protein
more than the denatured form. This has been demonstrated to be the
case for may proteins (Fersht, A. R., Curr. Op. Struct. Biol. 7:3-9
(1997)).
[0214] The methods and the apparatus of the present invention
provide a rapid, high throughput approach to screening for
combinations of biochemical conditions that favor the protein
folding. The method does not require cumbersome and time consuming
steps that conventional approaches to protein folding require. For
example, using the method of the present invention, it is not
necessary to dilute protein to large volumes and low protein
concentrations (.about.10 .mu.g/mL) in order to avoid aggregation
problems associated with conventional methods of recombinant
protein refolding. Suppression of protein aggregation will allow
for screening biochemical parameters that shift the protein folding
equilibrium (between the unfolded and the folded forms of proteins)
to the correct native conformation.
[0215] Like protein stabilization, protein folding, ligand
selection, and drug design, selection of conditions that promote
protein crystallization is another multi-variable optimization
problem that is solved using the methods and the apparatus of the
present invention.
[0216] The methods of the present invention are also useful for
determining conditions that facilitate protein crystallization. The
crystallization of molecules from solution is a reversible
equilibrium process, and the kinetic and thermodynamic parameters
are a function of the chemical and physical properties of the
solvent system and solute of interest (McPherson, A., In:
Preparation and Analysis of Protein Crystals, Wiley Interscience
(1982); Weber, P. C., Adv. Protein Chem. 41:1-36 (1991)) 1991).
Under supersaturating conditions, the system is driven toward
equilibrium where the solute is partitioned between the soluble and
solid phase instead of the unfolded and native states. The
molecules in the crystalline phase pack in ordered and periodic
three dimensional arrays that are energetically dominated by many
of the same types of cohesive forces that are important for protein
folding, i.e. van der Waals interactions, electrostatic
interactions, hydrogen bonds, and covalent bonds (Moore, W. J., In:
Physical Chemistry, 4th Ed., Prentice Hall, (1972), pp.
865-898).
[0217] Thus, in many ways protein crystallization can be viewed as
a higher level variation of protein folding where whole molecules
are packed to maximize cohesive energies instead of individual
amino acid residues. Moreover, for both protein crystallization and
protein folding, the composition of the solvent can make very
important contributions to the extent of partitioning between the
soluble (unfolded) and crystalline (native) forms. The cohesive
interactions present in protein macromolecules and the role played
by solvent in modulating these interactions for both protein
folding and protein crystallization are complex and not fully
understood at the present time. In this regard, biochemical
conditions that promote protein stabililty and protein folding also
promote protein crystallization.
[0218] For example, biochemical conditions that were found to
increase the stability of D(II)FGF receptor 1 (FIGS. 19-24)
correlate with the conditions that facilitated the crystallization
of x-ray diffraction quality protein crystals. Conditions that were
employed to obtain crystals of D(II) FGFR1 protein are shown in
Table 1.
[0219] Protein crystals were obtained in the pH range 7.4 to 9.2 in
the presence of the Hofmeister salt Li.sub.2SO.sub.4 (65 to 72%).
These crystallization conditions correlated with the pH optimum of
about 8.0 in FIG. 23. Other salts of the Hofmeister series such as
Na.sub.2SO.sub.4, (NH.sub.4).sub.2SO.sub.4 and Mg.sub.2SO.sub.4
were also found useful as additives for lowering the amount of
Li.sub.2SO.sub.4 required as the precipitant. Clearly, these
conditions for successful D(II) FGFR1 crystallization correlate
closely with the stabilizing conditions that were identified using
the microplate thermal shift assay.
[0220] Conditions that were identified as facilitating human
.alpha.-thrombin stabilization also facilitate human
.alpha.-thrombin protein crystallization. FIGS. 17A-D and 18 show
the results of microplate thermal shift assays of conditions that
facilitate human .alpha.-thrombin stability. Table 2 contains a
summary of the conditions identified by three different
investigators that facilitate crystallization of x-ray diffraction
quality human .alpha.-thrombin crystals (Bode, W., et al., Protein
Sci. 1:426-471 (1992); Vijayalakshmi, J. et al., Protein Sci.
3:2254-22271 (1994); and Zdanov, A. et al., Proteins: Struct.
Funct. Genet. 17:252-265 (1993)).
[0221] The conditions summarized in Table 2 correlate closely with
the conditions identified in the microplate thermal shift assay as
facilitating human .alpha.-thrombin stability. Crystals formed near
a pH optimum of about 7.0. Furthermore, there is a clear preference
for the presence of 0.1 to 0.5 M NaCl (50% of the conditions) or
0.1 to 0.2 M NaBPO.sub.4. This is consistent with the recently
discovered Na.sup.+ binding site (Dang et al., Nature Biotechnology
15:146-149 (1997)) and microplate thermal shift assay results in
FIGS. 17A-D and 18. All of the human .alpha.-thrombin samples
described in Table 2 that have yielded good crystals are complexed
with a ligand, thereby further stabilizing the native structure of
this protein beyond that acquired from the biochemical
conditions.
1TABLE 1 D(II) FGFR1 Crystallization Conditions Buffer Precipitant
Additive Protein Concentration 50 mM Hepes pH 7.4 72% Li2SO4 10
mg/ml (10 mM Hepes pH 7.5) 50 mM Hepes pH 7.4 72% Li2SO4 3.4 mM
ZnSO4 10 mg/ml (10 mM Hepes pH 7.5) 50 mM Hepes pH 7.4 68% Li2SO4
1% PEG 8000 10 mg/ml (10 mM Hepes pH 7.5) 50 mM Hepes pH 7.4 66%
Li2SO4 3.4 mM Na2SO4 10 mg/ml (10 mM Hepes pH 7.5) 50 mM Hepes pH
7.4 66% Li2SO4 5.3 mM (NH4) 2SO4 10 mg/ml (10 mM Hepes pH 7.5) 50
mM Hepes pH 7.4 66% Li2SO4 2.1 mM MgSO4 10 mg/ml (10 mM Hepes pH
7.5) 10 mM Tris Hcl, 65% Li2SO4 10 mg/ml (10 mM Hepes pH 7.5) pH
8.0 20 mM glycine, 68% Li2SO4 10 mg/ml (10 mM Hepes pH 7.5) pH
5.2
[0222] Protein crystallization is a slow and tedious process that
has historically been the rate determining step for the x-ray
diffraction determination of protein and nucleic acid structures.
The method and apparatus of the present invention facilitate the
rapid, high-throughput elucidation of conditions that promote the
stability of a given protein and thus the formation of X-ray
quality protein crystals.
[0223] When a protein is more stable, it has fewer thermodynamic
motions that inhibit packing into a crystal lattice. With fewer
motions, the protein fits better into a crystal lattice. Using
conventional crystallization methods, crystallization experiments
are set up at room temperature for weeks at a time. Over time,
protein unfolding occurs. Using the methods of the present
invention, conditions that stabilize a protein are examined over a
temperature range.
[0224] In a further aspect of the present invention, an assay
apparatus is provided that includes a heating means for
simultaneously heating a plurality of samples, and a receiving
means for receiving fluorescence from the samples while the samples
are being heated. In yet a further aspect of the present invention,
an assay apparatus is provided that includes a temperature
adjusting means for simultaneously adjusting a temperature of a
plurality of samples in accordance with a pre-determined
temperature profile, and a receiving means for receiving
fluorescence from the samples while the temperature of the samples
is adjusted in accordance with the temperature profile.
[0225] In yet a further aspect, the present invention also provides
an assay apparatus that includes a movable platform on which are
disposed a plurality of heat conducting blocks. The temperature of
the heat conducting blocks, and their samples, are adjusted by a
temperature adjusting means. Each of the plurality of heat
conducting blocks is adapted to receive a plurality of samples. A
light source is provided for emitting an excitatory wavelength of
light for the samples. While the temperature of the samples is
being adjusted, a sensor detects the fluorescence from the samples
in response to the excitatory wavelength of light. The movable
platform is moved between heat conducting blocks to sequentially
detect fluorescence from the samples in each of the plurality of
heat conducting blocks.
[0226] The assay apparatus of the present invention is directed to
an automated temperature adjusting and fluorescence receiving
system that simultaneously adjusts the temperature of a
multiplicity of samples over a defined temperature range and
receives fluorescence from the samples. The assay apparatus of the
present invention is particularly useful for performing microplate
thermal shift assays of protein stability. The assay apparatus of
the present invention can be used to practice all of the methods of
the present invention.
2TABLE 2 Human .alpha.- Crystallization Conditions thrombin Protein
Complex Buffer Salt Precipitant Additive Conc. Comment
Vijayalakshmi et al. MDL-28050 75 mM NaHPO4 pH 7.3 0.375 M NaCl 1
mM NaN3 3 mg/ml protein (2.2 .ANG.) 100 mM NaHPO4 pH 7.3 24% PEG
4000 1 mM NaN3 well Hirugen/Hirulog 1 50 mM NaHPO4 pH 7.3 0.375 M
NaCl .5 mM NaN3 3-3.7 mg/ml protein (2.3 .ANG.) 0.1 M NaHPO4 pH 7.3
28% PEG 8000 1 mM NaN3 well FPAM + Hirugen 0.1 M NaHPO4 pH 7.3 5
mg/ml protein (2.5 .ANG.) 0.1 M NaHPO4 pH 7.3 28% PEG 8000 well
Hirulog 3 75 mM NaHPO4 pH 7.3 0.38 M NaCl 1 mM NaN3 5 mg/ml protein
(2.3 .ANG.) 0.1 M NaHPO4 pH 7.3 24% PEG 8000 1 mM NaN3 well Bode et
al. NAPAP 0.1 M KHPO4 pH 8.0 10 mg/ml protein (2.3 .ANG.) 0.1 M
KHPO4 pH 8.0 1.9 M NH4SO4 PPACK 2 mM MOPS pH 7 0.1 M NaCl 0.5% NaN3
10 mg/ml protein (1.9 .ANG.) 0.2 M PO4 pH 6-7 0.5 M NaCl 20% PEG
6000 well Zdanov et al. Hirutonin-2 50 mM NaHPO4 pH 5.5 0.1 M NaCl
10 mg/ml protein (2.1 .ANG.) 0.1 M Na Citrate pH 5.5 0.1 M NaCl 24%
PEG 4000 well
[0227] FIG. 29 shows a schematic diagram of one embodiment of an
assay apparatus 2900 of the present invention. Assay apparatus 2900
includes a heat conducting block 2912 that includes a plurality of
wells 2920 for a plurality of samples 2910. Heat conducting block
2912 is composed of a material that has a relatively high
coefficient of thermal conductivity, such as aluminum, stainless
steel, brass, teflon, and ceramic. Thus, heat conducting block 2912
can be heated and cooled to a uniform temperature but will not be
thermally conductive enough to require excess heating or cooling to
maintain a temperature.
[0228] Assay apparatus 2900 also includes a light source 2906 for
emitting an excitatory wavelength of light, shown generally at
2916, for the samples. Light source 2906 excites samples 2910 with
excitatory light 2916. Any suitable light source can be used. For
example a tungsten-halogen lamp can be used. Alternatively, a
Xenon-arc lamp, such as the Biolumin 960 (Molecular Dynamics) can
used. Alternatively, a high pressure mercury (Hg) Lamp can be used.
High pressure mercury lamps emit light of higher intensity than
Xenon (Xe) lamps. The intensity of light from a high pressure
mercury lamp is concentrated in specific lines, and are only useful
if the Hg lines are at suitable wavelengths for excitation of
particular fluorophores. Other types of light sources that could be
used include, a light-emitting diode, a light-emitting diode array,
a laser diode, or a laser diode array.
[0229] Some fluorescence plate readers employ lasers for excitation
in the visible region of the electromagnetic spectrum. For example,
the FluorImager.TM. (Molecular Dynamics, Palo Alto, Calif.) is such
a device. This technology is useful when using fluorescent dyes
that absorb energy at around 480 nm and emit energy at around 590
nm. Such a dye could then be excited with the 488 nm illumination
of standard argon, argon/krypton lasers. For example,
1,1-dicyano-2-[6-(dimethylamino)naphthalen-2-yl]prop- ene (DDNP) is
such a dye. The advantage in using a laser is that a laser is
characterized by very high intensity light, which results in an
improved signal to noise ratio.
[0230] Excitatory light 2916 causes fluorescence 2918 from samples
2910. Fluorescence 2918 is received by a photomultiplier tube 2904.
Photomultiplier tube 2904 is communicatively and operatively
coupled to a computer 2914 by an electrical connection 2902.
Computer 2914 functions as a data analysis means for analyzing
fluorescence as a function of temperature.
[0231] As discussed above, the fluorescence receiving means or
sensor of the assay apparatus of the present invention can comprise
a photomultiplier tube. Alternatively, the fluorescence receiving
means or sensor can include a charge coupled device or a charge
coupled device camera. In still another alternative, the
fluorescence receiving means or sensor can include a diode
array.
[0232] For measuring fluorescence in the microplate thermal shift
assay, one alternative to a fluorescence plate reader is a charge
coupled device (CCD). For example, high resolution CCD cameras can
detect very small amounts of electromagnetic energy, whether it
originates from distance stars, is diffracted by crystals, or is
emitted by fluorophores. A CCD is made of semi-conducting silicon.
When photons of light fall on it, free electrons are released. As
an electronic imaging device, a CCD camera is particularly suitable
for fluorescence imaging because it can detect very faint objects,
affords sensitive detection over a broad spectrum range, affords
low levels of electromagnetic noise, and detects signals over a
wide dynamic range--that is, a charge coupled device can
simultaneously detect bright objects and faint objects. Further,
the output is linear so that the amount of electrons collected is
directly proportional to the number of photons received. This means
that the image brightness is a measure of the real brightness of
the object, a property not afforded by, for example, photographic
emulsions.
[0233] FIG. 30 depicts a charge coupled device (CCD) camera 3000
for detecting fluorescence 2918 from samples 2910. CCD camera 3000
can be any CCD camera suitable for imaging fluorescence. For
example, suitable CCD cameras are available from Alpha-Innotech
(San Leandro, Calif.), Stratagene (La Jolla, Calif.), and BioRad
(Richmond, Calif.). Particularly preferred is a cooled CCD camera,
such as a liquid cooled CCD camera, or a CCD camera cooled by a
thermoelectric coolant system.
[0234] When a fluorescence imaging camera or a CCD camera is used,
excitatory light 2916 can be a suitable lamp that is positioned
over the plurality of samples 2910. Alternatively, excitatory light
2916 can be a suitable lamp that is positioned under the plurality
of samples 2910. In another alternative embodiment, excitatory
light 2916 can be delivered to each sample 2910 by a plurality of
fiber optic cables. Each fiber optic cable is disposed through one
of a plurality of tunnels in conducting block 2912. Thus, each of
samples 2910 receives excitatory light 2916 through a fiber optic
cable.
[0235] As shown in FIG. 30, source 2906 excites samples 2910 with
excitatory light 2916. Excitatory light 2916 causes fluorescence
2918 from samples 2910. fluorescence 2918 is filtered through an
emission filter 3002. Emission filter 3002 filters out wavelengths
of fluorescence 2918 that are not to be monitored or received by
CCD camera 3000. Preferably, the emission filter is an optical
filter. CCD camera 3000 receives the filtered fluorescence 2918
from all of samples 2910 simultaneously. For simplicity and ease of
understanding, only fluorescence form one row of samples 2910 are
shown in FIG. 30. CCD camera 3000 is communicatively and
operatively coupled to computer 2914 by electrical connection
2902.
[0236] With reference now to FIG. 31, one embodiment of assay
apparatus 2900 is shown in more detail. As shown in FIG. 31, many
apparatus components are attached to a base 3100. A heat conducting
block relative movement means 3128 is used to move heat conducting
block 2912 in directions 3150 and 3152. Heat conducting block
relative movement means 3128 is communicatively and operatively
connected to a servo controller 3144. Activation of heat conducting
block relative movement means 3128 by servo controller 3144 moves
heat conducting block 2912 in directions 3150 and 3152. Servo
controller 3144 is controlled by a computer controller 3142.
Alternatively, computer 2914 could be used to control servo
controller 3144.
[0237] A sensor is removably attached to a sensor armature 3120. An
exemplary sensor is a fiber optic probe 3122. Fiber optic probe
3122 includes a fiber optic cable capable of transmitting
excitatory light 2916 to samples 2910, and a fiber optic cable
capable of receiving fluorescence 2918 from samples 2910.
Electromagnetic radiation is transmitted from excitatory light
source 2906 to fiber optic probe 3122 by excitatory light input
fiber optic cable 3108. In one embodiment of the present invention,
a fluorescence receiving means comprising photomultiplier tube 2904
is used to detect fluorescence from samples 2910. In this
embodiment, electromagnetic radiation is transmitted from fiber
optic probe 3122 to photomultiplier tube 2904 by fiber optic cable
3110. In an alternative embodiment of the present invention, CCD
camera 3002 is used to detect fluorescence from samples 2910. In
this embodiment, fiber optic cable 3110 is not required.
[0238] A temperature sensor 3124 is removably attached to sensor
armature 3120. Temperature sensor 3124 is communicatively and
operably linked to a temperature controller 3162. Temperature
sensor 3124 monitors the temperature of heat conducting block 2912
and feeds temperature information back to temperature controller
3162. Temperature controller 3162 is connected to heat conducting
block 2912 by a thermoelectric connection 3164. Under the action of
temperature controller 3162, the temperature of heat conducting
block 2912 can be increased, decreased, or held constant.
Particularly, the temperature of heat conducting block 2912 can be
changed by temperature controller 3162 in accordance with a
predetermined temperature profile. Preferably, temperature computer
controller 3162 is implemented using a computer system such as that
described below with respect to FIG. 37.
[0239] As used herein, the term "temperature profile" refers to a
change in temperature over time. The term "temperature profile"
encompasses continuous upward or downward changes in temperature,
both linear and non-linear changes. The term also encompasses any
stepwise temperature change protocols, including protocols
characterized by incremental increases or decreases in temperature
during which temperature increases or decreases are interrupted by
periods during which temperature is maintained constant. In the
apparatus of the present invention, the temperature profile can be
pre-determined by programming temperature computer controller 3162.
For example, temperature profiles can be stored in a memory device
of temperature controller 3162, or input to temperature controller
3162 by an operator.
[0240] A sensor armature relative movement means 3130 is used to
move sensor armature 3120 in directions 3154 and 3156. A sensor
armature servo controller 3118 is fixedly connected to excitatory
light filter housing 3160. Activation of sensor armature servo
controller 3118 moves fiber optic probe 3122 in directions 3154 and
3156. It would be readily apparent to one of ordinary skill in the
relevant art how to configure servo controllers to move heat
conducting block 2912 and sensor armature 3120. It should be
understood that the present invention is not limited to the use of
servo controllers for movement of heat conducting block 2912 and
sensor armature 3120, and other suitable means known to one of
skill in the art can also be used, such as a motor.
[0241] Servo controllers 3118 and 3144 are both communicatively and
operatively connected to computer controller 3142. Computer
controller 3142 controls the movement of sensor armature 3120 in
directions 3154 and 3156. In addition, computer controller 3142
controls the movement of heat conducting block relative movement
means 3128 in directions 3150 and 3152.
[0242] In the assay apparatus of the present invention, excitatory
light source 2906 is used to excite samples 2910. Excitatory light
source 2906 is communicatively and operably connected to excitatory
light filter 3104, which is contained within excitatory light
filter housing 3160. Preferably, the excitation filter is an
optical filter. Excitatory light filter 3104 filters out all
wavelengths of light from excitatory light source 2906 except for
the wavelength(s) of light that are desired to be delivered by
fiber optic probe 3122 to samples 2910. An excitatory light filter
servo controller 3106 controls the aperture of excitatory light
filter 3104. Excitatory light source 2906 and excitatory light
filter servo controller 3106 are communicatively and operatively
connected to excitatory light computer controller 3102. Computer
controller 3102 controls the wavelength of excitatory light
transmitted to samples 2910 by controlling excitatory light filter
servo controller 3106. Excitatory light 2916 is transmitted through
excitatory light input fiber optic cable 3108 to fiber optic probe
3122 for transmission to samples 2912.
[0243] Fluorescence 2918 from samples 2910 is received by fiber
optic probe 3122 and is transmitted to fluorescence filter 3114 by
output fiber optic cable 3110. fluorescence filter 3114 is
contained within a fluorescence filter housing 3166. Fluorescence
filter housing 3166 is disposed on photomultiplier tube housing
3168. Photomultiplier tube housing 3168 contains photomultiplier
tube 2904. A fluorescence servo controller 3112 controls the
aperture of fluorescence filter 3114, thereby controlling the
wavelength of fluorescence 2918 that is transmitted to
photomultiplier tube 2904. Fluorescence servo controller 3112 is
controlled by a computer controller 3170.
[0244] Fluorescence 2918 from samples 2910 is transmitted from
photomultiplier tube 2904. Electrical output 3140 connects
photomultiplier tube 2904 to electric connection 2902. Electric
connection 2902 connects electrical output 3140 to computer 2914.
Driven by suitable software, computer 2914 processes the
fluorescence signal from samples 2910. Exemplary software is a
graphical interface that automatically analyzes fluorescence data
obtained from samples 2910. Such software is well known to those of
ordinary skill in the art. For example, the CytoFluor.TM.II
fluorescence multi-well plate reader (PerSeptive Biosystems,
Framingham, Mass.) utilizes the Cytocalc.TM. Data Analysis System
(PerSeptive Biosystems, Framingham, Mass.). Other suitable software
includes, MicroSoft Excel or any comparable software.
[0245] FIGS. 32A-C illustrate one embodiment of a thermal electric
stage or heat conducting block for the assay apparatus of the
present invention. FIG. 32A shows a side view of heat conducting
block 2912 and a heat conducting wire 3206. FIG. 32B shows a top
view of heat conducting block 2912 and heat conducting wire 3206.
Heat conducting wire 3206 is a temperature adjusting element that
adjusts the temperature of heat conducting block 2912. By means
readily known to one of skill in the art, temperature controller
3162 causes heat conducting wire 3206 to increase or decrease in
temperature, thereby changing the temperature of heat conducting
block 2912. For example, an exemplary temperature controller is a
resistance device that converts electric energy into heat energy.
Alternatively, the heating element can be a circulating water
system, such as that disclosed in U.S. Pat. No. 5,255,976, the
content of which is incorporated herein by reference. In another
alternative, the temperature adjusting element can be a heat
conducting surface upon which heat conducting block 2912 is
disposed. Particularly, the temperature of heat conducting wire
3206 can be changed by temperature controller 3162 in accordance
with a pre-determined temperature profile. Temperature controller
3162 is preferably implemented using a computer system such as that
described below with respect to FIG. 37. Alternatively, computer
2914 could be used to implement temperature controller 3162. An
exemplary set of specifications for temperature controller 3162 and
heat conducting block 2912 is as follows:
3 resolution 0.1.degree. C. accuracy +0.5.degree. C. stability
0.1.degree. C. repeatability 0.1.degree. C.
[0246] Temperature controller 3162 changes temperature in
accordance with a temperature profile as discussed below with
respect to FIGS. 36A and 36B.
[0247] The temperature of heat conducting block 2912 can be
controlled such that a uniform temperature is maintained across the
heat conducting block. Alternatively, the temperature of heat
conducting block 2921 can be controlled such that a temperature
gradient is established from one end of the heat conducting block
to the other. Such a technique is disclosed in U.S. Pat. Nos.
5,255,976 and 5,525,300, the entirety of both of which is
incorporated by reference.
[0248] Heat conducting block 2912 is preferably configured with
plurality of wells 2920 for samples 2910 to be assayed. In one
embodiment, each of wells 2920 is configured to receive a container
containing one of plurality of samples 2910. Alternatively, heat
conducting block 2912 is configured to receive a container
containing plurality of samples 2910. An exemplary container for
containing plurality of samples 2910 is a microtiter plate.
[0249] In yet a further alternate embodiment, heat conducting block
2912 is configured to receive a heat conducting adaptor that is
configured to receive a container containing one or more of samples
2910. The heat conducting adaptor is disposed on heat conducting
block 2912, and the container containing samples 2910 fits into the
heat conducting adaptor. FIGS. 32C-E show three exemplary
configurations of a heat conducting adaptor. An adaptor 3200 is
configured with round-bottomed wells. An adaptor 3202 is configured
with square-bottom wells. An adaptor 3204 is configured with
V-shaped wells. For example, adaptor 3200 can receive a plurality
of round-bottom containers, each containing one sample. Similarly,
adaptor 3202 can receive a plurality of square-bottom containers,
and adaptor 3204 can contain a plurality of V-shaped bottom
containers. Adaptors 3200, 3202, and 3204 can also receive a
carrier for a multiplicity of round-bottom containers. An exemplary
carrier is a microtitre plate having a plurality of wells, each
well containing a sample. When heat conducting block 2912 is
heated, heat conducting adaptors 3200, 3202, or 3204 are also
heated. Thus, the samples contained in the containers that fit
within adaptors 3200, 3202, or 3204 are also heated. Adaptors 3200,
3202, and 3204 can accept standard microplate geometries.
[0250] Another embodiment of the assay apparatus of the present
invention is shown in FIG. 33. In this embodiment, a plurality of
heat conducting blocks 2912 is mounted on a rotatable platform or
carousel 3306. Alternativeley, the platform can be a translatable
platform. Platform or carousel 3306 can be composed of a heat
conducting material, such as the material that heat conducting
block 2912 is composed of. Although six heat conducting blocks are
shown in FIG. 33, this number is exemplary and it is to be
understood that any number of heat conducting blocks can be used.
As shown in FIG. 33, an axle 3308 is rotatably connected to base
3100. Rotatable platform 3306 is axially mounted to rotate about
axle 3308. Rotation of axle 3308 is controlled by a servo
controller 3312. Servo controller 3312 is controlled by a computer
controller 3314 in a manner well known to one of skill in the
relevant arts. Computer controller 3314 causes servo controller
3312 to rotate axle 3308 thereby rotating rotatable platform 3306.
In this manner, heat conducting blocks 2912 are sequentially placed
under fiber optic probe 3122.
[0251] Each of the plurality of heat conducting blocks 2912 can be
controlled independently by temperature controller 3162. Thus, the
temperature of a first heat conducting block 2912 can be higher or
lower than the temperature of a second heat conducting block 2912.
Similarly, the temperature of a third heat conducting block 2912
can be higher or lower than the temperature of either first or
second heat conducting block 2912.
[0252] In a manner similar to that described above for FIG. 31,
relative movement means 3130 is also used to move sensor armature
3120 in directions 3150 and 3152 so that fiber optic probe 3122 can
be moved to detect fluorescence from samples 2910. A second sensor
armature relative movement means 3316 is used to move sensor
armature 3120 in directions 3154 and 3156.
[0253] The temperature of heat conducting blocks 2912 is controlled
by temperature controller 3162. Temperature controller 3162 is
connected to rotatable platform 3306 by connection 3164 to heat
conducting blocks 2912. Under the action of temperature controller
3162, the temperature of heat conducting blocks 2912 can be
increased and decreased. Alternatively, temperature controller 3162
can be configured to adjust the temperature of rotatable platform
3306. In such a configuration, when rotatable platform 3306 is
heated, heat conducting blocks 2912 are also heated. Alternatively,
the temperature of each of heat conducting blocks 2912 can be
controlled by a circulating water system such as that noted
above.
[0254] In a manner similar to that illustrated in FIG. 31,
excitatory light source 2906 is used to excite samples 2910.
Excitatory light source 2906 is communicatively and operably
connected to excitatory light filter 3104, which is contained
within excitatory light filter housing 3160. Excitatory light
filter 3104 filters out all wavelengths of light from excitatory
light source 2906 except for the wavelength(s) of light that are
desired to be delivered by fiber optic probe 3122 to samples 2910.
An excitatory light filter servo controller 3106 controls the
aperture of excitatory light filter 3104. Excitatory light source
2906 and excitatory light filter servo controller 3106 are
communicatively and operatively connected to excitatory light
computer controller 3102. Computer controller 3102 controls the
wavelength of excitatory light transmitted to samples 2910 by
controlling excitatory light filter servo controller 3106.
Excitatory light 2916 is transmitted through excitatory light input
fiber optic cable 3108 to fiber optic probe 3122 for transmission
to samples 2912.
[0255] Fluorescence 2918 from samples 2910 is received by fiber
optic probe 3122 and is transmitted to fluorescence filter 3114 by
fiber optic cable 3110. Fluorescence servo controller 3112 controls
fluorescence filter 3114 aperture and thus controls the wavelength
of fluorescence that is transmitted to photomultiplier tube 2904.
In a manner similar to that explained for FIG. 31, fluorescence
servo controller 3112 is controlled by computer controller
3170.
[0256] The assay apparatus of the present invention can detect
fluorescence from samples 2910 one sample at a time or
simultaneously from a subset of samples 2910. As used herein, the
term "subset of samples" refers to at least two of samples 2910. To
detect fluorescence simultaneously from a subset of samples in an
embodiment of the assay apparatus of the present invention
comprising photomultiplier tube 2904, a plurality of excitatory
light filters 3104, excitatory light input fiber optic cables 3108,
emission light output fiber optic cables 3110, and emission light
filters 3114 must be used.
[0257] The fluorescence signal is transmitted from photomultiplier
tube 2904 to computer 2914. Photomultiplier tube 2904 is
communicatively and operatively coupled to computer 2914 by
electrical connection 2902. Connection 2902 is connected to
photomultiplier tube 2904 through electrical output 3140. Computer
2914 functions as a data analysis means for analyzing fluorescence
as a function of temperature.
[0258] FIG. 34 illustrates a top view of the assay apparatus shown
in FIG. 33 with a housing 3400 that covers the apparatus. A door
3402 opens to reveal samples 2910. Door 3402 can be a hinge door
that swings open. Alternatively, door 3402 can be a sliding door
that slides open. A side view of the assay apparatus shown in FIGS.
33 and 34 is illustrated in FIG. 35. Cover 3400 is disposed on top
of base 3100. Cover 3400 can be made of any suitable material. For
example, cover 3400 can be made of plexiglass, fiberglass, or
metal.
[0259] FIGS. 36A and 36B illustrate a temperature profile and how
the temperature profile is implemented using the assay apparatus of
the present invention. FIG. 36A illustrates a temperature profile
3600 that shows the temperature of heat conducting blocks 2912 as a
function of time. Heat conducting blocks 2912 and samples 2910 are
heated in a continuous fashion in accordance with temperature
profile 3600. Alternatively, rotatable platform 3306 can be heated
along with heat conducting blocks 2912. Preferably, temperature
profile 3600 is linear, with temperatures ranging from about
4.degree. C. to about 110.degree. C.
[0260] Alternatively, temperature profile 3600 can be characterized
by incremental, stair step increases in temperature, in which heat
conducting blocks 2912 and samples 2910 are heated to a
predetermined temperature, maintained at that temperature for a
predetermined period of time, and than heated to a higher
predetermined temperature. For example, temperature can be
increased from 0.5.degree. C. to 20.degree. C. per minute. Although
the temperature range from about 4.degree. C. to about 110.degree.
C. is disclosed, it is to be understood that the temperature range
with which a given target molecule, for example, a protein, is to
be heated to generate thermal unfolding information can readily be
determined by one of ordinary skill in the art. The length of time
over which temperature profile 3600 is accomplished will vary,
depending on how many samples are to be assayed and on how rapidly
the sensor that receives fluorescence 2918 can detect fluorescence
2918 from samples 2910. For example, an experiment in which each of
six heat conducting blocks 2912 holds a total of 96 samples 2910
(for a total of 576 samples), and in which samples are scanned
using a fluorescent reader device having a single fiber optic
probe, and in which the temperature profile is from 38.degree. C.
and 76.degree. C., would take approximately 38 minutes to perform
using the apparatus shown in FIG. 33.
[0261] While heating in accordance with temperature profile 3600,
fluorescence 2918 from each sample 2910 in a first heat conducting
block 2912 is received through fiber optic probe 3122. As
illustrated in FIG. 36B, after fluorescence from all of samples
2910 in first heat conducting block 2912 have been received,
platform 3306 is rotated to move the next heat conducting block
2912 under fiber optic probe 3122 and fluorescence 2918 from
samples 2910 is received by fiber optic probe 3122. This process is
continued until reception of fluorescences from all samples in all
heat conducting blocks 2912 is complete. Fluorescence from samples
2910 on each heat conducting block 2912 can be received one at a
time, simultaneously from a subset of samples, simultaneously from
one row of samples at a time, or all of the samples at one
time.
[0262] The present invention may be implemented using hardware,
software, or a combination thereof, and may be implemented in a
computer system or other processing system. A flowchart 3800 for
implementation of one embodiment of the present invention is shown
in FIG. 38. Flowchart 3800 begins with a start step 3802. In a step
3804, temperature profile 3600 is initiated. For example,
temperature controller 3162 causes the temperature of heat
conducting block 2912 to increase. In a step 3806, a sensor such as
fiber optic probe 3122 or CCD camera 3000 is moved over a sample
2910, row of samples 2910, or all of samples 2910. In a step 3808,
excitatory light is transmitted to sample(s) 2910 using excitatory
light source 2906. In a step 3810, fluorescence is received by the
sensor from sample(s) 2910. In a decision step 3812, it is
determined whether fluorescence 2918 has been received from all of
the samples, rows of samples, in one heat conducting block 2912. If
fluorescence 2918 has not been received from all of the samples or
rows of samples, the sensor is moved over the next sample or row of
samples in a step 3814. Processing then continues at step 3808 to
transmit excitatory light 2916. Processing then continues to a step
3810 to receive fluorescence 2918 from sample(s) 2910.
[0263] If fluorescence 2918 has been received from all of samples
or rows of samples, processing continues to a decision step 3816.
In decision step 3816, it is determined whether fluorescence 2918
has been received from samples in all heat conducting blocks. If
not, rotatable platform 3306 is rotated in a step 3818 to place the
next heat conducting block 2912 and samples 2910 contained therein
under the sensor. Steps 3806 through 3818 are followed until
fluorescence 2918 has been received from all of the samples in all
of heat conducting blocks 2912. Processing then continues to a step
3820, in which temperature profile 3600 is completed and processing
ends at a step 3822.
[0264] A flowchart 3900 for implementation of an alternate
embodiment of the present invention is shown in FIG. 39. In this
embodiment, a sensor for simultaneously receiving fluorescence 2918
from all of samples 2910 on heat conducting block 2912, such as CCD
camera 3000, is positioned over heat conducting block 2912.
Flowchart 3900 begins with a start step 3902. In a step 3904,
temperature profile 3600 is initiated. For example, temperature
controller 3162 causes the temperature of heat conducting block
2912 to increase. In a step 3906, excitatory light is transmitted
to sample(s) 2910 using excitatory light source 2906. In a step
3908, fluorescence is received by CCD camera 3000 from sample(s)
2910. In a decision step 3910, it is determined whether
fluorescence 2918 has been received from all of heat conducting
blocks 2912. If not, rotatable platform 3306 is rotated in a step
3912 to place the next heat conducting block 2912 and samples 2910
contained therein under CCD camera 3000. Steps 3906 through 3912
are followed until fluorescence 2918 has been received from samples
2910 in all of heat conducting blocks 2912. Processing then
continues to a step 3914. In step 3914, temperature profile 3600 is
completed and processing ends at a step 3916.
[0265] As stated above, the present invention may be implemented
using hardware, software, or a combination thereof, and may be
implemented in a computer system or other processing system. An
exemplary computer system 3702 is shown in FIG. 37. Computer
controllers 3102, 3142, 3162, 3170, or 3314, can be implemented
using one or more computer systems such as computer system
3702.
[0266] After reading this description, it will become apparent to a
person skilled in the relevant art how to implement the invention
using other computer systems and/or computer architectures.
Computer system 3702 includes one or more processors, such as
processor 3704. Processor 3704 is connected to a communication bus
3706. Computer system 3702 also includes a main memory 3708,
preferably random access memory (RAM), and can also include a
secondary memory 3710. The secondary memory 3710 can include, for
example, a hard disk drive 3712 and/or a removable storage drive
3714, representing a floppy disk drive, a magnetic tape drive, an
optical disk drive, etc. The removable storage drive 3714 reads
from and/or writes to a removable storage unit 3716 in a well known
manner. Removable storage unit 3716 represents a floppy disk,
magnetic tape, optical disk, etc. which is read by and written to
by removable storage drive 3714. As will be appreciated, the
removable storage unit 3716 includes a computer usable storage
medium having stored therein computer software and/or data.
[0267] In alternative embodiments, secondary memory 3710 may
include other similar means for allowing computer programs or other
instructions to be loaded into computer system 3702. Such means can
include, for example, a removable storage unit 3718 and an
interface 3720. Examples of such can include a program cartridge
and cartridge interface (such as that found in video game devices),
a removable memory chip (such as an EPROM, or PROM) and associated
socket, and other removable storage units 3718 and interfaces 3720
which allow software and data to be transferred from the removable
storage unit 3718 to computer system 3702.
[0268] Computer system 3702 can also include a communications
interface 3722. Communications interface 3722 allows software and
data to be transferred between computer system 3702 and external
devices. Examples of communications interface 3722 can include a
modem, a network interface (such as an Ethernet card), a
communications port, a PCMCIA slot and card, etc. Software and data
transferred via communications interface 3722 are in the form of
signals 3724 which can be electronic, electromagnetic, optical or
other signals capable of being received by communications interface
3722. These signals 3724 are provided to communications interface
via a channel 3726. This channel 3726 carries signals 3724 and can
be implemented using wire or cable, fiber optics, a phone line, a
cellular phone link, an RF link and other communications channels.
In the assay apparatus of the present invention, one example of
channel 3726 is electrical connection 2902 that carries signal 3724
of fluorescence 2918 to computer 2914.
[0269] In this document, the terms "computer program medium" and
"computer usable medium" are used to generally refer to media such
as removable storage device, 3716 and 3718, a hard disk installed
in hard disk drive 3712, and signals 3724. These computer program
products are means for providing software to computer system
3702.
[0270] Computer programs (also called computer control logic) are
stored in main memory 3708 and/or secondary memory 3710. Computer
programs can also be received via communications interface 3722.
Such computer programs, when executed, enable the computer system
3702 to perform the features of the present invention as discussed
herein. In particular, the computer programs, when executed, enable
the processor 3704 to perform the features of the present
invention. Accordingly, such computer programs represent
controllers of the computer system 3702.
[0271] In an embodiment where the invention is implemented using
software, the software may be stored in a computer program product
and loaded into computer system 3702 using removable storage drive
3714, hard drive 3712 or communications interface 3722. The control
logic (software), when executed by the processor 3704, causes the
processor 3704 to perform the functions of the invention as
described herein.
[0272] In another embodiment, the invention is implemented
primarily in hardware using, for example, hardware components such
as application specific integrated circuits (ASICs). Implementation
of the hardware state machine so as to perform the functions
described herein will be apparent to persons skilled in the
relevant art(s).
[0273] In yet another embodiment, the invention is implemented
using a combination of both hardware and software.
[0274] Having now generally described the invention, the same will
become more readily understood by reference to the following
specific examples which are included herein for purposes of
illustration only and are not intended to be limiting unless
otherwise specified.
EXAMPLE 1
Ranking Ligands That Bind To The Active Site Of Human
.alpha.-thrombin
[0275] Using the computer controlled process DirectedDiversity.RTM.
(see U.S. Pat. No. 5,463,564), scientists at 3-Dimensional
Pharmaceuticals, Inc. have generated a combinatorial library of
compounds directed at the active site of human .alpha.-thrombin.
Approximately 400 compounds were synthesized and assayed by a
conventional spectrophotometric kinetic assay in which
succinyl-Ala-Ala-Pro-Arg-p-nitroanilide (Bachem, King of Prussia,
Pa.) served as substrate. Five of these compounds, which are
characterized by K.sub.i's that span almost four orders of
magnitude in binding affinity, were used to test the range and
limits of detection of the thermal shift assay. These five
proprietary compounds are listed in Table 3, along with the K.sub.i
for each respective compound, as measured by the kinetic assay
(last column). K.sub.i's for these compounds ranged from 7.7 nM for
3dp-4026 to 20.0 .mu.M for 3dp-3811.
[0276] A stock human .alpha.-thrombin solution (1.56 mg/mL) from
Enzyme Research Labs was first diluted to 0.5 mg/mL (11 .mu.M) with
50 mM Hepes, pH 7.5, 0.1 M NaCl (assay buffer, unless mentioned
otherwise), and stored on ice. The five ligands (recrystallized
solids characterized by mass spectrometry and NMR) were accurately
weighed out to be 1.5 to 2.0 mg and dissolved in 1.0 mL of 100%
DMSO so that the concentration was between 1.8 and 3.8 mM. A 96
well V-bottom Costar microplate was then set up such that 100 .mu.L
of the 11 .mu.M human .alpha.-thrombin solution was pipetted into
wells A1 through A6. This was followed by the addition of 2 .mu.L
of 3dp-3811 into well A2, 2 .mu.L of 3dp-3959 into well A3, 2 .mu.L
of 3dp-4077 into well A4, 2 .mu.L of 3dp-4076 into well A5, 2 .mu.L
of 3dp-4026 into well A6, and 2 .mu.L of 100% DMSO into control
well A1. The contents were mixed by repeated uptake and discharge
using a 100 .mu.L pipette tip. Finally, one drop of mineral oil
(Sigma, St. Louis, Mo.) was added on top of the wells to reduce
evaporation of samples at elevated temperatures. The microplate was
then placed on heating block 4 of a RoboCycler Gradient 96
Temperature Cycler (Stratagene, La Jolla, Calif.), set at
25.degree. C., for 1 minute. The plate was then placed into a
SPECTRAmax.TM. 250 spectrophotometer (set to 30.degree. C.) and the
absorbance at 350 nm was measured for each sample. This reading
served as the blank or reference from which all the other readings
at higher temperatures were compared. The assay was initiated by
setting heating block 1 to 38.degree. C., programming the
temperature cycler to move the microplate to heating block 1, and
keeping the microplate there for 3 minutes. Following the
equilibration at 38.degree. C., the plate was moved to the
25.degree. C. block (Block 4) for 30 seconds, inserted in the
spectrophotometer, and absorbance was read at 350 nm. The
microplate was then put back into the temperature cycler and was
moved to heating block 2, which had been pre-equilibrated at
40.degree. C. After 3 minutes at 40.degree. C., the plate was
returned to 25.degree. C. (on block 4) for 30 seconds, and was
returned to the spectrophotometer for a measurement of absorbance
at 350 nm. This process was repeated 18 more times until the
temperature had been raised to 76.degree. C. in 2.degree. C.
increments. After subtraction of the blank absorbance (A.sub.350 at
25.degree. C.), turbidity, reflected in the absorbance value, was
plotted as a function of temperature. The thermal denaturation
curves for this experiment are shown in FIG. 1.
[0277] The control (in well A1), which contained only 11 .mu.M
human .alpha.-thrombin in 2% DMSO, was found to undergo a thermal
denaturation transition starting at .about.50.degree. C., as
reflected in the large increase in A.sub.350. The midpoint in this
transition was observed to be .about.55.degree. C. This result was
consistent with differential scanning calorimetric measurements for
bovine prothrombin 1, which revealed a denaturation transition at
T.sub.m=58.degree. C. (Lentz, B. R. et al., Biochemistry
33:5460-5468 (1994)). The thermal denaturation curves for all of
the tested inhibitor compounds displayed a shift in the transition
towards higher temperatures. 3dp-4026 showed the largest shift in
T.sub.m:.about.9.degree. C. This result is consistent with the fact
that, among the compounds tested, 3dp-4026 exhibited the greatest
binding affinity, as judged by kinetic measurements with
succinyl-Ala-Ala-Pro-Arg- -p-nitroanilide as substrate. Indeed, the
rank order of shifts in T.sub.m, shown in FIG. 1, paralleled the
order of binding affinity as measured by conventional enzymology.
These results indicate that by simply observing the shift in
T.sub.m for a series of compounds relative to the control, one can
easily and correctly rank a series of compounds in increasing order
of binding affinity to the protein of interest.
[0278] It was possible to take the microplate thermal shift assay
one step further and estimate the binding affinity of each ligand
at T.sub.m. This was done by substituting T.sub.0, T.sub.m,
.DELTA.H.sub.u and .DELTA.C.sub.pu into equation (1). If
.DELTA.H.sub.u and .DELTA.C.sub.pu cannot be measured because a
calorimetric device is not available, one can make educated guesses
at .DELTA.H.sub.u and .DELTA.C.sub.pu for the therapeutic target.
In the case of human .alpha.-thrombin, it was possible to use
.DELTA.H.sub.u=200.0 kcal/mol, a value measured for the closely
related protein bovine prothrombin 1 (Lentz, B. R. et al.,
Biochemistry 33:5460-5468 (1994)). A value of .DELTA.C.sub.pu=2.0
kcal/mol-.degree. K was used to calculate K.sub.L at T.sub.m since
similar proteins of this size have been shown to yield similar
values. The binding affinities at T.sub.m of the five test ligands
closely paralleled the K.sub.i's measured with a spectrophotometric
substrate (Table 3).
4TABLE 3 Microplate Thermal Shift Assay for Ligands Binding to the
Active Site of Human .alpha.-thrombin. Turbidity as an Experimental
Signal. K.sub.d at K.sub.d at K.sub.i Protein/ [Ligand] T.sub.m
.DELTA.T.sub.m T.sub.m.sup.a 310.degree. K.sup.b (310.degree.
K).sup.c Ligand (.mu.M) (.degree. K) (.degree. K) (nM) (nM) (nM)
Thrombin none 327.15 0.0 (TH) TH/3dp- 37 328.15 1.0 14400 5880 2000
3811 TH/3dp- 76 332.15 5.0 660 224 250 3959 TH/3dp- 48 333.15 6.0
160 51.7 46 4077 TH/3dp- 60 334.15 7.0 76.3 23.6 26 4076 TH/3dp- 67
336.15 9.0 12.3 3.5 7.7 4026 .sup.aCalculations for K.sub.d at
T.sub.m were made using equation (1) with .DELTA.H.sup.T0.sub.u =
200.0 kcal/mole, as observed for prothrombin 1 by Lentz, B. R. et
al., Biochemistry 33: 5460-5468 (1994), and an estimated
.DELTA.C.sub.pu = 2.0 kcal/mole - .degree. K; and K.sub.d =
1/K.sub.a. .sup.bEstimates for K.sub.d at T = 310.degree. K were
made using equation (3), where .DELTA.H.sup.T.sub.L was estimated
to be -10.0 kcal/mole. .sup.cK.sub.i was measured by classical
enzymological methods that look at the [inhibitor] dependence of
the enzymatic hydrolysis of the spectrophotometric substrate
succinyl-Ala-Ala-Pro-Arg-p-nitroanilide at 310.degree. K (50 mM
Hepes, pH 7.5, 0.2 M NaCl, 0.05% .beta.-octylglucoside).
EXAMPLE 2
Ranking Ligands That Bind To The Heparin Binding Site of Human
.alpha.-thrombin
[0279] Assays for ligands that bind to the heparin binding site of
human .alpha.-thrombin are more difficult to perform than assays
for ligands that bind to the active site of human .alpha.-thrombin.
At the heparin binding site, no substrate is hydrolyzed, so no
spectrophotometric signal can be amplified for instrumental
detection. Heparin activity is usually estimated in biological
clotting time assays. Alternatively, heparin binding affinity for
human .alpha.-thrombin can be determined by laboriously conducting
15 to 20 single point assays, in which the concentration of low MW
heparin is varied over two logs, and monitoring the quenching of
the fluorescent probe, p-aminobenzamidine, bound to the active site
of human .alpha.-thrombin (Olson, S. T. et al., J. Biol. Chem.
266:6342-6352 (1991)). Thus, heparin binding to human
.alpha.-thrombin represents the kind of challenge encountered with
the vast majority of non-enzyme receptor/ligand binding events,
which are commonly observed for hormone/receptor interactions,
repressor/DNA interactions, neurotransmitter/receptor interactions,
etc. Several heparin-like sulfated oligosaccharides and sulfated
naphthalene compounds were assayed by the microplate thermal shift
assay. Using the thermal shift assay, it was possible to use a
single compound per well to quickly rank the compounds in order of
increasing binding affinity, with K.sub.d's ranging over three
orders of magnitude (see Table 4). Like the experiment in Example
1, the thermal shift assay results agreed closely with the results
obtained through an alternative method, which required a series of
laborious (15 to 20 single determinations) fluorescence quench
assays over a wide range of concentrations of low MW heparin
(Olson, S. T. et al., J. Biol. Chem. 266:6342-6352 (1991)). These
results confirm that by simply observing the shift in T.sub.m for a
series of compounds, relative to the control, one can easily and
correctly rank a series of compounds in increasing order of binding
affinity for the protein of interest.
[0280] A search of the literature did not locate alternatively
measured binding results for the other ligands, which may attest to
the difficulty of these experiments. However, the literature did
reveal that pentosan polysulfate (PSO.sub.4) (Sigma, St. Louis,
Mo.), dextran SO.sub.4 (Sigma, St. Louis Mo.), and suramin
(CalBiochem, LaJolla, Calif.) have been observed to have
anticoagulant properties. Indeed, pentosan polysulfate and suramin
were tested previously in clinical trials for anti-angiogenic
activity, but were discounted due to toxic effects, many of which
were described as coagulation anomalies (Pluda, J. M. et al., J.
Natl. Cancer Inst. 85:1585-1592 (1993); Stein, C. A., Cancer Res.
53:2239-2249 (1993)). The affinities of pentosan PSO.sub.4 and
suramin at T.sub.m, as measured by the thermal shift assay, were
found to be 7-fold and 5700-fold higher, respectively, than the
affinity of heparin 5000 (Table 4). These results suggested that
these ligands may alter clotting rates by interfering with the
heparin mediated binding of human .alpha.-thrombin to anti-thrombin
III (AT III), a protein co-factor for human .alpha.-thrombin
activity.
[0281] The results in Table 4 revealed another advantage of the
microplate thermal shift assay for screening compound libraries:
the process is blind and unbiased in the sense that it detects
ligand binding regardless of whether it is at the active site, an
allosteric cofactor binding site, or at a protein subunit
interface. The ability to detect ligands that bind with high
affinity to sites outside an enzyme's active site will greatly
facilitate discovery of lead molecules.
5TABLE 4 Microplate Thermal Shift Assay for Ligands Binding to the
Heparin Binding Site of Human .alpha.-thrombin. Turbidity as an
Experimental Signal. K.sub.d at K.sub.i 298.degree. K.sup.b
(289.degree. K) K.sub.d at (nM) (nM) Protein/ [Ligand] T.sub.m
.DELTA.T.sub.m T.sub.m.sup.a Ob- Litera- Ligand (.mu.M) (.degree.
K) (.degree. K) (nM) served ture Throm- none 329.15 0.0 bin (TH)
TH/ 61 329.65 0.5 38,300 7,570 -- Heparan SO.sub.4 TH/ 50 330.15
1.0 19,700 3,810 -- Heparin 3000 TH/ 44 330.15 1.0 17,200 3,490
5,400.sup.c Heparin 5000 TH/ 40 332.15 3.0 2,425 427 -- Pento- san
PSO.sub.4 TH/ 48 336.15 7.0 68.8 10.1 -- Dextran SO.sub.4 TH/ 102
340.15 11.0 3.02 0.37 -- Suramin .sup.aCalculations for K.sub.d at
T.sub.m were made using equation (1) with .DELTA.H.sup.T0.sub.u =
200.0 kcal/mole, as observed for pre-thrombin 1 by Lentz, B. R. et
al., Biochemistry 33: 5460-5468 (1994), and an estimated
.DELTA.C.sub.pu = 2.0 kcal/mole-.degree. K; and K.sub.d =
1/K.sub.a. The thrombin, human .alpha.-thrombin (Factor IIa), from
Enzyme Research Labs (South Bend, IN) was diluted to 0.5 mg/mL (11
.mu.M) using 50 #mM Hepes, pH 7.5, 0.1 M NaCl (3-fold dilution).
All ligands were dissolved in the same buffer. .sup.bEstimates for
K.sub.d at T = 298.degree. K were made using equation (3), where
.DELTA.H.sup.T.sub.L is estimated to be -10.0 kcal/mole.
.sup.cOlson, S. T. et al., J. Biol. Chem. 266: 6342-6352
(1991).
EXAMPLE 3
Ranking aFGF Ligands
[0282] The second therapeutic receptor tested in the microplate
thermal shift assay was acidic fibroblast growth factor (aFGF), a
growth factor that plays a key role in angiogenesis (Folkman, J. et
al., J. Biol. Chem. 267:10931-10934 (1992)). A synthetic gene for
this protein was purchased from R&D Systems (Minneapolis,
Minn.), and was cloned and expressed in E. coli using methods
similar to those described for basic fibroblast growth factor
(bFGF) (Thompson, L. D. et al., Biochemistry 33:3831-3840 (1994);
Pantoliano, M. W. et al., Biochemistry 33:10229-10248 (1994);
Springer, B. A. et al., J. Biol. Chem. 269:26879-26884 (1994)).
Recombinant aFGF was then purified by heparin-sepharose affinity
chromatography as described (Thompson, L. D. et al., Biochemistry
33:3831-3840 (1994)). aFGF is also known to bind heparin/heparan,
which is a cofactor for mitogenic activity. Heparin-like molecules,
such as pentosan PSO.sub.4 and suramin, inhibit the growth factor's
biological activity. A microplate thermal assay of these compounds
was set up in a way similar to that described above for human
.alpha.-thrombin. The change in turbidity, as a function of
temperature, for each of the ligands suramin, heparin 5000, and
pentosan PSO.sub.4, is shown in FIG. 2. The results are summarized
in Table 5. The affinity constants covered a fairly broad range of
binding affinities, with pentosan PSO.sub.4 showing the highest
affinity. The order of ligand binding affinity of pentosan
PSO.sub.4, heparin 5000 and suramin paralleled that found for bFGF,
as measured using isothermal titrating calorimetry (Pantoliano, M.
W. et al., Biochemistry 33:10229-10248 (1994)). The lack of
alternatively measured binding affinities for these compounds
probably attests to the difficulty of making these measurements
using assays which do not monitor physical, temperature-dependent
changes.
[0283] The results in Table 5 are consistent with the results in
Tables 3 and 4. Simply observing the shift in T.sub.m for a series
of compounds relative to the control, one can easily and correctly
rank a series of compounds in increasing order of binding affinity
to the protein of interest.
6TABLE 5 Microplate Thermal Shift Assay for Ligands Binding to
aFGF. Turbidity as an Experimental Signal. K.sub.d at K.sub.i
298.degree. K.sup.b (298.degree. K).sup.c Protein/ [Ligand] T.sub.m
.DELTA.T.sub.m K.sub.d at T.sub.m.sup.a (nM) (nM) Ligand (.mu.M)
(.degree. K) (.degree. K) (nM) Observed Literature aFGF none 317.15
0.0 aFGF/EEEEE 50 317.15 0.0 >50,000 -- aFGF/Dermatan SO.sub.4
50 318.15 1.0 37,000 12,700 -- aFGF/EEEEEEEE 50 322.15 5.0 10,076
3,040 -- aFGF/.beta.-CD 14 SO.sub.4 47 329.15 12.0 1055 213 1500
aFGF/suramin 200 330.15 13.0 3220 622 aFGF/Heparin 5000 50 331.15
14.0 576 106 470 aFGF/Heparan SO.sub.4 61 333.15 16.0 357 60 --
aFGF/Pentosan PSO.sub.4 100 336.15 19.0 208 31 88
.sup.aCalculations for K.sub.d at T.sub.m were made using equation
(1) with an estimated .DELTA.H.sup.T0.sub.u = 60.0 kcal/mole, and
an estimated .DELTA.C.sub.pu = 0.95 kcal/mole - .degree. K; and
K.sub.d = 1/K.sub.a. All ligands, except .beta.-CD 14 SO.sub.4,
were purchased from Sigma and used without further purification.
.beta.-CD 14 SO.sub.4 was purchased from American Maize Products
Co. (Hammond, IN). The aFGF was diluted to 0.25 mg/mL in 50 mM
#Hepes, pH 7.5, 0.1 M NaCl. All ligands were dissolved in the same
buffer. .sup.bEstimates for K.sub.d at T = 298.degree. K were made
using equation (3), where .DELTA.H.sup.T.sub.L is estimated to be
-10.0 kcal/mole. .sup.cNo published binding affinity data for these
ligands was found in the literature, but the affinities for these
ligands binding to bFGF, as measured by isothermal titrating
calorimetry, are shown (Thompson, L.D. et al., Biochemistry 33:
3831-3840 (1994), Pantoliano, M. W. et al., Biochemistry 33:
10229-10248 (1994)).
EXAMPLE 4
Ranking bFGF Ligands
[0284] The microplate thermal shift assay was used to assess
ligands for binding to the heparin binding site of basic fibroblast
growth factor (bFGF). The gene for bFGF was purchased from R&D
Systems and was cloned and expressed in E. coli as previously
described (Thompson, L. D. et al., Biochemistry 33:3831-3840
(1994); Pantoliano, M. W. et al., Biochemistry 33:10229-10248
(1994);. Springer, B. A. et al., J. Biol. Chem. 269:26879-26884
(1994)). It was found that pentosan PSO.sub.4 and suramin bound to
bFGF with binding affinities of 55 .mu.M and 3.5 .mu.M,
respectively. This result for PSO.sub.4 compared very well with the
affinity of 88 nM observed for PSO.sub.4 binding to bFGF, as
determined by isothermal titrating calorimetry.
EXAMPLE 5
Ranking Human .alpha.-thrombin Ligands Using Fluorescence
Emission
[0285] Because fluorescence measurements are more sensitive than
absorbance measurements, a fluorescence thermal shift assay was
used to assess ligand binding to human .alpha.-thrombin. The
fluorescence emission spectra of many fluorophores are sensitive to
the polarity of their surrounding environment and therefore are
effective probes of phase transitions for proteins (i.e., from the
native to the unfolded phase). The most studied example of these
environment dependent fluorophores is
8-anilinonaphthalene-1-sulfonate (1,8-ANS), for which it has been
observed that the emission spectrum shifts to shorter wavelengths
(blue shifts) as the solvent polarity decreases. These blue shifts
are usually accompanied by an increase in the fluorescence quantum
yield of the fluorophore. In the case of ANS, the quantum yield is
0.002 in water and increases to 0.4 when ANS is bound to serum
albumin.
[0286] ANS was used as a fluorescence probe molecule to monitor
protein denaturation. In the fluorescence assay, the final
concentration of human .alpha.-thrombin was 0.5 .mu.M, which is
20-fold more dilute than the concentrations used in the turbidity
assays. This concentration of human .alpha.-thrombin is in the
range used for the kinetic screening assays.
[0287] ANS was excited with light at a wavelength of 360 nm. The
fluorescence emission was measured at 460 nm using a CytoFluor II
fluorescence microplate reader (PerSeptive Biosystems, Framingham,
Mass.). The temperature was ramped up as described above for the
turbidity assays (see Example 1). The plot of fluorescence as a
function of temperature is shown in FIG. 3 for human
.alpha.-thrombin alone, and for the 3dp-4026/human .alpha.-thrombin
complex. The denaturation transition for human .alpha.-thrombin was
clearly observed at 57.degree. C., a temperature which is only
slightly higher than that observed in the turbidity experiment. The
result from the fluorescence assay is, nonetheless, in close
agreement with the T.sub.m of 58.degree. C. observed for
prothrombin 1 from differential scanning calorimetry experiments.
Importantly, 3dp-4026 (at 67 .mu.M) was found to shift the
denaturation transition to .about.66.degree. C. to give a shift in
T.sub.m of 9.degree. C., which is identical to that found using
turbidity as the detection signal (Table 3).
[0288] The results in FIG. 3 and Table 4 illustrate several
important points. First, at least a 20-fold increase in sensitivity
can be gained by switching from an absorbance to a fluorescence
emission detection system. This can be critical for those receptor
proteins for which supplies are limited.
[0289] Second, in the fluorescence assays, the denaturation
transition signal is much cleaner than the signal in the turbidity
assays. In the turbidity assays, higher concentrations of protein
led to precipitation of denatured protein. Precipitated protein
contributed to the noisy signal.
[0290] Third, shifts in T.sub.m measurements from the microplate
thermal shift assays are reproducible from one detection system to
another.
EXAMPLE 6
Ranking Ligands To The D(II) Domain of FGFR1
[0291] The microplate thermal-shift assay was employed to test the
binding of heparin 5000 and pentosan PSO.sub.4 to the known heparin
binding site in the D(II) domain of fibroblast growth factor
receptor 1 (FGFR1). D(II) FGFR1 is a 124 residue domain which is
responsible for most of the free energy of binding for bFGF. D(II)
FGFR1 was cloned and expressed in E. coli. Recombinant D(II) FGFR1
was renatured from inclusion bodies essentially as described
(Wetmore, D. R. et al., Proc. Soc. Mtg., San Diego, Calif. (1994)),
except that a hexa-histidine tag was included at the N-terminus to
facilitate recovery by affinity chromatography on a Ni.sup.2+
chelate column (Janknecht, R. et al., Natl. Acad. Sci. USA
88:8972-8976 (1991)). D(II) FGFR1 was further purified on a
heparin-sepharose column (Kan, M. et al., Science 259:1918-1921
(1993); Pantoliano, M. W. et al., Biochemistry 33:10229-10248
(1994)). Purity was>95%, as judged by SDS-PAGE. The D(II) FGFR1
protein was concentrated to 12 mg/mL (.about.1 mM) and stored at
4.degree. C.
[0292] The D(II) FGFR1 protein was dissolved in an ANS solution to
a concentration of 1.0 mg/mL (70 AM). The quantum yield for ANS
bound to the denatured form of D(II) FGFR1 was lower than the
quantum yield for ANS bound to human .alpha.-thrombin. Because ANS
fluorescence is very environment dependent (see Lakowicz, I. R.,
Principles of Fluorescence Spectroscopy, Plenum Press, New York
(1983)), the quantum yield observed for the denaturation of
different proteins will vary. For D(II) FGFR1, the signal for the
turbidity version of the assay, however, was nearly undetectable.
Despite the decreased sensitivity for D(II) FGFR1, ANS rescued this
system for the microplate assay. A similar result was obtained for
Factor Xa, except that the fluorescence quantum yield for ANS bound
to denatured Factor Xa was almost as good as it was for human
.alpha.-thrombin. It was found that the fluorescence quantum yield
for ANS bound to denatured bFGF was as high as the quantum yield
for ANS binding to human .alpha.-thrombin.
[0293] The results of D(II) FGFR1 binding experiments, as
determined by the microplate thermal shift assay, are shown in FIG.
4 and Table 6. As was previously demonstrated for all of the other
receptor proteins described above, the microplate thermal shift
assay facilitated the ranking of ligand binding affinities for
D(II) FGFR1.
7TABLE 6 Microplate Thermal Shift Assay for Ligands Binding to
D(II) FGFR1. Fluorescence Emission as an Experimental Signal.
K.sub.d at K.sub.d 298.degree. K.sup.b (298.degree. K).sup.c
Protein/ [Ligand] T.sub.m .DELTA.T.sub.m K.sub.d at T.sub.m.sup.a
(.mu.M) (.mu.M) Ligand (.mu.M) (.degree. K) (.degree. K) (.mu.M)
Observed Literature D(II) FGFR1 none 312.8 0.0 D(II) FGFR1/ 150
317.9 5.1 30.0 13.6 85.3 Heparin 5000 D(II) FGFR1/ 156 319.4 6.6
19.1 4.9 10.9 Pentosan PSO.sub.4 .sup.aCalculations for K.sub.d at
T.sub.m were made using equation (1) with an estimated
.DELTA.H.sup.T0.sub.u = 60.0 kcal/mole, and an estimated
.DELTA.C.sub.pu = 0.95 kcal/mole - .degree. K; and K.sub.d =
1/K.sub.a. The D(II) FGFR1 was diluted to 1.0 mg/mL (70 .mu.M) in
50 mM Hepes, pH 7.5, 0.1 M NaCl with 136 .mu.M ANS present. All
ligands were dissolved in the same buffer and diluted 50-fold into
the protein solution. .sup.bEstimates for K.sub.d at T =
298.degree. K were made using equation (3), where
.DELTA.H.sup.T.sub.L = -12.1, and -7.48 kcal/mole for the pentosan
PSO.sub.4 and heparin 5000, respectively, as determined by
isothermal titrating calorimetry (Pantoliano, M. W. et al.,
Biochemistry 33: 10229-10248 (1994)). .sup.cPublished binding
affinity data for these ligands binding to D(II)-D(III) FGFR1 as
determined by titrating calorimetry (Pantoliano, M. W. et al.,
Biochemistry 33: 10229-10248 (1994)).
EXAMPLE 7
Microplate Thermal Shift Assay of Factor D
[0294] In order to further demonstrate the cross target utility of
the microplate thermal shift assay, another enzyme, Factor D, was
tested for its ability to undergo thermal unfolding transitions.
Factor D is an essential serine protease involved in the activation
of the alternative pathway of the complement system, the major
effector system of the host defense against invading pathogens.
Factor D was purified from the urine of a patient with Fanconi's
syndrome (Narayana et al., J. Mol. Biol. 235:695-708 (1994)) and
diluted to 4 .mu.M in assay buffer (50 mM Hepes, pH 7.5, 0.1 M
NaCl). The assay volume was 10 .mu.L and the concentration of
1,8-ANS was 100 .mu.M. The experiment was carried out using 15
.mu.L round bottom dimple plates (an 8.times.12 well array). The
protein was heated in two degree increments between 42.degree. C.
to 62.degree. C., using a Robocycler.TM. temperature cycler. After
each heating step, and prior to fluorescence scanning using the
CytoFluor II.TM. fluorescence plate reader the sample was cooled to
25.degree. C. (see Example 1). The non-linear least squares curve
fitting and other data analysis were performed as described for
FIG. 3. The results of the microplate thermal shift assay of Factor
D is shown in FIG. 5 and reveal a thermal unfolding transition that
occurs near 324 K (51.degree. C.) for the unliganded form of the
protein. No reversible ligands of significant affinity are known
for Factor D. The results in FIG. 5 show that the microplate
thermal shift assay can be used to screen a library of compounds
for Factor D ligands. The results in FIG. 5 also show that the
microplate thermal shift assay is generally applicable to any
target molecule.
EXAMPLE 8
Microplate Thermal Shift Assay of Factor Xa
[0295] Human Factor Xa, a key enzyme in the blood clotting
coagulation pathway, was chosen as yet another test of the cross
target utility of the microplate thermal shift assay. Factor Xa was
purchased from Enzyme research Labs (South Bend, Ind.) and diluted
to 1.4 .mu.M in assay buffer (50 mM Hepes, pH 7.5, 0.1 M NaCl). The
assay volume was 100 .mu.L and the concentration of 1,8-ANS was 100
.mu.M. The protein was heated in two degree increments between
50.degree. C. to 80.degree. C. using a Robocycler.TM. temperature
cycler. After each heating step, prior to fluorescence scanning
using the CytoFluorII.TM. fluorescence plate reader, the sample was
cooled to 25.degree. C. (see Example 1). The results of a
microplate thermal shift assay of Factor Xa is shown in FIG. 6. A
thermal unfolding transition was observed at 338K (65.degree. C.).
Data analysis was described as described for FIG. 3. The results in
FIG. 6 show that the microplate thermal shift assay of protein
stability is generally applicable to any target molecule.
EXAMPLE 9
Miniaturization of the Microplate Thermal Shift Assay of Ligands
Binding to Human .alpha.-Thrombin
[0296] A miniaturized form of the microplate thermal shift assay
was developed to minimize the amount of valuable therapeutic
protein and ligands required for the assay. In the first attempt at
decreasing the assay volume, the assay volume was decreased from
100 .mu.L to 50 .mu.L without adversely affecting the fluorescent
signal. When the assay volume was reduced further by a factor of
ten, to 5 .mu.L, favorable results were obtained for human
.alpha.-thrombin. As shown in FIG. 7, the human .alpha.-thrombin
unfolding transition could be easily observed at its usual T.sub.m.
More importantly, an active site inhibitor was observed to shift
the T.sub.m of the unfolding transition by 8.3.degree. K to yield
an estimate of the K.sub.d of 15 nM at the T.sub.m. The K.sub.a at
T.sub.m was calculated using the relationship: 4 K L T m = exp { -
H u T 0 R [ 1 T m - 1 T 0 ] + C pu R [ ln ( T m T 0 ) + T 0 T m - 1
] } [ L T m ] ( equation 1 )
[0297] where
[0298] K.sub.L.sup.T.sup..sub.m=K.sub.a at T.sub.m (ligand
associate constant at T.sub.m)
[0299] T.sub.m=332.2.degree. K (midpoint of the unfolding
transition in the absence of a ligand)
[0300] T.sub.0=323.9.degree. K
[0301] H.sub.u=200.0 kcal/mol (enthalpy of unfolding for pre
thrombin observed by Lentz et al., 1994)
[0302] C=2.0 kcal/mol (estimated change in heat capacity of
unfolding for human .alpha.-thrombin)
[0303] .sub.T=50.0 .mu.M
[0304] The Kd at temperatures near 25 or 37.degree. C. will be of
higher affinity if the enthalpy of binding, .DELTA.H.sub.b, is
negative for this ligand. Using a spectrophotometric assay, an
apparent K.sub.i of approximately 8 nM was observed at 37.degree.
C. (310.degree. K).
[0305] The measurements shown in FIG. 7 were obtained using the
CytoFluor II fluorescence plate reader (PerSeptive Biosystems,
Framingham, Mass.). In the experiment, the excitation wavelength of
light was 360 nm and the emission was measured at 460 nm. The
microplates employed for this miniaturized assay were either the
conventional polycarbonate V-bottom 96 well plate (Stratagene, or
Costar) or polycarbonate plates that contain 15 .mu.L dimples in an
8.times.12 array (Costar plate lids). In the reaction, the
concentration of human .alpha.-thrombin was .mu.M in assay buffer
(50 mM Hepes, pH 7.5, 0.1 M NaCl). The assay volume was 5 .mu.L and
the concentration of 1,8-ANS was 100 .mu.M. The protein was heated
in two degree increments between 44.degree. C. to 64.degree. C.
using a Robocycler.TM. temperature cycler. After each heating step,
and prior to fluorescence scanning using the CytoFluor II.TM.
fluorescence plate reader the sample was cooled to 25.degree. C.
for 30 seconds (see Example 1). The non-linear least squares curve
fitting and other data analysis were performed as described for
FIG. 3.
EXAMPLE 10
Miniaturization of the Microplate Thermal Shift Assay of Ligands
Binding to D(II) FGFR1
[0306] Recombinant D(II) FGFR1 was purified from inclusion bodies
and purified by affinity chromatography on heparin sepharose. A
stock solution of D(II) FGFR1 (15 mg/mL; 1.1 mM) was diluted to 50
.mu.M in assay buffer (50 mM Hepes, pH 7.5, 0.1 M NaCl). The assay
volume was 10 .mu.L and the concentration of 1,8-ANS was 250 .mu.M.
The unfolding transition in the absence of ligands was found to be
about 312 K (39.degree. C.) as shown in FIG. 8. In the presence of
the heparin mimic aprosulate (300 uM), the unfoding transition was
observed to increase by about 8 K to about 320 K. Using this
temperature midpoint T.sub.m, it is possible to estimate the
binding affinity of aprosulate to D(II)FGFR1 to be about 18 .mu.M
at the T.sub.m (Table 6). These results demonstrate the ability of
the microplate thermal shift assay to estimate ligand binding
affinity to a non-enzyme target molecule.
EXAMPLE 11
Miniaturization of the Microplate Thermal Shift Assay of
Urokinase
[0307] Another target molecule analyzed was human urokinase-type
plasminogen activator (u-PA). U-PA enzymatically converts
plasminogen into the active protease plasmin. U-PA is involved in
tissue remodeling, cellular migration and metastases. The gene for
u-PA was obtained from ATCC (Rockville, Md.) and modified to
appropriately express active enzyme in E. coli. u-PA was cloned,
overexpressed in E. coli, and purified using procedures similar to
those described by Winkler et al. (Biochemistry 25:4041-4045
(1986)). The last step of u-PA purification was performed in the
presence of the active site inhibitor
glu-gly-arg-chloromethylketone (CMK) and hence the u-PA utilized
for this experiment was the CMK-u-PA complex. The experiment was
performed in the miniaturized format in 5 .mu.L well volume. One
.mu.L of concentrated CMK-u-PA (13 g/L, 371.4 .mu.M) was added to 4
.mu.L of 62.5 mM MOPS, pH 7, 125 mM NaCl, and 250 .mu.M 1,8-ANS, in
multiple wells of a 96-well polycarbonate V-bottom microtiter
plate. A thermal denaturation curve was generated as previously
described for thrombin, aFGF, D(II)FGFR1, Factor D, and Factor Xa,
by incremental heating of the microplate followed by a fluorescence
reading after each temperature increase. Analysis and non-linear
least squares fitting of the data for this experiment show that the
T.sub.m for CMK-u-PA under these conditions is 81.degree. C., which
is considerably higher than that seen for thrombin, aFGF,
D(II)FGFR1, Factor D, and Factor Xa (55, 44, 40, 51, 55, and
65.degree. C., respectively). This experiment demonstrates the
utility of the current invention in determining the T.sub.m for
relatively thermostable proteins or proteins stabilized by the high
affinity binding of ligand(s) and further demonstrates the ability
to perform such an experiment in a miniaturized format.
EXAMPLE 12
Further Miniaturization of the Microplate Thermal Shift Assay of
Human .alpha.-thrombin
[0308] A stock thrombin solution was diluted to 1 .mu.M in 50 mM
Hepes, pH 7.5, 0.1 M NaCl and 100 .mu.M 1,8-ANS. An electronic
multi-channel pipettor was used to dispense either 2 .mu.L or 5
.mu.L of diluted thrombin solution into wells of a 96-well
polycarbonate microtiter plat. The plate was subjected to 3 minutes
of heating in a thermal block capable of establishing a temperature
gradient across the microplate, followed by 30 seconds cooling to
25 .degree. C., and subsequent reading in the CytoFluor II
fluorescence plate reader. Data were analyzed by non-linear least
squares fitting and plotted as shown in FIGS. 10 and 11. Each curve
represents a replicate experiment. Standard deviations for T.sub.m
determinations were very good for experiments utilizing either 5
.mu.L or 2 .mu.L volumes (+/-1.73 and +/-0.90 K, respectively),
demonstrating the ability of the current invention to operate at
very low volumes. In fact, the volume which one could employ in the
current invention seems to be limited only by the technology
available to dispense small volumes accurately.
[0309] The assay volume was reduced to 2 .mu.L, as shown for human
.alpha.-thrombin (1.0 .mu.M) in FIG. 11. Reproducible pipetting of
2 .mu.L in a 96 well array requires the employment of specialized
pipetting tools such as the multi-channel pipettor available from
Matrix Technologies Corp. (Lowell, Mass.) which has .+-.2.0% or
0.15 .mu.L precision and .+-.2.5% or 0.15 .mu.L accuracy for
volumes 0.5 to 12.5 .mu.L.
EXAMPLE 13
Single Temperature Mode of the Microplate Thermal Shift Assay
[0310] Results of a single temperature assay are shown in FIG. 12.
The compounds 3DP-3811, 3DP-3959, 3DP-4076, and 3DP-4660 bind to
the active site of human .alpha.-thrombin. The K.sub.i's
(enzymatically determined) of these four compounds for human
.alpha.-thrombin are of 20,000 nM, 250 nM, 25nM, and 8 nM,
respectively. Each of these four compounds were equilibrated with
human .alpha.-thrombin in separate 5 .mu.l assay volumes in a 96
well plate. The final ligand concentration was 50 .mu.M.
[0311] For the ligands that bind to human .alpha.-thrombin with
higher affinity, low levels of fluorescence emission were observed,
relative to the control reaction (human .alpha.-thrombin alone) at
55.degree. C. The result for the sample containing the weakly
binding ligand 3DP-3811 was little different from the result
obtained for the control sample. The decrease in fluorescence
emission for 3DP-4076 was not as large as expected, given its high
affinity (K.sub.i of 25 nM) for human .alpha.-thrombin. This result
could be due in part to the lower solubility of chloride salts of
this compound.
[0312] The data in FIG. 12 clearly demonstrate the utility of the
single temperature embodiment of the microplate thermal shift assay
for quickly identifying ligands with binding affinities (K.sub.d's)
of 250 nM or better when the ligand concentration is 50 .mu.M.
EXAMPLE 14
Microplate Thermal Shift Assay of Intrinsic Protein Tryptophan
Fluorescence Emission
[0313] The intrinsic Trp fluorescence of human .alpha.-thrombin was
assayed in a microplate thermal shift assay. 100 .mu.L samples
contained 2 .mu.M human .alpha.-thrombin. The samples were exposed
to light from a Xenon-Arc lamp at 280 nm. Emission was detected at
350 nm using the BioLumin 960 (Molecular Dynamics). Temperature
cycling, between 44.degree. C. and 66.degree. C., was performed as
described in previous examples. The results of the assay are shown
in FIGS. 13 and 14. A small increase in fluorescence emission was
observed at 350 nm with increasing temperature. However, this
increase in fluorescence emission was barely detectable above the
level of fluorescence in the blank wells that contained no protein
(FIG. 13). Subtracting an average blank improved the signal to
noise ratio (FIG. 14), but the observed unfolding transition was
different from that typically observed in assays employing 1,8-ANS.
In contrast to the transition observed using 1,8-ANS, the
transition in FIG. 14 appears broader and has a midpoint
temperature T.sub.m at 334.4.+-.5.1.degree. K, some five degrees
higher than the T.sub.m observed for human .alpha.-thrombin in
assays performed with 1,8-ANS.
EXAMPLE 15
Assay of Multi-Ligand Binding Interactions
[0314] As previously demonstrated, the thermal shift assay can be
used for the screening of ligands for binding to single sites on
target proteins. In light of the underlying physical principles
upon which the microplate thermal shift assay is based, the near
additivity of the free energy of ligand binding and protein
unfolding, it is possible to employ the microplate thermal shift
assay for analyzing multi-ligand binding interactions with a target
protein. If the free energy of binding of different ligands binding
to the same protein are nearly additive, then one can analyze
multi-ligand binding systems, whether the ligands bind in a
cooperative (positive) fashion or a non-cooperative (negative)
fashion.
[0315] Multiple ligand binding to human .alpha.-thrombin was
assayed in a microplate thermal shift assay. Human .alpha.-thrombin
it has at least four different ligand binding sites: (1) the
catalytic binding site; (2) the fibrin binding site (exosite I);
(3) the heparin binding site (exosite II); and (4) the Na.sup.+
binding site, located .about.15.ANG. from the catalytic site.
First, independent binding of three individual ligands was assayed:
3DP-4660, Hirugen (hirudin 53-64) (Bachem), and heparin 5000
(CalBiochem). These ligands bind to the catalytic site, the fibrin
binding site and the heparin binding site, respectively.
[0316] A stock thrombin solution was diluted to 1 .mu.M in 50 mM
Hepes, pH 7.5, 0.1 M NaCl, 1 mM CaCl.sub.2, and 100 .mu.M 1,8-ANS.
Each thrombin ligand was included singly and in various
combinations to 1 .mu.M thrombin solutions at final concentrations
of 50 .mu.M each, except for heparin 5000, which was 200 .mu.M. 100
.mu.L of thrombin or thrombin/ligand(s) solution was dispensed into
wells of a 96-well V-bottom polycarbonate microtiter plate. The
plate was subjected to 3 minutes of heating in a thermal block
capable of establishing a temperature gradient across the
microplate, followed by 30 seconds cooling at 25.degree. C., and
subsequent reading in a fluorescence plate reader. Data were
analyzed by non-linear least squares fitting.
[0317] The results of these individual binding reactions are shown
in FIGS. 15 and 16. The rank order of binding affinity was
3DP-4660>Hirugen>heparin 5000, corresponding to K.sub.d
values of 15 nM, 185 nM and 3434 nM, respectively, for the ligands
binding at each T.sub.m (see Equation (4)).
[0318] The results reveal thermal unfolding shifts that are
slightly smaller than would be expected if the free energies of
binding were fully additive. For example, Hirugen alone displays a
.DELTA.T.sub.m of 5.8.degree. C., and 3DP-4660 alone displays a
.DELTA.T.sub.m of 7.7.degree. C. In combination, however, Hirugen
and 3DP-4660 display a .DELTA.T.sub.m of 12.2.degree. C. This
result means that the binding affinity of one or both ligands is
diminished when both ligands are bound, and is an example of
negative cooperativity in binding between the fibrin and catalytic
binding sites. Such a negatively cooperative effect is consistent
with the human .alpha.-thrombin literature, in which the kinetics
of hydrolysis of various chromogenic substrates were found to
depend upon ligands binding to exosite I. Indeed, a 60% decrease in
K.sub.m for the hydrolysis of D-phenylalanylpipecolyl
arginyl-p-nitroanilide was observed when Hirugen was present
(Dennis et al., Eur. J Biochem. 188:61-66 (1990)). Moreover, there
is also structural evidence for cooperativity between the catalytic
site and exosite I. A comparison of the isomorphous structures of
human .alpha.-thrombin bound to PPACK (a human .alpha.-thrombin
catalytic site inhibitor) and Hirugen revealed conformational
changes that occur at the active site as a result of Hirugen
binding at the exosite I (Vijayalakshmi et al., Protein Science
3:2254-2271 (1994)). Thus, in the microplate thermal shift assay,
the apparent cooperativity observed between the catalytic center
and the exosite I is consistent with functional and structural data
in the literature.
[0319] Similarly, when the binding of all three ligands was
assayed, a .DELTA.T.sub.m of 12.9.degree. C. was observed (FIG.
16). If the free energies of binding were fully additive, one would
expect to observe a .DELTA.T.sub.m of 17.7 .degree. C. The observed
result means that further negative cooperativity occurs via ligand
binding at all three protein binding sites. This result is
consistent with the literature. In a ternary complex with heparin
and fibrin monomer, human .alpha.-thrombin has decreased activity
toward tri-peptide chromogenic substrates and pro-thrombin (Hogg
& Jackson, J. Biol. Chem. 265:248-255 (1990)), and markedly
reduced reactivity with anti-thrombin (Hogg& Jackson, Proc.
Natl. Acad. Sci. USA 86:3619-3623 (1989)). Also, recent
observations indicate that ternary complexes also form in plasma
and markedly compromise heparin anticoagulant activity (Hotchkiss
et al., Blood 84:498-503 (1994)). A summary of these multi-ligand
binding results is shown in Table 7.
[0320] The results in FIG. 15, FIG. 16, Table 7 illustrate the
following advantages of using the microplate thermal shift assay to
perform multi-variable analyses. First, the same microplate thermal
shift assay can be used to simultaneously detect the binding of
multiple ligands at multiple binding sites in a target protein.
Second, the microplate thermal shift assay can be used to detect
the same ligand binding to two or more sites in a therapeutic
target. Third, the microplate thermal shift assay affords the
detection of cooperativity in ligand binding. Information about
ligand binding cooperativity can be collected and analyzed very
quickly. Thus, multi-ligand binding experiments that would take
months to perform using alternative technologies take only hours to
perform using the microplate thermal shift assay.
8TABLE 7 Microplate thermal shift assay for Ligands Binding to the
Active Site, Exosite, and Heparin Binding Site of Human
.alpha.-thrombin [Ligand] T.sub.m .DELTA. T.sub.m K.sub.d at
T.sub.m.sup.a K.sub.d at 298.sup..degree.b Protein/Ligand (.mu.M)
(.degree. K) (.degree. K) (nM) (nM) Thrombin (TH) none 323.75 0.0
TH/Heparin 5000 200 327.95 4.2 3434 470 TH/Hirudin 50 329.52 5.8
185 23 53-65 TH/3dp-4660 50 331.40 7.7 29 3 TH/Heparin 5000 200
327.95 TH/Hep./Hir. 50 330.57 2.6 4254 478 TH/Heparin 5000 200
327.95 TH/Hep.3dp 4660 50 333.20 5.3 350 32 TH/Hirudin 50 329.52
53-65 TH/Hir./Hep. 200 330.57 1.1 75422 8467 TH/Hirudin 50 329.52
53-65 TH/Hir.3dp-4660 50 335.97 6.5 117 9 TH/3dp-4660 50 331.40
TH/3dp-4660/Hep 200 333.20 1.8 38205 351 TH/3dp-4660 50 331.40
TH/3dp-4660/Hir. 50 335.97 4.6 731 54 .sup.aCalculations for
K.sub.d at T.sub.m were made using equation (1) with
.DELTA.H.sub.u.sup.T.degree. = 200.0 kcal/mole, as observed for
pre-thrombin 1 by Lentz et al., (1994), and an estimated
.DELTA.C.sub.pu = 2.0 kcal/mole - .degree. K; and K.sub.d =
1/K.sub.a. .sup.bEstimates for K.sub.d at T = 298.degree. K were
made using the equation (3), where .DELTA.H.sub.L.sup.T is
estimated to be -10.0 kcal/mole.
EXAMPLE 16
Screening Biochemical Conditions that Increase Human
.alpha.-thrombin Stability
[0321] The microplate thermal shift assay was used, with four
different fluorophores, to simultaneously screen the effects of
multiple pH values, sodium chloride concentrations, and
reduction-oxidation compounds on human .alpha.-thrombin stability.
Thrombin solution was diluted to 1 .mu.M in 50 mM Hepes, pH 7.5,
NaCl at either 0.1 M or 0.5 M, 10 mM EDTA, 10 mM CaCl.sub.2, 10 mM
dithiothreitol, 10 1 mM CaCl.sub.2, and 100 .mu.M 1,8-ANS, 10%
(v/v) glycerol, or 0.1% (w/v) polyethylene glycol (PEG) 6000.
Reaction volume was 100 .mu.L.
[0322] The results of these multi-variable experiments are shown in
FIGS. 17A-D and FIG. 18. FIGS. 17A-D summarize the stability data
collected in a single 96 well plate for human .alpha.-thrombin. In
FIG. 17A, the fluorophore is 1,8-ANS. In FIG. 17B, the fluorophore
is 2,6-ANS. In FIG. 17C, the fluorophore is 2,6-TNS. In FIG. 17D,
the fluorophore is bis-ANS. The results in FIGS. 17A-D show a pH
optimum of about 7.0 and an increase in stability with increasing
NaCl concentration. A .DELTA.T.sub.m of about 12.degree. C. was
observed when the NaCl concentration was increased from 0 to 0.5 M.
FIG. 18 shows a stabilizing effect of 10% glycerol and a
destabilizing effect of dithiothreitol. From FIGS. 17A-D and 18 is
evident that the flourophores 1,8-ANS and 2,6-TNS are most
effective in the microplate thermal shift assay.
[0323] The stabilizing effect of NaCl is particularly interesting
since there are recent reports in the literature of a weak Na.sup.+
binding site (K.sub.d of 30.+-.3 mM in 5 mM Tris buffer pH 8.0,
0.1% PEG, 25 .degree. C.) approximately 15 .ANG. from the catalytic
center of thrombin (Dang et al., Nature Biotechnology 15:146-149
(1997)). Using equation (1), it is possible to estimate the NaCl
binding to be .about.6 mM near the T.sub.m (53.degree. C.) in 50 mM
Hepes pH 8.0 buffer (zero and 0.10 M NaCl).
[0324] The additional stabilization that occurs at a NaCl
concentration of greater than 0.10 M may come from additional
Na.sup.+ and/or Cl.sup.- binding events summed over the entire
structure of human .alpha.-thrombin. Alternatively, the source of
this further stabilization may come from less specific salting out
effect that is usually observed at 0.5 to 2 M NaCl and is due to
the preferential hydration of proteins induced by salts (Timasheff
& Arakawa, In: Protein Structure, A Practical Approach, T. E.
Creighton, ed., IRL Press, Oxford, UK (1989), pp. 331-354)). The
stabilizing effect of glycerol on proteins has been attributed to a
balance between the preferential exclusion of glycerol (i.e.
preferential hydration of proteins) and the specific binding to
polar regions on the surface of proteins (Timasheff& Arakawa,
In: Protein Structure, A Practical Approach, T. E. Creighton, ed.,
IRL Press, Oxford, UK (1989), pp. 331-354)).
EXAMPLE 17
Screening Biochemical Conditions that Increase D(II) FGF Receptor 1
Stability
[0325] The microplate thermal shift assay was used to
simultaneously screen the effects of multiple biochemical
conditions on D(II) FGF receptor 1 stability. The assays were
performed by mixing 1 .mu.L of D(II) FGFR1 (from a 500 .mu.M
concentrated stock in 50 mM HEPES pH 7.5) with 4 .mu.L of each
biochemical condition in wells of a 96-well polycarbonate
microtiter plate. Final protein concentration after mixing was 100
.mu.M and final 1,8-ANS concentration was 200 .mu.M. Biochemical
conditions were tested as follows: The pH's tested were 5 (Na
acetate), 6 (MES), 7 (MOPS), 8 (HEPES), and 9 (CHES), with final
buffer concentrations of 50 mM.
[0326] The salt concentrations tested were 0.1 or 0.5 M NaCl.
Additives were tested in 50 mM MOPS, pH 7, 0.1 M NaCl, at final
concentrations of 1 mM (EDTA, dithiothreitol), 10 mM (CaCl.sub.2,
MgCl.sub.2, MgSO.sub.4, NiSO.sub.4), 50 mM (arginine), 100 mM
((NH.sub.4).sub.2SO.sub.4, LiSO.sub.4, Na.sub.2SO.sub.4,
ZnSO.sub.4), 5% w/v (polyethylene glycol 6000), and 10% v/v
glycerol.
[0327] Thermal denaturation profiles were generated as previously
described for thrombin, aFGF, Factor D, and Factor Xa, by
incremental heating of the microplate followed by a fluorescence
reading after each temperature increase. Data were analyzed by
non-linear least squares fitting as described previously.
[0328] The results of these multi-variable experiments are shown in
FIGS. 19-24. As shown in FIG. 19, stability increased with
increasing NaCl concentration. A .DELTA.T.sub.m of about 5.degree.
C. was observed as NaCl concentration was increased from 0.1 to 0.5
M. As shown in FIG. 20, both MgSO.sub.4 and arginine stabilized the
protein. As shown in FIG. 21, 10% glycerol stabilized the protein.
Further, salts of the Hofmeister series such as Li.sub.2SO.sub.4,
Na.sub.2SO.sub.4, (NH.sub.4).sub.2SO.sub.4 and Mg.sub.2SO.sub.4 all
had stabilizing effects (FIG. 21). As shown in FIG. 22,
dithiothreitol destabililzed the protein. These results are not
very different form that of human .alpha.-thrombin. As shown in
FIG. 23, a pH optimum of about 8.0 was observed. The relative
stabilizing effects of EDTA, CaCl.sub.2, MgCl.sub.2, MgSO.sub.4,
arginine, (NH.sub.4).sub.2SO.sub.4, Li.sub.2SO.sub.4,
Na.sub.2SO.sub.4, glycerol, polyethylene glycol 6000, and
dithiothreitol are shown in FIG. 24.
EXAMPLE 18
Screening Biochemical Conditions that Increase Urokinase
Stability
[0329] The microplate thermal shift assay was used to
simultaneously screen the effects of multiple biochemical
conditions on human urokinase stability. This experiment was
performed by mixing 1 .mu.L of urokinase (from a 371 5M
concentrated stock in 20 mM Tris pH 8) with 4 .mu.L of each
biochemical condition in wells of a 96-well polycarbonate
microtiter plate. Final protein concentration after mixing was 74
.mu.M and final 1,8-ANS concentration was 200 .mu.M. Biochemical
conditions were tested as follows: The pH's tested were 5
(acetate), 6 (MES), 7 (MOPS), 8 (HEPES), and 9 (CHES) with final
buffer concentrations of 50 mM. The salt concentrations tested were
0.1 or 0.5 M NaCl. Glycerol was tested at 10% v/v in 50 mM MOPS, pH
7, 0.1 M NaCl.
[0330] Thermal denaturation profiles were generated as previously
described for thrombin, aFGF, Factor D, D(II) FGFR1, and Factor Xa,
by incremental heating of the microplate followed by a fluorescence
reading after each temperature increase. Data were analyzed by
non-linear least squares fitting as described previously.
[0331] The results of these multi-variable experiments are shown in
FIG. 25. A pH optimum of about 7.0 was observed. Increasing
concentrations of sodium chloride stabilized the protein. 10%
glycerol also stabilized the protein. These results are consistent
with the results reported in the literature (Timasheff &
Arakawa, In: Protein Structure, A Practical Approach, T. E.
Creighton, ed., IRL Press, Oxford, UK (1989), pp. 331-354).
[0332] FIGS. 17-25 illustrate the advantage of using the microplate
thermal shift assay to simultaneously screen for multi-variable
biochemical conditions that optimize protein stability. Using the
methods and apparatus of the present invention, one can rapidly
screen large arrays of biochemical conditions for conditions that
influence the stability of proteins. Thus, the present invention
can be used to rapidly identify biochemical conditions that
optimize protein shelf-life.
EXAMPLE 19
Screening Biochemical Conditions that Facilitate Protein
Folding
[0333] Factorial experiments were performed to identify biochemical
conditions that increased the yield of correctly folded
His.sub.6-D(II)-FGFR1. His.sub.6-D(II)-FGFR1 is recombinant D(II)
FGF receptor 1 protein, to which a polyhistidine tag is attached to
the N-terminus. The results are summarized in Table 8. When the
final guanidinium hydrochloride concentration was 0.38 M, a
refolded protein yield of 13.5.+-.0.2% was obtained at pH 8.0 and
0.5 M NaCl. This yield could be increased to 15.5.+-.0.3% if
glycerol was present at 7% (v/v). A further increase in
His.sub.6-D(II)-FGFRI refolding yield to about 18% was observed
when the pH was increased to 8.9. In fact, increasing the pH from
8.0 to 8.9 improved the yields in all experiments. These results
demonstrate that a pH between 8 and 9, and 7% glycerol, are two
important conditions that facilitate D(II)-FGFRI folding. Each of
these conditions increased the folded protein yield by about 15 to
20% over the starting conditions at pH 8.0 and 0.5 M NaCl.
[0334] Importantly, the effects of pH and glycerol appear to be
nearly additive. The increased yield of refolded protein at pH 8.9
and 7% glycerol was found to be 17.8%, 32% higher than the yield
obtained at a pH 8.0 and 0.5 M NaCl (13.5.+-.0.2% yield). The near
additivity of refolding determinants has important consequences
since it suggests that the small individual free energy components
that comprise the overall free energy of folding can be
incrementally combined to optimize the yield of folded protein.
9TABLE 8 Factorial Experiment to Optimize the Protein Folding Yield
for Immobilized His.sub.6D(II)-FGFRl at a final Gdn-HCl
concentration of 0.38 M.sup.a 7% Glycerol/ 500 mM NaCl 50 mM NaCl
50 mM NaCl pH 8.0 13.3%.sup.b 9.3% 15.1% pH 8.0 13.6% 9.4% 15.8% pH
8.9 16.1% 13.5% 17.8% pH 8.9 10.3% 17.8% .sup.aRefolding was
initiated by diluting a 3.2 mL suspension of Ni.sup.2+NTA/6M
Gdn-HCl to 50 mL in the respective refolding buffers (1:15.6
dilution) so that the final Gdn-HCl concentration was 0.38 M.
.sup.bYields are based on measured A.sub.280 values for fractions
eluted off a Heparin Sepharose column. The immobilized protein
concentration was 1.2 mg/mL, as measured by a Bio-Rad protein
assay. Since the column size was 21 mL, 25.2 mg of D(II) FGFRl was
bound to the resin.
[0335] Results of a second round of refolding experiments at a
final Gdn-HCl concentration of 0.09 M revealed that the Gdn-HCl is
an even more important factor affecting the folding of
His.sub.6-D(II)FGFR1 (Table 9). At pH 8.0 and 0.5 M NaCl,
decreasing the Gdn-HCl concentration to 0.09 M doubled the refolded
protein yield, relative to the yield obtained at pH 8.0, 0.5 M
NaCl, and 0.38 M Gdn-HCl (Table 9). In accordance with the results
obtained at a Gdn-HCl concentration of 0.38 M, the yield of
refolded His.sub.6-D(II)-FGFR1 in 0.09 M Gdn-HCl was also increased
in the presence of glycerol. These results suggest that the
improved yield of refolded His.sub.6D(II)-FGFR1 in glycerol (5 to
10%) and lower Gdn-HCl concentration are additive. Further, the
results in Table 9 reveal that the Hofmeister salt Na.sub.2SO.sub.4
increases the yield of refolded protein almost as well as 5 to 10 %
glycerol.
10TABLE 9 Factorial Experiment to Optimize the Protein Folding
Yield for Immobilized His.sub.6 D(II)-FGFR1. Final Gdn-HCl of 0.09
M.sup.a 5% 10% Glycerol Glycerol 500 mM 50 mM 50 mM 50 mM 100 mM
300 mM NaCl NaCl NaCl NaCl Na.sub.2SO.sub.4 Na.sub.2SO.sub.4 pH
25.6%.sup.b 29.7% 36.5% 35.6% 32.2% 33.4% 8.0 .sup.aRefolding was
initiated by diluting a 7.5 mL suspension of Ni.sup.2+NTA/6 M
Gdn-HCl to 50 mL in the respective refolding buffers (1:6.7
dilution) so that the final Gdn-HCl concentration was 0.09 M.
.sup.bYields are based on measured A.sub.280 values for fractions
eluted off a Heparin Sepharose column. The immobilized protein
concentration was 1.6 mg/mL, as measured by Bio-Rad protein assay.
Since the column size was 20 mL, 32 mg of D(II) FGFR1 was bound to
the resin.
[0336] Upon comparison of the biochemical conditions that increase
the yield of refolded Ni.sup.2+NTA bound His.sub.6-D(II)-FGFR1
(Tables 8 and 9) and those conditions that increase the overall
protein stability of His.sub.6-D(II)-FGFR1 (FIGS. 19-24), it is
clear that there is a strong correlation between the protein
folding results and the protein stability results. Glycerol, salts
of the Hofmeister series, and pH 8.5 to 8.9 improve protein folding
yield and overall protein stability of His.sub.6-D(II)-FGFR1.
[0337] These results are consistent with the model of protein
folding in FIG. 26. If the aggregation of unfolded
His.sub.6-D(II)-FGFR1 is suppressed when immobilized to
Ni.sup.2+NTA, and a simple two state equilibrium exists between U
and N, then the factors that influence the relative position of the
equilibrium between U and N should be the same whether one starts
from U (in the refolding experiment) or start from N (in the
microplate thermal shift assay protein stability screen). Since
thermodynamics are path independent, only the initial and final
states of this reaction should be important. Since similar
biochemical conditions facilitate protein stability and folded
protein yield, the simple model for protein folding depicted in
FIG. 26 is accurate for this protein. Thus, the microplate thermal
shift assay can serve as a rapid and general method for screening
biochemical conditions that optimize protein folding.
EXAMPLE 20
[0338] FIG. 28 shows the results of microplate thermal shift assays
of using each of four fluorescence probe molecules: bis-ANS,
2,6-TNS, 1,8-TNS, and 2,6-ANS. Thrombin solution was diluted to 1
.mu.M in 50 mM Hepes, pH 7.5, and 0.1 M NaCl.
EXAMPLE 21
Comparison of Assay Results for a Fluorescence Scanner and a Charge
Coupled Device Camera
[0339] A Gel Documentation and Analysis System (Alpha Innotech
Corp., San Leandro, Calif.) was used to perform a microplate
thermal shift assay. This system uses a CCD camera to detect
fluorescence emission from stained gels, dot blot assays, and 96
well plates. The excitatory light source was a long wavelength UV
trans-illumination box located directly below the CCD camera. The
96 well plate to be assayed was placed on the trans-illumination
box within the focal viewing area of the CCD camera (21.times.26
cm).
[0340] A 2 .mu.M solution of human .alpha.-thrombin was prepared in
50 mM Hepes, pH 7.5, 0.1 M NaCl by diluting a 34 .mu.M stock
solution (1:17) of purified human .alpha.-thrombin (Enzyme Research
Labs, Madison, Wis.). The human .alpha.-thrombin solution also
contained 100 .mu.M 1,8-ANS. 100 .mu.L of the human
.alpha.-thrombin-1,8-ANS solution was aliquoted into each of twelve
wells of a single row (row A) of a V-bottom polycarbonate
microplate (Costar). A gradient block (RoboCycler.TM., Stratagene)
was used to heat the twelve samples, from 44 to 66.degree. C.,
across the rows of the microplate. i.e. a temperature gradient of
2.degree. C. per well was established. Thus, well A1 was at
66.degree. C. and well A12 was at 44.degree. C. The control
solution that contained 100 .mu.M 1,8 ANS in the same buffer (no
protein) was placed in each of wells B1 to B12. After adding a drop
of mineral oil to each well to prevent evaporation, the plate was
heated on the gradient block for 3 min. The contents of each well
were then allowed to reach room temperature and transferred to a
flat bottom microplate.
[0341] In this experiment, no filters were employed to narrow the
excitatory wavelength to .about.360 nm and the emission wavelength
to 460 nm, which are optimal wavelengths for the 1,8 ANS
fluorophore. The flat bottom plate was then placed on the near UV
transillumination box and the CCD camera was used to measure the
amount of emitted light. The plate was also read using a
conventional fluorescence plate reader (CytoFluor II), in order to
compare the results obtained by the two different detection
methods. The results for the two detection methods are plotted in
FIG. 40. The results in FIG. 40 show that the CCD camera is useful
as a fluorescence emission detector for monitoring the unfolding of
a protein in the microplate thermal shift assay.
EXAMPLE 22
Microplate Thermal Shift Assay Using a Charge Coupled Device
Camera
[0342] An emission filter was used to block out all stray light
outside the region of the emission region for 1,8-ANS (.about.460
nm). In addition, the 5 .mu.L miniaturized form of the microplate
thermal shift assay was employed to test the CCD camera detection
method in this configuration. Both the polycarbonate V-bottom and
dimple plates were tested. The experiment was essentially the same
as described in Example 21, except that the volume of the assay was
5 .mu.L in either the V-bottom or dimple 96 well plates. The
temperature range was 44 to 66.degree. C. (right to left) for the
V-bottom plate, and 46 to 70.degree. C. (right to left) for the
dimple plate. Photographs of the CCD images are shown in FIG. 41.
The V-bottom well microplate image is shown in FIG. 41A. The dimple
plate image is shown in FIG. 41B. The results obtained from the
plate in FIG. 41A is shown in FIG. 42. The results in FIG. 42 show
that data obtained using a CCD camera compare very well with data
obtained using a fluorescence plate reader that employs a
photo-multiplier tube (PMT) for fluorescence detection.
EXAMPLE 23
Comparison of Fluorescence Background Due to Contaminants Collected
Using Different Bandpass Filters
[0343] An empty 384-well black polypropylene thermocycler plate
(Matrix, Inc.) was imaged in an enclosed, black-walled metal box
using two ultraviolet lamps (365 nm peak emission). The images were
recorded using a charge-coupled device (CCD) camera (Cohu) equipped
with optical filters. In FIG. 43A, data were collected using a long
pass filter (435 cut-on wavelength) was combined with a short pass
filter (550 nm cut-off wavelength) to allow transmittance of light
from 435 nm to 550 nm into the CCD camera. In FIG. 43B, data were
collected using a long pass filter (475 cut-on wavelength) was
combined with a short pass filter (550 nm cut-off wavelength) to
allow transmittance of light from 475 nm to 550 nm into the CCD
camera.
[0344] The images shown in FIGS. 43A and 43B were recorded using an
empty, black plate. Therefore, anything present in the image other
than the black background is due to unwanted background
fluorescence or light scattering coming from contaminants on the
surface of the plate (e.g. dust particles). FIG. 43A shows that the
amount of background interference is much greater for the 435
longpass filter than for the 475 nm longpass filter (FIG. 43B).
This illustrates the importance of imaging at longer wavelengths
(greater than 475 nm), and the value of using a reporter dye
molecule that emits as much light as possible at wavelengths
greater than 475 nm.
EXAMPLE 24
Comparison of the Fluorescence Signals of
1-Anilinonaphthalene-8-Sulfonate and
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole Sulfonate When
Interacting to Unfolded Pyruvate Kinase
[0345] A 0.2 mg/mL solution of chicken muscle pyruvate kinase
(Sigma Chemical Co., catalog # P6406) was incubated with either 10
mM 1-anilinonaphthalene-8-sulfonate (1,8-ANS) (FIG. 44, open
squares) or 10 mM 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole
sulfonate (Molecular Probes catalogue no. D-12800) (FIG. 44, closed
squares) in a 500 uL four-sided quartz cuvette. Fluorescence
spectra were recorded using a spectrofluorimeter (Florolog,
SPEX/ISA), with the excitation monochromator set to 370 nm, and the
excitation and emission bandpass slit widths set at 1 nm, The
instrument was operated in front-face collection mode, so that
fluorescence was collected from the same face of the cuvette that
was illuminated by the exciting light source. Emission spectra of
native protein+dye were recorded after mixing the protein and dye
solutions at room temperature. Emission spectra of denatured
protein and fluorescence dye were recorded after the protein/dye
solutions were heated to 75.degree. C. for 2 minutes, and then
cooled to room temperature immediately prior to data collection.
The spectra shown in FIG. 44 are difference spectra that were
calculated by subtracting the native protein fluorescence from the
denatured protein fluorescence for each dye at 25.degree. C. These
difference spectra represent the dependence of the fluorescence
signal at the emission wavelength for each reporter dye, and show
the increase in fluorescence signal upon the thermal unfolding of
pyruvate kinase.
[0346] This example illustrates that at wavelengths above 480 nm,
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate emits an
approximately 3.2-fold higher fluorescence signal than 1,8-ANS,
when pyruvate kinase is converted from the folded form to the
unfolded form.
EXAMPLE 25
Comparison of Fluorescence Signals Generated Using 1,8-ANS and
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole Sulfonate for Human
Thrombin Protein in a Multi-Well Thermal Unfolding Study
[0347] A 1 .mu.M thrombin solution was mixed with
5-(4"-dimethylaminopheny- l)-2-(4'-phenyl)oxazole sulfonate dye to
yield a final concentration of 100 .mu.M
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate. This
solution was pipetted into all the wells of a 384-well black
thermocycler plate with a final volume of 4 uL per well, and 3 uL
of mineral oil was then added to each well. The fluorescence signal
from each well was recorded in a closed, black-walld metal box
using a cooled CCD camera (SenSys, Photometrix, Inc.) equipped with
a 500+/-25 nm bandpass filter. An identical experiment was
performed separately, using the same instrument, camera, and
filters, except that a final concentration of 100 .mu.M 1,8-ANS was
used in place of 5-(4"-dimethylaminophenyl)-2-(4'-pheny- l)oxazole
sulfonate as the reporter dye. As shown in FIGS. 45A and 45B, the
fluorescence signal deflection obtained using
5-(4"-dimethylaminophen- yl)-2-(4'-phenyl)oxazole sulfonate (FIG.
45B) was significantly larger than the signal obtained using 1,8
ANS as the reporter dye molecule (FIG. 45A).
[0348] The ratio of signals from
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)o- xazole sulfonate and
1,8-ANS was calculated by averaging the signals of all 384 wells on
each plate, and dividing the average signal from 1,8-ANS into that
for 5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate.
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate was found
to generate 4.25 times more signal than 1,8-ANS. Thus,
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate yields
substantially more signal than 1,8-ANS, under the conditions
employed, showing that
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate is
superior to 1,8-ANS for practicing the thermal unfolding screening
assays in the optimal wavelength range.
EXAMPLE 26
Utility of 5-(4"-dimethylaminophenyl)-2-(4 phenyl)oxazole Dyes In
Measuring Thermal Midpoint Transition Ttemperatures For Many
Different Classes of Proteins
[0349] It has been found that the fluorescence emission of
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate can be
used to collect thermal unfolding data for many different types of
proteins, proteins that encompass a wide range of biological
functions. Shown in Table 10 are the midpoint transition
temperatures from fluorescence thermal shift assays performed using
nine different proteins that vary widely in their sizes,
stabilities, and biological activities. Thermal shift assays were
performed as follows: 10 uL of each reaction mixture was dispensed
into a single well of a 384-well polypropylene thermocycler plate,
and either 5 uL or 10 uL of mineral oil was added to the top of the
mixture (overlaid). Data were recorded at multiple temperatures
separated by 1 degree intervals over different temperature
ranges.
[0350] For each unfolding study, thermal transitions were measured
by heating the samples at each temperature for 3 minutes, followed
by incubation at 25.degree. C. for 1 minute, followed by
illumination using a UV light source with peak output at 365 mm.
During illumination, fluorescence from the
5-(4"-dimethylaminophenyl)-2-(4'-phenyl)oxazole sulfonate was
recorded using a CCD camera equipped with a 500 nm bandpass filter.
In all experiments, the concentration of 5-(4"-dimethylaminopheny-
l)-2-(4'-phenyl) oxazole sulfonate was 100 .mu.M.
[0351] In the order they are presented in Table 10, the assay
conditions were as follows: human mdm2, 12kDa fragment (residues
17-127):0.084 mg/mL protein, 50 mM HBEPES, 150 mM NaCl, pH 7.5, 3
mM glutathione (reduced form), temperature range: 30-50.degree. C.,
measured in 1.5 degree increments; human plasminogen activator
inhibitor 1:0.05 mg/mL protein, 50 mM sodium phosphate pH 7.0, 150
mM NaCl, pH 7.5, temperature range: 30-60.degree. C., measured in
1.0 degree increments; bovine liver dihydrofolate reductase: 0.2
mg/mL protein, 50 mM HEPES, 100 mM NaCl, pH. 7.5, temperature
range: 30-90.degree. C., measured in 1.0 degree increments; human
basic fibroblast growth factor: 4 .mu.M protein, 45 mM HEPES pH
7.5, 88 mM NaCl, temperature range: 35-99.degree. C., measured in
1.0 degree increments; the D2/D3 fragment of human basic fibroblast
growth factor receptor 1:24 .mu.M protein, 1.times.phosphate
buffered saline (Gibco), 40 mM sodium citrate, 2% plycerol, 10 mM
magnesium chloride, temperature range: 30-84.degree. C., measured
in 2.0 degree increments; human alpha estrogen receptor: 0.9 .mu.M
protein, 50 mM Tris pH 8, 0.25 mM KCL, 5% glycerol, 1 mM EDTA, 2 mM
dithiothreitol, 1 mM sodium vanadate, 10 mM magnesium chloride,
temperature range: 30-75 .degree. C., measured in 1.0 degree
increments; for Halobacterium halobium bacteriorhodopsin: 5 .mu.M
protein, 5 mM sodium acetate pH 5.0, 6.5 mM
nonyl-.beta.-glucopyranoside, temperature range: 30-95.degree. C.,
measured in 1.0 degree increments; bovine muscle myosin: 0.5 mg/mL
protein, 50 mM HEPES, 100 mMNaCl, pH 7.5, temperature range:
30-90.degree. C., measured in 1.0 degree increments; for chicken
muscle pyruvate kinase: 0.5 mg/mL, protein, 50 mM HEPES, pH 7.5,
100 mM NaCl, temperature range: 30-90.degree. C., measured in 1.0
degree increments.
11TABLE 10 Transition midpoint temperatures for different proteins,
measured using 5-(4"-dimethylaminophenyl)-2-(4- '-phenyl)oxazole
sulfonate. Protein T.sub.m (.degree. C.) Human mdm2, 12 kDa
fragment (residues 17-127) 65.5 Human plasminogen activator
inhibitor 1 47.6 Bovine liver dihydrofolate reductase 52.5 Human
basic fibroblast growth factor 48.5 Human basic fibroblast growth
factor receptor, D2/D3 59.0 fragment Human alpha estrogen receptor
46.0 Halobacterium halobium bacteriorhodopsin 73.4 Bovine muscle
myosin 49.4 Chicken muscle pyruvate kinase 54.5
* * * * *